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ABSTRACT 
DEFINING THE NATURE OF CD8+ T CELL RESPONSES IN LYMPHOID 
TISSUES OF HIV ELITE CONTROLLERS 
Son N. Nguyen 
Michael R. Betts and James A. Hoxie 
Acquired Immunodeficiency Syndrome (AIDS) is an immunodeficiency caused by 
infection with Human Immunodeficiency Virus (HIV). Since its first documentation in 
1981, the AIDS pandemic has claimed the lives of 32 million people worldwide. The 
introduction of antiretroviral therapy drugs (ART) and combined therapy in 1995 has 
transformed HIV infections from a “death-sentence” into a manageable and often non-
fatal chronic condition. Still, no cure is available. While without ART most HIV-infected 
individuals (>99%) progress to AIDS, a subset of infected individuals (<1%), known as 
elite controllers (ECs), can spontaneously control viremia and maintain undetectable 
plasma viral load for many years. Effector functions of CD8+ T cells have been strongly 
correlated with the EC status. However, while this correlation has been established 
primarily in blood, HIV mainly replicates in lymphoid tissues (LTs) such as lymph nodes 
(LNs) and gut-associated lymphoid tissue (GALT), where CD8+ T cell-mediated immune 
responses are not well defined. Therefore, this study aims to investigate CD8+ T cell 
responses in LTs, specifically LNs, of HIV-infected individuals and to define mechanisms 
of viral control in LNs of ECs. In order to achieve this goal, we obtained LNs and blood 
samples from HIV- donors, ECs, ART-treated individuals (ARTs), and viremic individuals 
who are not on ART, hereafter termed chronic progressors (CPs). Using an integrative 
viii 
single-cell approach, we identified that most HIV-specific CD8+ T cells in LNs of HIV-
infected individuals, especially in ECs, were tissue-resident memory T cells (TRM). While 
CD8+ T cells in LNs of ECs could potently suppress viral replication, they surprisingly did 
not display strong cytolytic activities. Instead, these cells were more poised for trafficking 
into B cell follicles (BCFs), downregulated expression of inhibitory receptors, and 
concurrently produced multiple cytokines upon stimulation with HIV antigens, which 
could be functionally linked to efficient protein translation capacity. Together, these 
results suggest that CD8+ T cells in LTs controls HIV replication through non-cytolytic 
mechanisms, instead of cytotoxic mechanisms like CD8+ T cells in blood. In conclusion, 
this dissertation highlights the tissue compartmentalization of CD8+ T cells’ effector 
functions in anti-HIV immunity. Furthermore, the induction of TRM and CD8+ T cell-
mediated non-cytolytic mechanisms should be pursued as therapeutic strategies aiming 
to establish durable control of HIV. 
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CHAPTER 1: INTRODUCTION 
1.1 A brief history on the discovery of HIV as the causing agent of AIDS 
The term Acquired Immunodeficiency Syndrome (AIDS) was first coined in 1982 by the 
United States Center for Disease Control (CDC) to describe a previously undescribed 
condition that was “ at least moderately predictive of a defect in cell mediated immunity, 
occurring in a person with no known case for diminished resistance to that disease” 
(Centers for Disease, 1982b). The first cases of AIDS were documented in 1981 in 
communities of homosexual men in Los Angeles and New York (Centers for Disease, 
1981; Hymes et al., 1981). These previously healthy men experienced aggressive 
Kaposi’s sarcoma and in some cases infection with Pneumocystis carinii (Centers for 
Disease, 1981). Between 1981 and 1982 alone, 593 cases of AIDS (with 243 deaths) 
were reported to the CDC (Centers for Disease, 1982b). Among these cases, 75% were 
of homosexual or bisexual males and most of them (80%) occurred in major 
metropolitan areas in the United States (Centers for Disease, 1982b). Risk factors of the 
disease were blood transfusion, sexual interactions, and intravenous drug administration 
(Ammann et al., 1983; Centers for Disease, 1982a; Curran et al., 1984; Marmor et al., 
1982). AIDS patients all showed immunologic abnormalities including 
hypergammaglobulinemia, increased CD8+ T cell counts, and decreased CD4+ T cell 
counts, suggesting that the etiology of this disease likely involved an sexually-
transmitted or blood-born infectious agent targeting the immune system, more 
specifically CD4+ T cells (Stahl, Friedman-Kien, Dubin, Marmor, & Zolla-Pazner, 1982; 
Stahl, Friedman-Kien, & Zolla-Pazner, 1983). In May 1983, American (led by Robert 





retrovirus from AIDS patients, indicating that a retrovirus could be linked to the etiology 
of AIDS (Barre-Sinoussi et al., 1983; Gallo et al., 1983; Gelmann et al., 1983). In 1984, 
multiple studies found the presence of this new retrovirus and antibodies targeting it in 
90-100% of pre-AIDS and AIDS patients, confirming the etiological relationship between 
the virus and AIDS (Gallo et al., 1984; Levy et al., 1984; Marx, 1984; Popovic, 
Sarngadharan, Read, & Gallo, 1984; Sarngadharan, Popovic, Bruch, Schupbach, & 
Gallo, 1984; Schupbach et al., 1984). Initially, the American researchers termed this 
retrovirus HTLV-III, standing for human T-cell leukemia virus (HTLV)-III, because it 
appeared to be closely related to previously described HTLVs, especially HTLV-I (Gallo 
et al., 1984; Gallo et al., 1983; Gelmann et al., 1983). In contrast, the French scientists 
found that the isolated retrovirus was distinct from both HTLV-I and II and independently 
named it lymphadenopathy-associated virus or LAV (Barre-Sinoussi et al., 1983; 
Montagnier et al., 1984). This finding was corroborated by the independent isolation of a 
LAV-resembling retrovirus, termed AIDS-associated retrovirus or ARV, from AIDS 
patients in San Francisco, California (Levy et al., 1984). Subsequent analyses indicated 
that HTLV-III/LAV/ARV was morphologically and genetically more homologous to visna 
virus, a pathogenic nononcogenic sheep lentivirus, and other lentiviruses than to HTLV-I 
and HTLV-II (Gonda et al., 1986; Gonda, Wong-Staal, Gallo, Clements, & Gilden, 1985; 
Gonda, Wong-Staal, Gallo, Clements, Narayan, et al., 1985). In 1986, the virus was 




1.2 Biology of HIV pathogenesis 
Origin of HIV 
HIV belongs to the family Retroviridae and the genus Lentivirus. Two forms of HIV have 
been described: HIV-1 and HIV-2. HIV-1 is made up of four distinct genetic groups: M, 
O, N, and P. Group M (major) was the first one to be discovered and it is responsible for 
the AIDS pandemic (Sharp & Hahn, 2011).(Sharp & Hahn, 2011). This group can be 
further divided into subtypes, or clades, including A, B, C, D, F, G, H, J, and K, which are 
closely related in sequence but have been proposed to have different pathogenesis 
properties and global distribution (Taylor, Sobieszczyk, McCutchan, & Hammer, 2008). 
Group O (outlier) was isolated from two Cameroon individuals who were living in 
Belgium in 1990 (De Leys et al., 1990). Group O accounts for approximately 1% of all 
HIV-1 infections (Mourez, Simon, & Plantier, 2013). Group N (non-M, non-O) was 
discovered in 1998 in Cameroon and has been reported in only 15 cases (Mourez et al., 
2013; Simon et al., 1998). Group P was identified in 2009 from a Cameroonian woman 
living in France and there have been only two cases of confirmed infection from this 
group (Plantier et al., 2009; Vallari et al., 2011). While infections with group M are found 
worldwide, infections with non-M are largely restricted to Africa (Mourez et al., 2013).  
The different groups of HIV originated from independent transmission events of lentivirus 
from other primate species into humans. Lentivirus infecting non-human primate species 
are termed Simian immunodeficiency virus (SIV). SIV has been co-evolving with primate 




co-evolution between SIVs and non-human primate species, these viruses are not 
pathogenic in their natural hosts. Key features that distinguish non-pathogenic SIV 
infections in natural hosts from pathogenic infections in non-natural hosts include, but 
are not limited to, lack of chronic immune activation, CD4+ T cell depletion, microbial 
translocation, and perinatal transmission (Chahroudi, Bosinger, Vanderford, Paiardini, & 
Silvestri, 2012; Klatt, Silvestri, & Hirsch, 2012). SIV infections have been found only in 
African monkeys and apes, suggesting that these viruses emerged in Africa after the 
divergence between African and Asian Old World monkeys (Sharp & Hahn, 2011). 
Throughout history, several cross-species transmission events of SIV have occurred, 
generating new strains of virus. For example, SIVcpz is the result of a recombination 
event when two SIVs, SIVrcm and SIVgsn/SIVmus/SIVmon, crossed over from Red-capped 
mangabey and Mona monkey, respectively, into chimpanzees (Bailes et al., 2003). 
Sequentially, the transmission of SIVcpz to humans generated HIV-1, specifically group M 
and N (Gao et al., 1999; Hahn, Shaw, De Cock, & Sharp, 2000; Sharp & Hahn, 2011). 
Meanwhile, group O and P are thought to derive from SIVgor (gorilla), which was the 
product of SIVcpz crossing from chimpanzees into gorillas (D'Arc et al., 2015; Sharp & 
Hahn, 2011). The transmission events of SIVcpz into humans have been estimated to 
date back to the beginning of the 20th century, between 1915 and 1941 (Korber et al., 
2000; Worobey et al., 2008). How these cross-species transmission into humans exactly 
occurred is not known. Most likely, these events occurred via the exchange of blood 




Africans and ape species or in the context of bushmeat consumption (Sharp & Hahn, 
2011).  
Similar to HIV-1, HIV-2 is the result of an independent cross-species transmission. It was 
first identified in 1985 and isolated in 1986 from infected individuals in West Africa (Barin 
et al., 1985; Clavel et al., 1986). Studies revealed that HIV-2 originated from SIVsmm 
(sooty mangabey) (Chen et al., 1996; Gao et al., 1992; Hirsch, Olmsted, Murphey-Corb, 
Purcell, & Johnson, 1989). The original transmission event was dated back to be around 
1940 in Guinea-Bissau (Lemey et al., 2003). Genetically, HIV-1 and HIV-2 shares 
approximately 55% similarity at the nucleotide level (Motomura, Chen, & Hu, 2008). 
Nonetheless, the two viruses differ in pathogenicity and burden on public health. 
Compared to HIV-1, HIV-2 infection appears to be less pathogenic in humans, evident 
by the lower viral loads, the lower rate of transmission, and the lower frequency of 
progression to AIDS (Esbjornsson et al., 2019; Rowland-Jones & Whittle, 2007). 
Consequentially, HIV-2 has not caused a pandemic like HIV-1 (De Cock et al., 1993). 
Instead, HIV-2 has been looked upon as a model for protective immunity to HIV-1 
(Esbjornsson et al., 2019; Rowland-Jones & Whittle, 2007).  
In this dissertation, HIV is used to specifically refer to HIV-1 unless otherwise specified. 
HIV life cycle 
The life cycle of HIV is made up of several steps: attachment and entry, reverse 




The binding of HIV to target cells is mediated by proteins on the viral membrane and 
molecules on the host cell membrane. This attachment promotes the engagement of HIV 
Env(elope) and its primary receptor, CD4, on the host cell (Maddon et al., 1986; 
McDougal et al., 1986; Sattentau & Weiss, 1988). The interaction between Env and CD4 
is the first required step for infection to occur. Env is a glycosylated protein made up 
trimers of gp120 and gp41 heterodimers. Upon the binding of gp120 to CD4, Env 
undergoes conformational changes, allowing for coreceptor engagement to occur. The 
major coreceptors of HIV are chemokine receptors CCR5 and CXCR4 (Alkhatib et al., 
1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; 
Feng, Broder, Kennedy, & Berger, 1996). Once coreceptor engagement occurs, Env 
undergoes further rearrangements, exposing the fusion peptide of gp41. Due to its 
hydrophobic nature, the fusion peptide on each Env trimer can insert itself into the host 
cell membrane, permitting the formation of the six-helix bundle (Melikyan, 2008). The 
fusion of viral membrane and host cell membrane is the last step in the entry process, 
leading to the transport of viral materials into the host cell cytoplasm (Wilen, Tilton, & 
Doms, 2012). 
The next step in the viral life cycle is reverse transcription, which converts the viral (+) 
single-stranded RNA into DNA. The viral reverse transcriptase (RT) is generated via the 
proteolytic cleavage of the Gag-Pol polyprotein by the viral protease (Hu & Hughes, 
2012). HIV RT is a heterodimer of two subunits: p66 and p51 (di Marzo Veronese et al., 
1986; Lightfoote et al., 1986). The process begins with the generation of a (-) DNA 




end, allowing for continuous DNA synthesis. After the generation of (-) DNA strand, the 
(+) strand can be generated using the (-) strand as the template. The final product of 
reverse transcription is the double-stranded DNA version of the HIV genome (Hu & 
Hughes, 2012). Reverse transcription is a key driver of HIV diversity. HIV-encoded RT 
does not have a proofreading function, which results in the introduction of mutations. In 
vitro experiments have indicated that HIV RT can introduce mutations at a rate of 
between 5.9 x 10-4 and 5.3 x 10-5 mutations/base pair/replication cycle (Rezende & 
Prasad, 2004; Svarovskaia, Cheslock, Zhang, Hu, & Pathak, 2003). In addition to the 
infidelity of HIV RT, the family of host proteins known as APOBEC is another major 
contributor of mutations generated during reverse transcription (Hu & Hughes, 2012). In 
fact, 98% of mutations generated during the HIV life cycle are caused by APOBEC 
proteins (Smyth & Negroni, 2016). APOBECs, the most well-known being APOBEC3G, 
are cytidine deaminases. These enzymes are incorporated into newly made HIV virions. 
Upon the generation of the (-) DNA strand during reverse transcription, APOBECs 
convert up to 10% of Cs on this strand into Us (Malim & Bieniasz, 2012). As the result, 
these C-to-U conversions will lead to G-to-A hypermutations in the RNA genome of the 
next round of virion production. 
Once reverse transcription is completed, the newly synthesized HIV DNA genome is 
ready for integration into the host genome. The main orchestrator of this process is the 
virus-encoded enzyme integrase. Similar to RT, integrase is an enzyme generated from 
the cleavage of the Gag-Pol polyprotein. Viral DNA, viral proteins, including integrase,  




membrane and is transported into the nucleus through pore proteins. The first step of 
integration involves 3’ end processing when two nucleotides are removed by integrase. 
In the second step, this enzyme facilitates the attack of 3’ ends of viral DNA strands on a 
pair of phosphodiester bonds on opposite host DNA strands, creating the integration 
immediate. To complete the integration process, the 5’ end overhangs on the viral DNA 
strands are removed, the single-strand gaps are filled, and the 5’ ends of the viral DNA 
are ligated to the host DNA (Craigie & Bushman, 2012). Though HIV integration can 
occur at any location in the host genome, this process preferentially occurs in actively 
transcribed genomic regions (A. R. Schroder et al., 2002). 
The integrated HIV provirus now serves as a template for the production of new virions. 
Viral gene expression is regulated by two viral proteins, Tat and Rev (Karn & Stoltzfus, 
2012). These two proteins are among the first viral proteins produced after infection. 
Transcription is initiated by the recruitment of the host transcription factor NF-κB to the 
HIV long terminal repeat (LTR) region. As transcription generates transactivation-
responsive region (TAR) RNA, Tat and the elongation factor P-TEFb are recruited, 
promoting transcription elongation of viral genes. Viral transcription occurs in two waves. 
Completely spliced mRNAs encoding Tat, Rev, and Nef, are generated first, followed by 
incompletely spliced mRNAs, encoding Env and accessory proteins Vif, Vpr, and Vpu, 
and full-length unspliced mRNAs, encoding the viral RNA genome as well as the Gag-
Pol polyprotein (Karn & Stoltzfus, 2012). These two waves differ based on their 
dependency on Rev. While the first wave is Rev-independent, the second one is Rev-




allows the proper transport of these intron-containing mRNAs to the cytoplasm (Karn & 
Stoltzfus, 2012).  
Upon translation of viral mRNAs in the cytoplasm, viral proteins, cellular tRNA, 
molecules required to initiate cDNA synthesis, and two copies of full-length viral RNA 
genome are packaged into each new virion, which buds out from the host cell using the 
host ESCRT pathway (Sundquist & Krausslich, 2012) . After budding, virions undergo a 
multi-steps maturation process where the viral protease cleaves Gag-Pol polyprotein, 
generating fully processed MA (matrix), CA (capsid), NC (nucleocapsid), p6, PR 
(protease), RT, and integrase (Sundquist & Krausslich, 2012). This maturation process 
results in infectious virions that are ready for the next round of infection. 
HIV pathogenesis  
As mentioned in the previous section, HIV infection requires the expression of CD4 and 
a co-receptor, either CCR5 or CXCR4. Since these molecules are mainly expressed by 
CD4+ T cells, dendritic cells, and monocytes/macrophages, these cells are possible 
cellular targets of HIV. Between the two cell subsets, HIV has a preference for infecting 
CD4+ T cells and more specifically HIV-specific memory CD4+ T cells (Douek et al., 
2002; Klatzmann et al., 1984; Schnittman et al., 1990). 
The acquisition of HIV occurs primarily through the mucosa or blood. Upon transmission, 
the virus can replicate locally at the site of entry prior to disseminating systemically. 
While a large number of virions can be transmitted, most infections are established by 




of mucosal transmission, HIV virions are initially captured by epithelial dendritic cells. 
Subsequently, these cells can transport infectious HIV virions to permissive CCR5+ CD4+ 
T cells, which are abundant in the lamina propria of mucosal tissues (Xu, Wang, & 
Veazey, 2013). Alternatively, free HIV virions can cross from the mucosal epithelium to 
the lamina propria via paracellular passage or transcytosis (Gonzalez, Aguilar-Jimenez, 
Su, & Rugeles, 2019). Initial replication of HIV in mucosal CCR5+ CD4+ T cells establish 
a source of virus and infected cells, which ultimately spread through other sites in the 
body via lymphatic and blood circulation systems (Xu et al., 2013). In the case of 
intravenous transmission, HIV disseminate throughout the entire body as soon as it 
enters the bloodstream, which allows the concurrent establishment of infection at 
multiple sites.  
Early replication of HIV cannot be reliably detected by clinical tests on blood samples. 
This window of time is known as the eclipse phase and can last up to 10 days (Konrad, 
Taylor, Conway, Ogilvie, & Coombs, 2017). Between two and four weeks post-infection, 
HIV replicates vigorously throughout the body, causing high levels of viremia that peak 
at 107 copies of viral RNA (vRNA) per mL blood or more (Coffin & Swanstrom, 2013; 
Robb et al., 2016). Infected individuals commonly experience symptoms associated with 
other viral infections such as fever, sore throat, fatigue, weight loss, and myalgia (T. 
Schacker, Collier, Hughes, Shea, & Corey, 1996). This period is considered as the acute 
phase of infection. During this phase, the HIV reservoir is established and the immune 
response against HIV is initiated. At the end of the acute phase, the level of viremia is 




et al., 2016). Once the viral set point is established four weeks post-infection, the 
infection  enters the chronic phase where viremia persists stably for many years. During 
the chronic phase, the virus and host undergo a co-evolution battle in which the host 
immune system attempts to control/clear the virus while the virus continuously mutates 
in order to escape the pressure exerted by the host immune system (Bonsignori et al., 
2017; Goulder & Watkins, 2004). Unless ART is initiated, the host ultimately loses out to 
the virus and progresses to AIDS within 2-10 years (Giesecke, Scalia-Tomba, 
Hakansson, Karlsson, & Lidman, 1990). 
The first major hallmark of HIV pathogenesis is the progressive loss of CD4+ T cells. In 
fact, the nadir CD4+ T cell count is strongly correlated with disease progression and was 
previously used to determine the initiation of ART (Miller et al., 1999). During the acute 
phase of infection, CD4+ T cells are heavily depleted, especially in the gut mucosa 
(Guadalupe et al., 2003; Veazey et al., 1998). This depletion is likely caused by multiple 
mechanisms including but not limited to the cytopathic effect of viral replication, the 
pyroptotic death of the bystander cells, and the cytotoxic activity of CD8+ T cells (Doitsh 
et al., 2014; Okoye & Picker, 2013).The population of CD4+ T cells lost during the acute 
phase of infection can initially be replenished by the differentiation of central-memory 
CD4+ T cells (TCM) into effector-memory cells (TEM). However, during the chronic phase 
of infection, this replenishment fails over time as the homeostatic quality of TCM gradually 
deteriorates. On one hand, inflammation caused by ongoing viral replication induces 
fibrosis in gut and lymphoid tissues (Deeks, Tracy, & Douek, 2013; J. Estes et al., 2008; 




naïve CD4+ T cells (TN) to key factors required for their maintenance such as IL-7 (Zeng 
et al., 2011). Consequently, the pool of CD4+ TCM and TN ultimately fails to repopulate in 
order to sufficiently replenish the loss of TEM. On the other hand, intrinsic dysfunction of 
CD4+ T cells also contributes to their progressive loss. Evidently, HIV-specific CD4+ T 
cells exhibit a profile of immune exhaustion, in which they upregulate several inhibitory 
receptors such as PD-1, TIM-3, and CTLA-4 (Morou, Palmer, & Kaufmann, 2014). In 
addition, CD4+ T cells from HIV-infected individuals display impaired proliferative 
capacity and an abnormal cytokine profile (Cayota, Vuillier, Scott-Algara, Feuillie, & 
Dighiero, 1992). 
ART initiation can stop the loss and allow the recovery of CD4+ T cells (Ho et al., 1995; 
Wei et al., 1995). However, reconstitution of CD4+ T cells is not completely universal as 
20% of ART-treated individuals do not experience a rise in CD4+ T cell count even in the 
presence of full viral suppression (Piketty et al., 1998). The degree of CD4+ T cell 
recovery have been linked to several factors. Older age, coinfection with hepatitis C 
virus, and a low CD4 nadir contribute toward immunological nonresponsiveness (Wilson 
& Sereti, 2013). High levels of IL-6 and soluble CD14 have also been associated with 
poor CD4+ T cell recovery upon ART initiation (Hernandez-Walias et al., 2020). In 
contrast, a high pre-treatment viral load has been linked to better CD4+ T cell recovery 
during the first three months post-treatment (C. J. Smith et al., 2004). Early initiation of 
ART (< 4 months after the estimated time of HIV infection) is another factor liked to 
enhanced recovery of CD4+ T cell count (Le et al., 2013; Stirrup et al., 2018). 




inflammation, which in turn mitigates the extend of gut and lymphoid fibrosis (Deleage, 
Schuetz, et al., 2016; T. W. Schacker et al., 2005; Schuetz et al., 2014). Not only 
allowing a recovery of CD4+ T cell count early ART treatment also permits recovery in 
CD4+ T cell functionality. In fact, cytokine production (IFNγ) and proliferative capacity of 
HIV-specific CD4+ T cells is preserved when ART is initiated during the acute phase of 
infection (Ndhlovu et al., 2019).  
The second hallmark is chronic inflammation. Acute HIV infection is highly inflammatory 
as evident by an elevation in the frequencies of activated immune cells and in the 
production of proinflammatory cytokines (IL-6, TNF, IP-10, and type 1 interferons) 
(Deeks et al., 2013; Stacey et al., 2009). Immune activation creates a favorable 
environment for HIV replication, as productive infection predominantly occurs in 
activated memory CD4+ T cells (Blankson, Persaud, & Siliciano, 2002; Brenchley et al., 
2004; Stevenson, Stanwick, Dempsey, & Lamonica, 1990). Consequentially, as 
discussed above, CD4+ T cells are heavily depleted during acute infection (Douek, 
Picker, & Koup, 2003). After the acute phase, inflammation is not resolved but reaches a 
steady-state level and persists throughout the chronic phase (Klatt, Chomont, Douek, & 
Deeks, 2013). Chronic immune activation is often monitored by the frequencies of 
activated T cells expressing CD38 and HLA-DR  and the plasma levels of 
proinflammatory biomarkers such as IL-6, lipopolysaccharide, soluble CD14, soluble 
CD163, and IDO (Klatt, Chomont, et al., 2013). This steady-state level of inflammation is 
predictive of the rate of CD4+ T cell decline, plasma viral RNA level, and disease 




Microbial translocation is a key driver of chronic inflammation in HIV infection (Klatt, 
Funderburg, & Brenchley, 2013; Sandler & Douek, 2012). The phenomenon occurs as 
the integrity of the gut mucosal barrier is damaged, allowing microbes and microbial 
products, which are restricted to the gut lumen during homeostasis, to enter the lamina 
propria and gain access to the bloodstream (Sandler & Douek, 2012). In fact, HIV-
infected individuals and SIV-infected rhesus macaques have an increased plasma level 
of lipopolysaccharide, an indication of microbial translocation. The circulation of 
lipopolysaccharide triggers the secretion of soluble CD4 by activated 
monocytes/macrophages, which contributes to the systemic immune activation. In 
addition, an elevation in  plasma level of lipopolysaccharide is correlated with increased 
T cell activation and IFNα production (Brenchley et al., 2006). Microbial translocation 
happens early during infection, as early as 8-14 days post-infection in SIV-infected 
rhesus macaques (Ericsen et al., 2016; J. D. Estes et al., 2010). The cause of microbial 
translation involves the disruption of the gut epithelium and potentially the loss of gut IL-
17-producing CD4+ T cells (Klatt, Funderburg, et al., 2013; Sandler & Douek, 2012). 
During acute HIV infection, a large amount of gut epithelial cells undergo apoptosis, 
resulting in a loss of tight junction formation and an increase in barrier permeability to 
microbes (Epple et al., 2010; J. D. Estes et al., 2010). In addition, as previously 
discussed, CCR5+ CD4+ T cells in the gut are heavily depleted during HIV infection. 
Since these cells are crucial in maintaining gut homeostasis via IL-17 and IL-22 
secretion, their loss compromises the antimicrobial immunity in the gut (Bettelli, Korn, 




producing CD4+ T cells is positively correlated with plasma viremia (Cecchinato et al., 
2008). Other mechanisms such as decreased clearance of bacterial products from the 
gut by phagocytic cells can also contribute to the microbial translocation observed in HIV 
infection (J. D. Estes et al., 2010; Sandler & Douek, 2012).  
The levels of immune activation and microbial translocation are significantly reduced 
upon ART initiation. However, they are still higher than in HIV-uninfected individuals 
(Brenchley et al., 2006; Hunt et al., 2008). This is true even when ART is started early  
during acute infection (Deleage, Schuetz, et al., 2016; Hunt, Lee, & Siedner, 2016; 
Ponte et al., 2016; Sereti et al., 2017). Chronic inflammation can drive HIV persistence 
under ART as evident by the positive association between the level of T cell activation 
and the level of cell-associated HIV DNA or RNA (Hatano et al., 2013; Yukl et al., 2010). 
Mechanistically, this correlation can be due the continuous generation of target cells and 
progressive immune dysfunction (Klatt, Chomont, et al., 2013). In return, HIV 
persistence, combined with the replication of co-infecting pathogens such as 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV), can drive further inflammation, 
generating a positive feedback loop that makes inflammation-associated conditions, 
such as cardiovascular diseases, major comorbidities in ART-treated individuals (Deeks 
et al., 2013; Lerner, Eisinger, & Fauci, 2019).  
Another hallmark of HIV pathogenesis is the establishment of persisting viral reservoirs. 
As a retrovirus, HIV integrates its genome into the host’s genome upon infection. 
Consequently, the virus persists for the life of the infected cells as well as their daughter 




obstacle for curing individuals of HIV. Despite the effectiveness of ART in keeping 
plasma viremia below detectable levels by clinical standards (<40 copies/mL), HIV can 
rebound as quickly as 1-6 weeks of treatment interruption (Colby et al., 2018). 
Furthermore, it has been estimated to take approximately 73.4 years of continuous ART 
treatment to fully eradicate all HIV reservoirs in an individual (Siliciano et al., 2003). This 
estimation rules out the feasibility of using ART as the sole cure agent. 
The seeding of viral reservoirs occurs very early during the acute phase of infection. In 
rhesus macaques, SIV reservoirs are seeded within 2-5 days following intrarectal or 
intravenous infection, which precedes the onset of plasma viremia (Okoye et al., 2018; 
Whitney et al., 2014). In humans, the initiation of ART as early as during Fiebig I, the 
clinical stage when HIV RNA is first detectable in plasma (Fiebig et al., 2003), cannot 
prevent viral rebound upon therapy cessation, indicating that reservoirs are seeded 
within the first two weeks of infection (Colby et al., 2018). However, limiting the size and 
changing the cellular composition of HIV reservoirs with early ART treatment can 
sometimes result in long-term virologic remission. In fact, ART initiation on day 4-5 but 
not day 6-12 after SIV infection reduces the size of viral reservoirs and prevents viral 
rebound after treatment interruption with up to 9 months of follow-up (Okoye et al., 
2018). Similarly, some HIV-infected individuals who receive ART during the acute phase 
of infection (between Fiebig I and V) experience virologic remission for a median of 89 
months (Saez-Cirion et al., 2013). In these individuals, the cellular composition of virus-
harboring cells shift from longer-lived CD4+ TCM to shorter-lived transitional memory (TTM) 




HIV reservoirs are found to be distributed throughout the body. In rhesus macaques, 
most SIV vRNA+ cells in the body are actually located in lymphoid tissues, such as the 
gut and lymph nodes (LNs). In contrast, only 0.2% of vRNA+ cells are found in the blood 
(J. D. Estes et al., 2017). In humans, lymphoid tissues have been shown to be critical 
sites of HIV reservoirs during the chronic phase of infection (Pantaleo et al., 1991; 
Pantaleo et al., 1993; Pantaleo et al., 1994). Viral reservoir in tissues will be discussed in 
detail in section 1.7. 
1.3 HIV elite controllers (ECs) 
Identification of ECs 
While the majority (99%) of HIV-infected individuals progress to AIDS in the absence of 
ART, a rare subset of infected individuals can achieve spontaneous and durable control 
of HIV replication. Multiple terms have been used to described these individuals 
including long-term non progressors (LNTPs), viremic controllers, and elite controllers 
(ECs) (Deeks & Walker, 2007). LNTPs is the broadest term used to describe HIV-
infected individuals who maintain a normal amount of CD4+ T cells count and do not 
show any clinical progression towards AIDS regardless of viral loads. These individuals 
make up approximately 5%-15% of all infected individuals (Cao, Qin, Zhang, Safrit, & 
Ho, 1995; Deeks & Walker, 2007; Munoz et al., 1995; Pantaleo et al., 1995; Sheppard, 
Lang, Ascher, Vittinghoff, & Winkelstein, 1993). Once methods for measuring viral load 
became available in the mid 1990s, this criteria was used to define HIV non-progressors, 




load of 50-2000 copies/mL and are present at a prevalence of 2%-4% of all infected 
individuals, ECs <50 copies/mL and  <1% (Deeks & Walker, 2007; Hubert et al., 2000; 
Okulicz et al., 2009). Using ultrasensitive assays, on average 2.3 (0.2-14) copies of HIV 
RNA/mL are detected in the plasma of ECs (Pereyra et al., 2009). 
Earliest documented cases of ECs were the Sydney Blood Bank Cohort. In 1991, six 
individuals in New South Wales, Australia were identified to have remained clinically 
asymptomatic despite acquiring HIV via blood transfusions in the mid 1980s from a 
single common HIV-positive but asymptomatic donor (J. Learmont et al., 1992; 
Zaunders, Dyer, & Churchill, 2011). The donor, a homosexual man, was first recruited to 
the Sydney AIDS Prospective Study in 1984 when he was tested negative for HIV p-24 
antigen but positive for anti-HIV antibodies (J. Learmont et al., 1992). The fact that this 
donor had anti-HIV antibodies indicates that he had been infected with HIV despite the 
lack of viremia. The six recipients had received blood transfusions from this donor 
between 1982 and 1984 (J. Learmont et al., 1992). Though they were diagnosed with 
HIV infection in follow-ups, these individuals maintained stable CD4+ T cell counts and 
showed no signs of disease progression up to 7 to 10 years after infection (J. Learmont 
et al., 1992). Notably, all seven individuals, including the donor, did not receive any 
antiretroviral therapy (J. Learmont et al., 1992).  
Determinants of ECs 
What are determinants of ECs? Characterization of the HIV isolated from individuals in 




attenuated strain containing deletions in the nef  and U3-LTR regions (Deacon et al., 
1995). Therefore, elite control of HIV replication was originally thought to be entirely due 
to defective viral fitness. However, longitudinal follow-ups revealed that three out of the 
six recipients as well as the donor eventually displayed a low amount of viremia, ranging 
from 600 to 2500 copies/mL (J. C. Learmont et al., 1999; Zaunders et al., 2011). 
Especially, the donor showed symptoms of HIV-associated dementia and a viral load in 
cerebrospinal fluid of 750000 copies/mL in 1998, which was 14 years after the first 
positive test for anti-HIV antibodies (Churchill et al., 2004; Zaunders et al., 2011). These 
results suggested that the non-progression observed in the Sydney Blood Bank Cohort 
was not simply caused by infections with unfit viruses as these viruses were replication 
competent and ultimately caused disease. HIV isolated from other EC cohorts has been 
shown to robustly replicate in vitro,  generally lack genetic defects, and continuously 
evolve, which together further argue against low viral fitness as the main determinant of 
ECs (Blankson et al., 2007; Julg et al., 2010; Lamine et al., 2007; Mens et al., 2010; 
Miura et al., 2008).  
Currently, it is widely agreed that host factors, rather than viral factors, are mostly 
responsible for the EC status. Genetic studies have shown that certain HLA class I 
alleles such as B*5701 or B*27 are strongly enriched in EC populations (Bailey, 
Williams, Siliciano, & Blankson, 2006; Lambotte et al., 2005; Migueles et al., 2000; 
Pereyra et al., 2008). Conversely, certain alleles such as B*0702 and B*35 are more 
associated with disease progression (Emu et al., 2008; International et al., 2010); 




(Kloverpris et al., 2014; Matthews et al., 2012). Mechanistically, the quality of immune 
responses targeting epitopes presented by each HLA allele is likely responsible for the 
association between these alleles and either elite control or disease progression 
(Goulder & Walker, 2012; Kiepiela et al., 2007). However, the presence of “favorable” 
HLA alleles does not guarantee the establishment of the EC status (Emu et al., 2008). 
Vice versa, the presence of “unfavorable” does not preclude individuals from becoming 
ECs (Bendenoun et al., 2018; Emu et al., 2008). 
It has been proposed that CD4+ T cells from ECs are more resistant to HIV infection. 
Intracellular restriction factors such as APOBEC3G, BST2/tetherin, and TRIM5α can 
interfere with various stages in the HIV life cycle (Neil, Zang, & Bieniasz, 2008; Sheehy, 
Gaddis, Choi, & Malim, 2002; Stremlau et al., 2004; Van Damme et al., 2008). However, 
expression levels of these molecules were found to be no higher in ECs compared to 
non-ECs (Abdel-Mohsen et al., 2013). Concurrently, CD4+ T cells from ECs are not more 
resistant to HIV infection than CD4+ T cells from non-ECs (Julg et al., 2010; O'Connell, 
Rabi, Siliciano, & Blankson, 2011; Saag & Deeks, 2010). These results argue that 
effective immunity targeting infected cells rather than elevated intrinsic resistance to 
infection is more likely the main mechanism maintaining the undetectable viral loads in 
ECs.  
Various aspects of innate and adaptive immunity against HIV in ECs have been 
examined. Regarding innate immunity, natural killer (NK) cells have been suggested to 
play a role in ECs. The epistatic interaction of the KIR3DS1 allele, an activating receptor 




progression to AIDS (Martin et al., 2002). In vitro experiments have functionally 
confirmed this association where compared to those not bearing the KIR3DS1 allele, NK 
cells bearing the KIR3DS1 allele show superior ability to inhibit HIV replication in target 
cells expressing HLA-B Bw4-80 (Alter et al., 2007). In addition, ECs have a higher 
frequency of the CD11b+ CD57- CD161+ Siglec-7+ subpopulation of CD56dim CD16+ NK 
cells in their blood compared to non-controllers. This specific subpopulation of NK cells 
displays increased functionality compared to other subpopulations, as evident by a 
higher frequency interferon γ (IFNγ)+ and CD107a+ cells (Pohlmeyer et al., 2019). 
However, NK cells from ECs are phenotypically similar to NK cells from ART-treated 
patients, implying that NK cells might not be directly responsible for viral control in ECs 
(Barker, Martinson, Brooks, Landay, & Deeks, 2007). Therefore, it is unclear how 
significantly NK cells contribute to the EC status. Another population of innate immune 
cells that has been studied in ECs is plasmacytoid dendritic cells (pDCs). The quantity of 
these cells is preserved in ECs but not in ARTs and CPs (Machmach et al., 2012). Also, 
pDCs from ECs produce a higher amount of IFNα, which directly suppresses HIV 
replication in vitro, and better induce apoptosis of infected-CD4+ T cells through the 
expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) (Barblu et 
al., 2012; Machmach et al., 2012). Nevertheless, the in vivo importance of these effector 
functions exerted by pDCs remained to be examined. Though innate immunity possibly 
play a role the control of HIV in ECs, its direct contribution is unclear. This is partially due 




phase of infection whereas innate immunity primarily exerts its function during the acute 
phase of infection. 
On the other hand, the contribution of adaptive immunity, including both humoral and 
cell-mediated, to the EC status has been extensively investigated. Several lines of 
evidence; including low titers of neutralizing antibodies as well as low degree of 
sequence diversity, few N-linked glycosylation sites, and short variable loops in HIV env; 
suggest that humoral immunity does not exert a strong pressure on viruses in ECs and 
is not a key contributor to the EC status (Bailey, Lassen, et al., 2006; Deeks et al., 2006; 
Pereyra et al., 2008).  
In contrast, cell-mediated immunity has emerged as the clearest and most robust 
correlate of the EC status. Despite being a major target of HIV infection, CD4+ T cells 
from ECs are still highly functional. Indeed, HIV-specific CD4+ T cells are present at a 
higher frequency in ECs than in non-controllers (Ferrando-Martinez et al., 2012). These 
cells have low co-expression of inhibitory receptors, such as PD-1, TIGIT, and CTLA-4, 
implying that they are not exhausted (Noyan, Nguyen, Betts, Sonnerborg, & Buggert, 
2018). Consequentially, upon stimulation, HIV-specific CD4+ T cells can robustly 
proliferate and are highly polyfunctional, evident by their production of multiple cytokines, 
such as IL-2, TNF, IFNγ, and beta-chemokines (Emu et al., 2005; Harari, Petitpierre, 
Vallelian, & Pantaleo, 2004; Rosenberg et al., 1997). These cytokines can either have a 
direct effect by suppressing HIV replication or an indirect effect by boosting the CD8+ T 
cell response. Though cytolytic activity is often ascribed to CD8+ T cells, a subset of 




individuals, cytolytic CD4+ T cells are identified by their expression of CD57 (Johnson et 
al., 2015). These cells are maintained in ECs but not in non-controllers (Phetsouphanh 
et al., 2019). In addition, they emerge early during infection and are associated with a 
lower viral set point (Johnson et al., 2015; Soghoian et al., 2012). However, the 
importance of cytolytic CD4+ T cells in ECs has been called into question as these cells 
are relatively absent from lymphoid tissues (LTs) of ECs (Buggert, Nguyen, McLane, et 
al., 2018). 
Similar to CD4+ T cells, multiple aspects of CD8+ T cell response have been correlated 
with the ECs. These aspects are going to be discussed in more detailed in section 1.6.  
1.4 CD8+ T cell subsets and their trafficking properties 
CD8+ T cells were originally recognized as a distinct subset of T lymphocytes in 1975 
(Cantor & Boyse, 1975; Kisielow et al., 1975; Shiku et al., 1975). At this point, it was 
thought that all CD8+ T cells are homogenous and can recirculate between blood, non-
lymphoid tissues, and lymphoid tissues. However, in the late 1990s and early 2000s, 
phenotypic heterogeneity of CD8+ T cells began to be elucidated. In 1999, TCM and TEM 
were described as distinct subsets of memory CD8+ T cells (Sallusto, Lenig, Forster, 
Lipp, & Lanzavecchia, 1999). TCM  preferentially home to secondary lymphoid organs 
due to their high expression of CCR7 and CD62L. Meanwhile, TEM do not express CCR7 
and CD62L, therefore preferentially home to inflamed peripheral tissues instead of 
secondary lymphoid organs (Sallusto et al., 1999). In terms of functions, TEM can readily 




TCM preferentially produce IL-2, lack immediate cytotoxic function, but are highly 
proliferative (Sallusto, Geginat, & Lanzavecchia, 2004; Sallusto et al., 1999). Similar to 
TCM, stem-cell memory T cells (TSCM) are a rare subset of memory cells that have a long 
life spans and high proliferative capacity (Gattinoni et al., 2011; Gattinoni, Speiser, 
Lichterfeld, & Bonini, 2017). Upon stimulation, TCM (or T`SCM) can proliferate and 
differentiate into TEM (Sallusto et al., 2004; Schmueck-Henneresse et al., 2015). This 
observation leads to the classic model that TEM are the cells that surveil peripheral 
tissues and respond immediately to an insult while TCM surveil lymphoid tissues and 
serve as the reservoir that can resupply the TEM population during the course of a 
response. This model was recently refined using the expression pattern of the fractalkine 
receptor CX3CR1(Bottcher et al., 2015; Gerlach et al., 2016). According to this new 
model, CX3CR1- memory T cells coincides with TCM while CX3CR1+ cells can be 
subdivided into CX3CR1hi, which coincides with TEM, and CX3CR1int, which is termed 
peripheral memory cells (Gerlach et al., 2016). It is the peripheral memory cells but not 
TEM cells that surveil peripheral tissues.  
Another subset of CD8+ T cells with distinct trafficking properties was described in 2001 
and these cells are tissue-resident memory cells or TRM (Masopust, Vezys, Marzo, & 
Lefrancois, 2001). Recent studies have clearly demonstrated the critical role of TRM in 
anti-pathogen and anti-tumor immunity (Amsen, van Gisbergen, Hombrink, & van Lier, 
2018; Muruganandah, Sathkumara, Navarro, & Kupz, 2018). Similar to TEM, these cells 
also do not express CCR7. However, instead of recirculating in a similar pattern to TEM, 




Tissue residency is largely established through the upregulation of CD69, which 
downregulates the expression of the tissue-egress receptor sphingosine-1-phosphate 
receptor 1 or S1PR1 (Bankovich, Shiow, & Cyster, 2010; Mackay, Braun, et al., 2015; 
Skon et al., 2013). Under homeostasis, T cells exit LNs by following a gradient of 
sphingosine-1-phosphate toward peripheral blood (Baeyens, Fang, Chen, & Schwab, 
2015). Therefore, the downregulation of S1PR1 mediated by CD69 prevents cells from 
leaving tissues and allows them to stay resident. Another molecule that has been 
implicated in the mechanism of residency is CD103. This is an integrin (αΕ) that 
interacts with E-cadherin to act as a tether for cell retention within a tissue. Its 
expression appears to be more common on TRM in the epithelia than in other locations 
(Topham & Reilly, 2018). Though CD69 and CD103 are canonical markers used to 
identify TRM, these cells can be distinguished from other subsets by their unique 
transcriptional program, including but not limited to the upregulation of transcription 
factors such as TCF-1, Blimp-1, Hobit, and Runx3 (Behr, Chuwonpad, Stark, & van 
Gisbergen, 2018).  
1.5 Effector functions of CD8+ T Cells 
Cytotoxicity 
The first major effector function of CD8+ T cells is cytotoxicity. Though it was first 
observed in the early 1920s by James Murphy through a series of experiments on the 
rejection of allograft tumors, cytotoxicity was not ascribed to T cells, specifically CD8+ T 




then, the exact mechanisms of how CD8+ T cells execute their cytotoxic functions have 
been well worked-out. Upon the recognition of their cognate antigens that are presented 
on MHC-class I molecules, CD8+ T cells undergo major cytoskeletal reorganization in 
order to form an immunological synapse with their targets (Griffiths, Tsun, & 
Stinchcombe, 2010). This formation of the immunological synapse allows the CD8+ T 
cells to release lytic granules containing perforin and granzymes, which trigger apoptosis 
in the target cells (Peters et al., 1991). 
Perforin, also known as Perforin-1, was first isolated from lytic granules of CD8+ T cells 
in the mid 1980s (Henkart, Millard, Reynolds, & Henkart, 1984; Podack, Young, & Cohn, 
1985). It is a 67 kDa protein with structural homology to the complement component C9. 
Upon release, perforin monomers can oligomerize on the membrane of target cells in a 
Ca2+-dependent manner. This oligomerization results in the formation of pores on the 
membrane of target cells in a similar fashion as the complement system (Lichtenheld et 
al., 1988; Shinkai, Takio, & Okumura, 1988; Tschopp, Masson, & Stanley, 1986; Young, 
Cohn, & Podack, 1986). The activity of perforin is highly independent on pH and Ca2+ as 
it is only active at a neutral pH and an Ca2+ concentration of at least approximately 
100μM (Young, Damiano, DiNome, Leong, & Cohn, 1987). Therefore, perforin is inactive 
when it is stored in the acidic environment of secretory lysosomes, which prevents the 
self-destruction of CD8+ T cells (Voskoboinik, Whisstock, & Trapani, 2015).  
Granzymes, which are also known as granule-associated enzymes, are a family of 30-50 
kDa serine proteases that are found in lytic granules of CD8+ T cells along with perforin 




in humans (A, B, H, K, and M) and ten in mice (A, B, C, D, E, F, G, L, M, and N) 
(Chowdhury & Lieberman, 2008). Among all the granzymes, granzyme B has been the 
most well studied given its high abundance in both human and mouse CD8+ T cells as 
well as its well-established function in cell-mediated cytotoxicity. Granzyme B is highly 
expressed by late-differentiated cells, such as TEM and TEMRA (Takata & Takiguchi, 
2006). Upon delivery to target cells, granzyme B triggers apoptosis by directly cleaving 
the executor caspase, caspase-3 (Darmon, Nicholson, & Bleackley, 1995). In addition, it 
can cleave caspase-8, PARP-1, BID, lamin B, ICAD, DNA-PK, and Nu-Ma, all of which 
can lead to the death of target cells (Chowdhury & Lieberman, 2008). 
Though the delivery of granzyme B, as well as other granzymes, to target cells is mainly 
mediated by perforin, the specific mechanism of this process has been a topic of 
controversy and extensive investigation. It is generally thought that granzymes enter the 
cytosol of target cells through membrane pores created by perforin (Masson & Tschopp, 
1985; Tschopp et al., 1986). In fact, the crystal structure of perforin and the three-
dimensional reconstruction of perforin pores suggest that the lumen of these pores is 
130-300 Å, which is sufficient to allow the entrance of granzymes, including granzyme B, 
into target cells (Law et al., 2010). Alternatively, as the two cytolytic molecules are taken 
up together by target cells through endocytosis or macropinocytosis, perforin can pore 
the endosomal membrane to trigger granzyme B delivery into the cytoplasm (Thiery et 
al., 2011; Trapani et al., 2003). There is also evidence for perforin-independent 
endocytosis of granzyme B (Froelich et al., 1996; Motyka et al., 2000). In fact, granzyme 
B can autonomously cross the plasma membrane in the absence of perforin (Shi et al., 




6-phosphate receptor in perforin-independent delivery of granzyme B into target cells 
(Dressel et al., 2004; Motyka et al., 2000; Trapani et al., 2003).  
Despite the debate on the exact mechanism of granzyme B delivery by perforin, there is 
a strong consensus on the essence of both molecules in CD8+ T cell-mediated 
cytotoxicity. Perforin deficiency in mice and humans both result in impaired immunity 
against viral infection and tumors (Davis, Smyth, & Trapani, 2001; Kagi et al., 1994; 
Stepp et al., 1999). In addition, though it can bind to and enter target cells, soluble 
granzyme B cannot trigger apoptosis in the absence of perforin (Froelich et al., 1996; Shi 
et al., 2005). On the other hand, granzyme B-deficient CD8+ T cells are less efficient in 
inducing DNA fragmentation and apoptosis in allogenic target cells compared to wild-
type cells (Davis et al., 2001; Heusel, Wesselschmidt, Shresta, Russell, & Ley, 1994). 
These cells are also impaired in mediating graft versus host disease in mice (Graubert, 
Russell, & Ley, 1996). In most circumstances, the cooperation between perforin and 
granzyme B is required to achieve maximal killing efficiency.  
In addition to perforin and granzyme B, lytic granules of CD8+ T cells contain other 
proteins with cytotoxic activities. Granulysin is a pore-forming protein that belongs to the 
saposin-like protein family. It is synthesized in the full length but inactive form of 15 kDa. 
Proteolytic cleavage of the full length protein generates the active form of 9 kDa 
granulysin (Dotiwala & Lieberman, 2019; Krensky & Clayberger, 2009). Though both 
forms are found in cytoplasmic granules, only the 9 kDa active form of granulysin is 
found in secretory lytic granules (Pena, Hanson, Carr, Goralski, & Krensky, 1997). The 




lipids leads to the release of cytochrome c, caspase-3 activation, and eventually 
apoptosis in target cells (Anderson et al., 2003; Kaspar et al., 2001). Granulysin has 
been shown to be important in anti-microbial immunity. Upon delivery to infected cells by 
perforin, granulysin can deliver granzymes into intracellular parasites such as T.cruzi, T. 
gondii, L. major, and P. vivax, and intracellular bacteria such as E. coli, 
L.monocytogenes, and S. aureus, causing the generation of superoxide in these 
microbes and their death (Dotiwala & Lieberman, 2019; Dotiwala et al., 2016; Junqueira 
et al., 2018; Krensky & Clayberger, 2009; Walch et al., 2014). Different from perforin, 
which has a preference for cholesterol-rich plasma membrane of mammalian cells, 
granulysin has a preference for cholesterol-poor plasma membrane, which is typically 
found in bacteria and parasites (Barman et al., 2006). Therefore, granulysin is generally 
thought to be less important than perforin when it comes to targeting virally infected and 
cancerous mammalian cells. However, there are precedents for the involvement of 
granulysin in these forms of immunity. Granulysin is capable of inducing lysis of YAC-1 
tumor cells in vitro, as measured by 51Cr-release (Pena et al., 1997). This result has 
been extended to multiple myeloma cell lines and primary tumors from B-CLL patients 
(Aporta et al., 2014).  The model of athymic “nude” mouse receiving human breast 
adenocarcinoma or multiple myeloma xenografts has demonstrated a protective role of 
granulysin in vivo (Al-Wasaby et al., 2015).  
Other granzymes beside granzyme B can induce apoptosis in target cells. Granzyme A, 
which along with granzyme B is the most abundant granzyme in human and mouse 
CD8+ T cells, can trigger cell death in a caspase-independent manner. This granzyme is 




complex, a protein complex that protects cells from DNA damage, which allows the 
nuclear endonuclease NM23-H1 to generate single-strand DNA nicks (Chowdhury & 
Lieberman, 2008; Lieberman, 2003). Granzyme K is also found in both human and 
mouse CD8+ T cells, though at a much lower level (Bratke, Kuepper, Bade, Virchow, & 
Luttmann, 2005). The mechanism of apoptosis induction by granzyme K is similar to that 
of granzyme A. Though granzyme M can initiate apoptosis, there are conflicting reports 
on whether the process is caspase dependent or independent (Chowdhury & Lieberman, 
2008). The expression of this granzyme is originally thought to be restricted to innate 
immune cells such as NK cells but has recently been shown to be expressed by CD8+ T 
cells (de Koning et al., 2010; Sayers et al., 2001). Little is known about granzyme H 
except the fact that it is highly homologous to granzyme B and induces apoptosis 
independent of caspase-3 activation and of cytochrome c release. In addition, its role in 
cell-mediated cytotoxicity is likely limited to NK cells, given its expression is not 
detectable in CD8+ T cells (Chowdhury & Lieberman, 2008; Fellows, Gil-Parrado, Jenne, 
& Kurschus, 2007; Sedelies et al., 2004). 
The knock-out of perforin and/or granzyme B in mouse models resulted in major, but 
incomplete, reduction in target cell killing, indicating the existence of an alternative 
mechanism of CD8+ T cell-mediated cytotoxicity. Cell surface receptor-mediated 
cytotoxicity is one such alternative mechanism. The main mediators of this mechanism 
are Fas/FasL and the TNF-related apoptosis-inducing ligand (receptor) TRAILR/TRAIL 
(Brincks, Katewa, Kucaba, Griffith, & Legge, 2008; Falschlehner, Schaefer, & Walczak, 
2009; Lowin, Hahne, Mattmann, & Tschopp, 1994; Rouvier, Luciani, & Golstein, 1993). 




receptor (either Fas or TRAILR) on the surface of target cells recruits pro-caspase 8 to 
the cytoplasmic domain of Fas, initiating the cleavage of pro-caspase 8 to active 
caspase 8. Once activated, caspase 8 can cleave Bid, resulting in mitochondrial 
membrane damage and the release of cytochrome C, which ultimately triggers apoptosis 
in target cells. In contrast to perforin-mediated cytotoxicity, cell surface receptor-
mediated cytotoxicity is Ca2+-independent (Rouvier et al., 1993).  
Cytokine and chemokine secretion 
In addition to cytotoxicity, cytokine secretion is another important effector function of 
CD8+ T cells. This effector function can either exert direct antimicrobial activities or 
regulate adaptive immune responses. Early studies on alloreactive CD8+ T cell clones 
showed that these cells could secrete cytokines such as IFNγ, TNF and IL-2, similar to 
TH1 CD4+ T cells (Fong & Mosmann, 1990). In addition, the ability of CD8+ T cells to 
concurrently produce multiple cytokines, which is also known as polyfunctionality, has 
been correlated to control of viral infections such as HIV and EBV (Betts et al., 2006; 
Lam et al., 2018) 
IFNγ is the only member of type II IFN. Though various immune cell subsets can 
produce IFNγ, CD4+ and CD8+ T cells are major producers of this cytokine during 
adaptive immune responses (K. Schroder, Hertzog, Ravasi, & Hume, 2004). During the 
initiation of an adaptive immune response, IFNγ produced by CD8+ T cells synergizes 
with IL-12 produced by antigen presenting cells to polarize CD4+ T cells toward a TH1 




2001; Szabo et al., 2002; Teixeira et al., 2005). Besides its role in regulating adaptive 
immune responses, IFNγ can directly inhibit viral replication (Wheelock, 1965).  
TNF is another major cytokine that can be produced by CD8+ T cells. It can be 
expressed in a transmembrane form as well as secreted in a soluble form after cleavage 
by ADAM family metalloprotease. Both forms have been shown to be biologically active. 
For example, while soluble TNF is critical for controlling primary Listeria infection, 
transmembrane TNF is sufficient for controlling secondary infection (Mehta, Gracias, & 
Croft, 2018). In addition to its direct antimicrobial effect, TNF can modulate immune 
responses by signaling through its receptor TNFR1/2. Specifically, it can increase the 
ability of CD8+ T cells to produce cytokine, proliferate, and survive during the priming 
phase of immune responses. However, TNF signaling can induce apoptosis of effector 
CD8+ T cells during the contraction phase (Mehta et al., 2018).  
Though IL-2 produced by CD8+ T cells does not have a direct antiviral effect, it is an 
important regulator of adaptive immune responses. Autocrine IL-2 aids CD8+ T cell 
proliferation during the primary and secondary expansion. In addition, it is mainly 
produced by less differentiated populations of CD8+ T cells such as central memory cells 
(Wherry et al., 2003).  
Beside the cytokines mentioned above, CD8+ T cells can secrete other interleukins. IL-
17-producing CD8+ T cells can concurrently produce other cytokines including IL-21, IL-
22, TNF, and IFNγ. These cells have been largely associated with inflammatory 
diseases such as psoriasis, multiple sclerosis, and type-1 diabetes (Srenathan, Steel, & 




their cytotoxic capacity as well as their ability to attract inflammatory immune cells to 
sites of inflammation (Ciric, El-behi, Cabrera, Zhang, & Rostami, 2009). IL-9 producing 
CD8+ T cells have been shown be more potent than classical type-1 CD8+ T cells at 
antitumor responses (Lu et al., 2014; Lu et al., 2012). IL-4, IL-5, and IL-10 producing 
CD8+ T cells have also been identified. These cells can either enhance type-2 immune 
responses, providing B cell help or suppressing type-1 immune responses (Le Gros & 
Erard, 1994). 
Similar to cytokines, chemokines are soluble molecules. However, their main function is 
to direct traffic of immune cells. The ability of CD8+ T cells to secrete chemokines has 
been demonstrated. One such family of chemokines are beta-chemokines, including 
CCL3, CCL4, and CCL5. These molecules bind to their cognate receptor CCR5 to 
recruit cells to sites of inflammation. Their production by CD8+ T cells have exhibited a 
protective role in HIV infection (Cocchi et al., 1995). Another chemokine that is produced 
by CD8+ T cells is CXCL10. In response to CD27/CD70 co-stimulation, CD8+ T cells 
produce CXCL10 to recruit other primed CD8+ T cells within a LN to form a pool of CD8+ 
effector T cells (Peperzak et al., 2013). 
1.6 CD8+ T cells in anti-HIV immunity 
Shortly after the identification of HIV as the etiological agent of AIDS, HIV-specific CD8+ 
T cells were detected in HIV-seropositive individuals (B. D. Walker et al., 1987; C. M. 
Walker, Moody, Stites, & Levy, 1986). These cells are detectable as early as day 3 post-
infection (Ndhlovu, Kamya, et al., 2015). The emergence of virus-specific CD8+ T cells 




viral control (Borrow, Lewicki, Hahn, Shaw, & Oldstone, 1994; Demers et al., 2016; Koup 
et al., 1994; Ndhlovu, Stampouloglou, et al., 2015). This concept was definitely 
demonstrated in the rhesus macaque model where the depletion of CD8+ T cells in SIV-
infected animals, both during acute and chronic phases of infection, resulted in a 
complete loss of viral control (Fukazawa et al., 2015; Jin et al., 1999; Matano et al., 
1998; Schmitz et al., 1999). Even when the viral load is extremely low during ART, CD8+ 
T cells still actively antagonize viral replication as their removal results in an increase in 
viremia (Cartwright et al., 2016). Genetic and virologic studies have also implicated an 
important role of CD8+ T cells in controlling HIV. As mentioned in section 1.3, within the 
EC population, there is an enrichment of specific HLA alleles such as HLA-B*5701 and 
B*27, which implies the involvement of CD8+ T cells in viral control (Bailey, Williams, et 
al., 2006; Lambotte et al., 2005; Migueles et al., 2000; Pereyra et al., 2008). Longitudinal 
analyses of viral sequences reveal that HIV continuously mutates in order to escape 
from the immune pressure exerted by CD8+ T cells (T. M. Allen et al., 2005; T. M. Allen 
et al., 2000; Barouch et al., 2002; Borrow et al., 1997; N. A. Jones et al., 2004; Phillips et 
al., 1991). Together, these findings argue that CD8+ T cells are an essential immune 
subset for HIV control. 
HIV-specific CD8+ T cells are detectable in all chronically infected individuals and they 
can target all viral proteins (Betts et al., 2001). These cells have a skewed maturation 
phenotype. They predominantly (70%) are CCR7- CD45RA-/CD45RO+ CD27+, which 
reflects a TTM phenotype . This is in stark contrast with CMV-specific CD8+ T cells where 
most cells are TEMRA (CCR7- CD45RA+/CD45RO- CD27-) (Appay et al., 2000; 




of producing antiviral cytokines such as IFNγ, TNF, and MIP-1β but are impaired in their 
cytolytic function, typified by a low frequency of perforin+ cells and low ex vivo target 
lysis capacity (Appay et al., 2000). However, this cytolytic capacity is dynamic 
throughout the course of infection as it is high during the acute phase before collapsing 
as the infection moves into the chronic phase (Demers et al., 2016; Roberts et al., 2016; 
Trautmann et al., 2012). In addition to the low cytotoxicity, HIV-specific CD8+ T cells 
have a low proliferative capacity upon activation (Appay et al., 2000). This diminished 
proliferation is linked to immune exhaustion, a phenomenon caused by prolonged 
antigen during chronic viral infections and cancers (McLane, Abdel-Hakeem, & Wherry, 
2019). HIV-specific CD8+ T cells, indeed, exhibit a molecular profile of exhaustion 
including the expression of multiple inhibitory receptors such as PD-1, TIGIT, 2B4, and 
CD160; and a high expression level of the transcription factors Eomes and BATF but low 
T-bet; (Buggert, Tauriainen, et al., 2014; Day et al., 2006; Quigley et al., 2010; 
Tauriainen et al., 2017; Trautmann et al., 2006; J. Y. Zhang et al., 2007). Initiation of 
ART does alleviate the exhaustion of CD8+ T cells but does not fully restore their 
functionality (Jensen et al., 2015; Rutishauser et al., 2017; Trautmann et al., 2006; 
Yamamoto et al., 2011). A complete preservation of CD8+ T cell functionality most likely 
requires the initiation of ART  as early as 2 days post-diagnosis during Fiebig I or II 
(Ndhlovu et al., 2019).  
Through the studies of ECs, several features of CD8+ T cell response have been 
associated with effective HIV control. The targeting of specific epitopes has been linked 
to different disease outcomes. Responses targeting a broad range of epitopes within 




Pereyra et al., 2008). Meanwhile, Gag-specific responses, including their breadth, are 
associated with lower viremia (Edwards et al., 2002; Kiepiela et al., 2007; Rolland et al., 
2008). Furthermore, CD8+ T cells from ECs largely target immunodominant B*5701- and 
B*27-restricted Gag epitopes (Almeida et al., 2007; Migueles et al., 2000; Pereyra et al., 
2008). Mutations of these epitopes reduce viral fitness while still maintaining a high level 
of antigen-specific CD8+ T cell-responses (Bailey, Williams, et al., 2006; Martinez-Picado 
et al., 2006; Miura et al., 2009; Schneidewind et al., 2007). This is potentially due to the 
flexible binding grooves of the protective HLA alleles, which allows them to better 
tolerate mutations in the binding epitopes (Goulder & Walker, 2012). 
Cellular functionality of CD8+ T cells appears to be preserved in ECs. HIV-specific CD8+ 
T cells exhibit a higher proliferation capacity that is positively correlated with the 
expression of HLA-DR (Saez-Cirion et al., 2007). In addition, these cells are primed for 
survival and are resistant to apoptosis (Yan et al., 2013). Preservation of functionality 
allows CD8+ T cells from ECs to exhibit superior viral inhibition capacity (Saez-Cirion et 
al., 2007; Shasha et al., 2016). This viral inhibition capacity is contact-dependent, is 
stable over time, strongly correlates with the magnitude of Gag-specific response, and is 
cross-reactive with other human lentiviruses (Saez-Cirion et al., 2007; Saez-Cirion et al., 
2009). 
The ability of CD8+ T cells to inhibit HIV replication in ECs has been attributed to the 
enhancement of effector functions. Cytotoxic capacity of CD8+ T cells is elevated in ECs. 
Specifically,  HIV-specific CD8+ T cells from ECs quickly express a high level of perforin 




is associated with an increase in T-bet expression (Hersperger et al., 2011; Hersperger 
et al., 2010). The high level of perforin expression by these cells is also coupled to a 
high level of cellular proliferation after 6 days of stimulation (Migueles et al., 2002) . In 
addition, efficient delivery of granzyme B is required for the elimination of HIV-infected 
cells associated with the EC status (Migueles et al., 2008). These phenomena have 
been extended to the rhesus macaque model (Mendoza et al., 2013). 
Beside cytotoxicity, cytokine production is another effector function that is augmented in 
EC CD8+ T cells. Upon stimulation with HIV peptides, HIV-specific CD8+ T cells from 
ECs exhibit polyfunctionality as they can concurrently upregulate the expression of the 
degranulation marker CD107a and produce multiple cytokines including IFNγ, TNF, and 
MIP-1β (Betts et al., 2006; Ferre et al., 2009). MIP-1β (also known as CCL4) and other 
beta-chemokines such as CCL3 and CCL5 are antiviral as they interfere with viral entry 
by binding to CCR5, a key co-receptor of HIV (Cocchi et al., 1995). TNF has also been 
shown to inhibit HIV replication in macrophages (Lane et al., 1999). The production of 
the cellular antiviral factor (CAF) is also higher in ECs (Blackbourn et al., 1996; Killian, 
Johnson, Teque, Fujimura, & Levy, 2011). CAF was first described in 1986 when it was 
observed that CD8+ T cells can suppress HIV replication without killing infected cells in 
vitro (C. M. Walker et al., 1986). However, though certain characteristics of this factor 
have been described, its exact identity remains elusive (Levy, 2003). 
1.7 Lymphoid tissues in immunity and in HIV infection 
Lymphoid tissues (LTs) are organized structures that support immune responses. There 




lymphocytes are generated and mature prior to entering circulation. Secondary LTs are 
sites of immunosurveillance where adaptive immune responses are induced. These 
secondary LTs include but are not limited to LNs, tonsils, spleen, and Peyer’s patches. 
In the context of this dissertation, LNs are the main focus of investigation and discussion 
as the representative secondary lymphoid tissue. 
Cellular architecture of lymph nodes  
LNs are organized into two main regions: the medulla and the cortex (von Andrian & 
Mempel, 2003). The medulla is made up of lymph-draining sinuses that are divided by 
medullary cords. This area contains mostly antibody-secreting plasma cells, 
macrophages, and memory T cells (von Andrian & Mempel, 2003). The cortex area is 
subdivided into the parcortex (or T cell zone, TCZ) and the B cell follicles (BCF). The 
paracortex is the induction site of cellular adaptive immunity, the BCFs of humoral 
adaptive immunity. The paracortex is segmented into paracortical cords by cortical 
sinuses. Each paracortical cord stretches from below BCFs toward the medulla and 
ultimately merge into medullary cords. Besides T cells, the paracortex contains a large 
number of dendritic cells (von Andrian & Mempel, 2003). On the other hand, BCFs 
contain mainly B cells, follicular CD4+ T cells (either helper or regulatory), and follicular 
CD8+ T cells. Upon the induction of humoral immune response, BCFs become germinal 
centers where B cells undergo somatic hypermutation and affinity maturation as they go 
through rounds of proliferation and selection in areas known as the dark zone and the 




In addition to the hematopoietic cells, LNs are architecturally supported by a network of 
endothelial and non-endothelial stromal cells (Chang & Turley, 2015). Endothelial cells in 
LNs include lymphatic endothelial cells and vascular endothelial cells. High endothelial 
venules are structures that contain most vascular endothelial cells in LNs. These 
structures are found at the center of paracortical cords, which allows lymphocytes in 
blood to enter LNs. Non-endothelial stromal cells, such as lymphoid tissue organizer 
cells, are largely responsible for the formation of LNs. These cells also differentiate into 
other stromal populations in LNs such as follicular dendritic cells (FDC), fibroblastic 
reticular cells (FRC), and marginal reticular cells (MRCs) (Chang & Turley, 2015). MRCs 
are primarily found beneath the subcapsular sinus where they constitutively produce 
CXCL13 (Chang & Turley, 2015). FRCs are a heterogenous group of cells that densely 
populates the TCZ. These cells are critical for the maintenance of high endothelial 
venule integrity, recruitment of T cells via the secretion of CCL19 and CCL21, and the 
homeostatic maintenance of these cells via the production of IL-7 (Brown & Turley, 
2015; Link et al., 2007). FDCs are mainly found in BCFs. These cells are important for 
the formation of germinal centers through their efficient capture and retention of 
antigens, promotion of B cell survival by the secretion of BAFF and APRIL, and B cell 
and follicular helper T fells (TFH) trafficking to BCFs via the production of CXCL13 
(Chang & Turley, 2015). 
 All cellular subsets present in LNs, both hematopoietic and stromal, coordinate with 




Lymph nodes as sites of adaptive immune priming 
LNs, as well as other LTs, are connected by a system of lymphatic vessels. These 
vessels collect fluid that drains from tissues, known as lymph, pass it through the 
network of hundreds of LNs distributed throughout the body, and ultimately channel it 
back to the blood. As lymph passes through LNs, it is surveilled by the different cell 
subsets in those LNs. If antigens and the immune cells that can recognize them are 
present in a specific LN, their interaction will result in the induction of an adaptive 
immune response.  
Lymph enters a LN through an afferent lymphatic vessel. The fluid travels through the 
subcapsular sinus, trabecular sinuses, medullary sinuses, and eventually exits via an 
efferent lymphatic vessel. As lymph travels through a LN, its content is sampled for the 
presence of microorganisms and debris by FRCs, macrophages, and dendritic cells that 
are present in intranodal lymph channels (von Andrian & Mempel, 2003). As these cells 
take up antigenic content present in lymph, they can process them and present to B cells 
and T cells. Antigen presentation to B cells is often performed by subcapsular sinus 
macrophages and FDCs (Phan, Gray, & Cyster, 2009). Meanwhile, antigen presentation 
to T cells is mainly executed by dendritic cells, both resident and migratory ones. Naïve 
T cells (both CD4+ and CD8+) will be activated upon their interaction with antigen 
presenting cells, presenting the cognate antigens for their T cell receptor. Upon 
activation, these antigen-specific effector T cells will proliferate prior to exiting LNs via 




or S1P (Cyster & Schwab, 2012). As these cells enter circulation, they can traffic to sites 
of inflammation to execute effector functions during the course of an immune response. 
Lymph nodes as sites of HIV reservoirs  
Since HIV mainly targets CD4+ T cells and LNs contain a large number of these cells, it 
is rational to postulate that LNs are critical sites of HIV infection. In fact, this concept was 
recognized very early on as AIDS patients presented with signs of lymphadenopathy 
(Goudsmit, Tersmette, Kabel, Miedema, & Melief, 1983; Harris et al., 1983). After the 
identification of HIV as the etiological agent of AIDS, it was observed that major HIV 
reservoirs are found in LTs, such as LNs (Pantaleo et al., 1991). In addition, HIV 
replication remains active in these tissues even during the clinically latent stage of the 
disease when minimal replication activity is observed in blood (Pantaleo et al., 1993). 
Full body quantification of SIV-infected rhesus macaques also reveals that over 99% of 
SIV-RNA+ cells are found in LTs, such as gut and LNs (J. D. Estes et al., 2017).  
HIV viremia in the periphery is quickly suppressed to undetectable levels upon ART 
initiation. However, in LNs, even when ART is started as early as Fiebig I, viral RNA is 
still detectable (Colby et al., 2018; J. D. Estes et al., 2017; Wong et al., 1997). Studies in 
the rhesus macaque model have indicated that even when infection is well-controlled, 
productive SIV infection still occurs in LNs (Fukazawa et al., 2015). Furthermore, viral 
reservoirs are seeded in LNs extremely early, by 3-5 days and as quickly as 3 hours 
post-infection (Okoye et al., 2018; Whitney et al., 2014; Whitney et al., 2018). 




infection still does not prevent viral rebound post-treatment interruption (Okoye et al., 
2018; Whitney et al., 2014). 
Virus persistence in LNs is driven largely by TFH. These cells are highly permissive to 
infection, being the most frequent HIV-DNA+ and RNA+ cells after ART initiation; and 
they produce the highest amount of virions upon activation (Banga et al., 2016; Kohler et 
al., 2016; Perreau et al., 2013). In rhesus macaques that naturally control SIV infection, 
productive infection is restricted almost exclusively to TFH (Fukazawa et al., 2015). This 
persistence of HIV in TFH is largely due to the localization of these cells to BCFs, which 
are considered to be immunologically privileged (Bronnimann, Skinner, & Connick, 
2018). CD8+ T cells, though capable, are largely restricted from trafficking into BCFs 
(Connick et al., 2014; Connick et al., 2007; Folkvord, Anderson, Arya, MaWhinney, & 
Connick, 2003; Folkvord, Armon, & Connick, 2005). As a result, infected TFH do not 
experience the same level of immune pressure compared to infected non-TFH. In fact, 
when CD8+ T cells are depleted from EC rhesus macaques, productive SIV infection is 
redistributed to non-TFH and upon CD8+ T cell recovery, the restriction of productive 
infection to TFH is restored (Fukazawa et al., 2015). Besides TFH, another driver of viral 
persistence in BCFs is FDCs as free HIV virions can remain infectious for months to 
years when retained on these cells (Heesters et al., 2015; Heesters, Myers, & Carroll, 
2014; B. A. Smith et al., 2001). 
How viral reservoirs in LNs are maintained under ART is still a matter of debate. On one 
hand, it has been argued that they are maintained by ongoing viral replication. This 




(Lorenzo-Redondo et al., 2016). In addition, lower concentrations of ART measured in 
LNs compared to blood can potentially allow HIV to replicate and infect new cells 
(Fletcher et al., 2014). On the other hand, multiple studies have found no signs of viral 
evolution in LNs, arguing against the concept of ongoing replication during ART. These 
studies suggest that viral reservoirs in LNs are maintained by cellular proliferation of 
cells that are infected prior to ART initiation (McManus et al., 2019). There is also 
evidence for the contribution of both ongoing viral replication and cellular proliferation in 
maintaining viral reservoirs in LTs (Boritz et al., 2016). Irrespective of the exact 
mechanism of persistence, HIV reservoirs in LNs (and other LTs and NLTs) present a 
major hurdle for a cure strategy to overcome. 
1.8 Objectives 
As laid out in the sections above, a cure for HIV remains unavailable. Typically, there are 
two types of HIV cure in discussion: functional cure and sterilizing cure. While a 
functional cure primarily aims to suppress viral replication and inhibit disease 
progression in the absence of ART, a sterilizing cure aims to completely eradicate HIV 
from the body. The successful development of a cure strategy most likely will involve the 
identification of immune mechanisms required to effectively control the replication of HIV 
reservoirs, in the case of a functional cure, or to eliminate these reservoirs, in the case of 
a sterilizing cure. Though a sterilizing cure might be the ultimate goal, a functional cure 
is more attainable. Over the past four decades, a robust body of literature has supported 
the essential role of CD8+ T cells in controlling HIV replication, especially in ECs, 




ART. In fact, the presence of these cells is required for the maintenance of the EC status 
in the rhesus macaque model of infection (Fukazawa et al., 2015). Furthermore, specific 
aspects of CD8+ T cell functions, such as cytotoxicity, proliferation, and polyfunctionality, 
have been strongly correlated with the EC status. It is worth emphasizing that these 
correlates were established in the peripheral blood. However, as discussed in section 
1.7, most of HIV viral reservoirs are located in tissues, mainly in LTs, and not the blood. 
Though it has historically been reasonable to assume that T cells in blood accurately 
represent T cells in tissues, the identification of T cell subsets with different trafficking 
properties, including TRM, has challenged this assumption. On one hand, a large number 
of T cells in tissues are TRM (Farber, Yudanin, & Restifo, 2014; Thome et al., 2014). 
Since these cells, by definition, stay resident in a tissue, they are not found in the blood. 
One the other hand, different microenvironmental stimuli can affect T cell functions. As a 
result, the functional properties of T cells in tissues might not be accurately represented 
by T cells in blood.  
With these notions in mind, the overarching goal of this dissertation is to define the 
identity of CD8+ T cells that are involved in maintaining HIV control in LTs of ECs, with a 
focus on LNs. Specifically, this project aims to determine, first, if TRM are involved in anti-
HIV immunity in LNs and, second, which properties of LN CD8+ T cells are linked to the 
effective immune-mediated control of HIV replication in ECs. The results from this study 
will hopefully be insightful for the future development of a HIV cure strategy. 
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CHAPTER 2: LYMPHOID TISSUES OF HIV ELITE CONTROLLERS 
HABOR A LARGE FREQUENCY OF TISSUE-RESIDENT MEMORY 
CD8+ T CELLS 
This chapter is presented as a re-print (with permission) of the article titled “Identification and 
characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue” by 
Buggert M, Nguyen S, Salgado-Montes de Oca G, Bengsch B, Darko S, Ransier A, Roberts ER, 
Del Alcazar D, Brody IB, Vella LA, Beura L, Wijeyesinghe S, Herati RS, Del Rio Estrada PM, 
Ablanedo-Terrazas Y, Kuri-Cervantes L, Sada Japp A, Manne S, Vartanian S, Huffman A, 
Sandberg JK, Gostick E, Nadolski G, Silvestri G, Canaday DH, Price DA, Petrovas C, Su LF, 
Vahedi G, Dori Y, Frank I, Itkin MG, Wherry EJ, Deeks SG, Naji A, Reyes-Terán G, Masopust D, 
Douek DC, Betts MR.  Science Immunology. 2018 Jun 1, 3(24), eaar4526. 
doi:10.1126/sciimmunol.aar4526 
2.1 Introduction 
It is well established that CD8+ T cells are required for effective immune control of HIV. 
The contemporary literature is also replete with studies describing the qualitative 
characteristics of effective HIV-specific CD8+ T cell responses. For example, allotype 
restriction, antigen sensitivity and specificity, clonotype distribution, cytolytic activity, 
polyfunctionality, proliferative reserve, and response magnitude  have all been 
associated with differential rates of disease progression (Migueles & Connors, 2015). 
However, most of these correlates are based on data acquired from peripheral blood, 
despite the fact that HIV replicates primarily in lymphoid tissues (LTs).  
HIV seeds, replicates, and persists in LTs (J. D. Estes, 2013). It is therefore important to 
develop an anatomically consistent view of immunosurveillance, especially in light of the 
fact that follicular helper T cells (TFH) facilitate viral replication and harbor much of the 




efficacy of live-attenuated SIV vaccines can be predicted from the magnitude of virus-
specific T cell responses in LTs (Fukazawa et al., 2012). In addition, CD8+ T cell 
depletion is associated with a rapid redistribution of productive SIV infection to non-TFH 
in EC macaques, suggesting active viral suppression by CD8+ T cells in LTs (Fukazawa 
et al., 2015). However, very little is known about the antiviral properties of HIV/SIV-
specific CD8+ T cells that reside in LTs. 
Gowans and colleagues have demonstrated that lymphocytes recirculate between 
tissues and blood through lymph via the thoracic and lymphatic ducts (Gowans, 1959). 
More recent studies of human blood have categorized memory CD8+ T cells broadly into 
two circulating subsets based on their tissue homing properties. Central memory T cells 
(TCM) express lymphoid homing receptors (CCR7 and CD62L) and recirculate between 
blood, LTs, and lymph, while effector memory T cells (TEM) lack CCR7 and CD62L and 
recirculate between blood, non-lymphoid tissues (NLTs), and lymph to survey visceral 
organs and body surfaces (Sallusto et al., 1999). Recently, a new subset known as 
resident memory T cells (TRM), that reside within NLTs, has been identified (Gebhardt et 
al., 2009; Masopust et al., 2010; Masopust et al., 2001; Wakim, Waithman, van Rooijen, 
Heath, & Carbone, 2008). Most TRM constitutively express CD69 (Masopust, Vezys, 
Wherry, Barber, & Ahmed, 2006), which downregulates the sphingosine-1-phosphate 
receptor 1 (S1PR1) (Shiow et al., 2006), thereby preventing tissue egress. NLTs are 
seeded with TRM soon after immune priming (Masopust et al., 2010), establishing a front-
line tissue defense that can eliminate pathogens largely without the involvement of 




functional, phenotypic, and transcriptomic profiles attuned to their compartmentalized 
state (Mackay et al., 2013).   
TRM have been identified in murine LTs (Schenkel, Fraser, & Masopust, 2014), where 
they are relatively sparse compared with circulating T cells (Steinert et al., 2015). CD8+ 
TRM have also been observed in human LTs (Sathaliyawala et al., 2013; Thome et al., 
2014; Woon et al., 2016). The notion that TRM may exist in LTs could transform our 
understanding of CD8+ T cell-mediated control of HIV infection. In line with this 
possibility, the frequency of HIV-specific CD8+ T cells is generally higher in lymph nodes 
(LNs) compared with matched peripheral blood samples (Altfeld et al., 2002; Connick et 
al., 2007), despite the fact that most circulating HIV-specific CD8+ T cells lack classical 
lymphoid homing characteristics (Buggert, Tauriainen, et al., 2014; Champagne et al., 
2001). Moreover, CD8+ T cells accumulate in HIV-infected LTs (Lederman & Margolis, 
2008) and respond poorly to S1PR1-mediated signals (J. C. Mudd et al., 2013). 
However, it remains unclear if HIV-specific CD8+ T cells with a TRM phenotype exist in 
HIV-infected LTs. To resolve this issue, we conducted a detailed assessment of CD8+ T 
cells in the peripheral blood and LTs of healthy and HIV+ subjects. Our data show that 
TRM most often dominate the HIV-specific CD8+ T cell response in LTs, and identify a link 






HIV+ LNs harbor an abundance of CD69+ CD8+ T cells 
CD69 has often been considered as a marker of early T cell activation (Chattopadhyay & 
Roederer, 2010). We examined CD69 expression on LN CD8+ T cells from HIV+ and 
HIV– subjects (Table 2.1). Irrespective of adherence to antiretroviral therapy (ART), 
higher frequencies of LN CD69+ CD8+ T cells and CCR7- (TEM) cells were present in HIV+ 
compared with HIV– subjects (Fig 2.1A and 2.2A). In HIV+ subjects, higher frequencies 
of CD8+ T cells expressed CD69 in LNs compared with blood (Fig 2.1B). A strong 
association was also detected between the frequency of memory CD8+ T cells and the 
frequency of CD69+ CD8+ T cells in LNs (Fig 2.1C and 2.2B). Moreover, LN CD69+ 





Table 2.1 Clinical data of subjects included in the study 
 
To determine if LN CD8+ T cells express CD69 as a consequence of activation, we 
stained blood and LT CD8+ T cells for canonical activation markers. Of note, CD69+ 
CD8+ T cells expressed lower levels of multiple activation markers compared to in vitro 
stimulated T cells (Fig. 2.3). In addition, we obtained samples from HIV+ subjects in the 
acute/early stages of infection (Fiebig IV-VI), a time when early cycling (Ki-67+) CD8+ T 
cells are prevalent in blood (Ndhlovu, Kamya, et al., 2015). Substantially higher 
frequencies of LN CD8+ T cells expressed Ki-67 in acutely infected HIV+ compared with 
HIV– subjects (Fig 2.1E). These LN Ki-67+ CD8+ T cells also showed evidence of HIV 
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specificity (Fig. 2.4A), as demonstrated previously in blood (Ndhlovu, Kamya, et al., 
2015; Takata et al., 2017). However, only a minority of LN CD69+ CD8+ T cells 






Figure 2.1. CD69 is not coupled to an early immune activation signature in HIV-
infected LNs. (A) Frequency of CD69 expression on total LN CD8+ T cells from 
HIV+ and HIV− subjects. Red indicates ART− and orange indicates ART+ in the 
HIV+ scatter plot group. (B) Frequency of CD69 expression on total blood (top) and LN 
(bottom) CD8+ T cells. Matched samples from one subject are shown in the 
representative flow cytometry plots. Lines connect matched samples across all subjects 
in the graph. (C) Correlation between the frequency of memory (non-CCR7hi non-
CD45RO−) CD8+ T cells and CD69 expression on total blood (top) and LN (bottom) 
CD8+ T cells. Blue: HIV− subjects: red: HIV+ ART− subjects; orange 
HIV+ ART+ subjects. (D) Frequency of CCR7− CD69+ memory CD8+ T cells in HIV− (blue) 
and HIV+ (red: ART−; orange: ART+) subjects. (E) Co-expression pattern of Ki-67 and 
CD69 in/on total LN CD8+ T cells from an HIV− subject (left) and an HIV+ ART− subject 
(right) with acute infection (Fiebig V). (F) Frequency of Ki-67–/+ CD69+ CD8+ T cells in 
LNs from HIV+ subjects with acute infection (n = 7). (G) Expression intensity of CD69, 
ICOS, Ki-67, and CD38 in multidimensional viSNE space. viSNE plots were derived 
using 27576 cells (n = 17 subjects) and the markers shown in Fig. 2.1I. (H) The same 
viSNE display with sub-populations colored using the PhenoGraph implementation of 
Cytofkit (top). Distribution of CD69 expression over all 14 sub-populations derived using 
PhenoGraph (bottom). (I) Hierarchical clustering of expression intensity (z-score) for all 
assessed markers within the different sub-populations derived using PhenoGraph. 
Median and IQR are shown for all scatter/bar plots. **P < 0.01; ***P < 0.001. 
Conventional (fluorescence) flow cytometry was used for all stains in (A-F) and mass 
cytometry (CYTOF) was used in (G-I). 
 
In addition, we utilized mass cytometry to assess the expression of multiple activation 
markers on LN CD8+ T cells in HIV+ subjects with chronic disease (Fig 2.1G). Fourteen 
CD8+ T cell clusters were identified algorithmically in t-distributed stochastic neighbor 
embedding (tSNE) space, where one cluster (#4) displayed high co-expression of 
several activation markers (CD38, Ki-67, ICOS), but not CD69 (Fig 2.1H). In contrast, 
CD69 expression intensity was high on unique clusters (#7, #8) with elevated levels of 
CD38, but also dissociated with CD38 expression in other dominant CD69 clusters (#2, 




CD69 intensity (Fig. 2.1I), but these clusters also expressed low to high intensity of BCL-
6, CD95 and CXCR5 (#10) as well as CXCR3 and CCR6 (#14), suggestive of memory 
stem T cell (TSCM)-like features (Gattinoni et al., 2011; Im et al., 2016). Hierarchical 
clustering confirmed that CD69 expression was more closely related to PD-1, CD95, and 
CXCR3 expression than CD38, Ki-67, and ICOS expression (Fig 2.1I). Collectively, 
these data indicate that high levels of CD69 expression on memory CD8+ T cells in HIV-
infected LTs cannot be explained by an increased early/cycling immune activation 
profile. 
 
Figure 2.2. Maturation of LN CD8+ T cells. (A) Flow cytometry and frequency of LN 
naïve (CCR7+CD45RO-/CD45RA-), TCM (CCR7+CD45RO+/CD45RA-), TEM (CCR7-
CD45RO+/CD45RA-) and Teff (CCR7-CD45RO-/CD45RA+) CD8+ T cells between HIV- 
and HIV+ subjects. Red indicate ART- and orange ART+ in the HIV+ group. (B) 
Correlation between the frequency of LN naïve, TCM, TEM or TEff CD69 expression on 
total CD8+ T cells. Blue marks HIV- subjects, red HIV+ART-, and orange HIV+ ART+ 





Figure 2.3. Expression of immune activation markers by LT CD8+ T cells. 
Frequency of different immune activation markers on CD69- (white) and CD69+ (black) 
CD8+ T cells in blood (n = 12) and LTs (Iliac LN: n = 6; Mes LN: n = 6; Tonsil: n = 6, 
Spleen: n = 6); all data points are derived from HIV– subjects. Anti-CD3-CD28 stimulated 
blood memory CD8+ T cells (red) were used as a positive control (n = 4). Median and 
IQR are shown for all bar plots. 
 
Figure 2.4. Cycling CD8 T cells in acute HIV-infected LNs. (A) Flow cytometry plots 
of negative background (mock) and a CD8+ HIV-tetramer+ response in an acute HIV-




LN CD69+ CD8+ T cells display characteristics of TRM 
To determine if human LT CD69+ CD8+ T cells have a transcriptional signature 
resembling TRM, we sorted mesenteric LN (MesLN) memory CD69– and CD69+ CD8+ T 
cells (Fig 2.5A) and performed RNA sequencing (RNA-seq) analysis. We identified a 
core signature of genes that were either upregulated or downregulated in LN memory 
CD69– and CD69+ CD8+ T cells (fold change > 2; P < 0.05), where particular genes that 
are downregulated in NLT TRM, such as S1pr1, Klf3, and Sell (Pan et al., 2017), were 
also poorly expressed in LN memory CD69+ CD8+ T cells (Fig 2.6A). Of note, Znf683 
(Hobit), previously associated with murine TRM formation (Mackay et al., 2016), was 
downregulated in LN memory CD69+ CD8+ T cells. Gene-set enrichment analysis 
(GSEA) revealed that genes linked with human lung CD69+ CD103+ CD8+ T cells 
(Hombrink et al., 2016a) were also enriched in LN CD69+ CD8+ T cells (Fig 2.5B). 
Ingenuity pathway analysis further demonstrated that the major differences between 
CD69– and CD69+ CD8+ T cells included cell-mediated immune responses and cell 
trafficking (Fig 2.6B). In addition, many genes typically associated with TRM and TCM/TEM 
(Appay et al., 2007; Mackay et al., 2013) were upregulated (Itgae, Rgs1, Rgs2, Xcl1, 
Tbx21, Ifng) or downregulated (Fam65b, Klf2, Rasgrp2, S1pr1, Sell, Ccr7, Lef1, Tcf7, 
Cxcr3, Cxcr4) in CD69+ CD8+ T cells (Fig 2.6C). Most of these genes followed the 
patterns observed in splenic CD69+ CD8+ T cells and TCM (CD69– CD62L+) isolated from 
P14 T cell receptor (TCR)-transgenic mice (Fig 2.6C). We further conducted Assay for 
Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq) to 




CD69– and CD69+ CD8+ T cells. OCRs adjacent to genes known to be involved in the 
establishment of residency and immune responses displayed marked differences 
between these two subsets of LN memory CD8+ T cells (Fig 2.6D). For example, several 
OCRs were present next to Ifng, Xcl1, and Xcl2 primarily in CD69+ CD8+ T cells (Fig 
2.6E), suggesting a readiness to upregulate these effector functions (Hombrink et al., 
2016b; Mackay et al., 2013). Prdm1 (encoding Blimp-1), recently associated with TRM 
formation (Mackay et al., 2016), were also enriched for OCRs in CD69+ CD8+ T cells 
(Fig 2.5C). In contrast, CD69– CD8+ T cells were more likely to have multiple OCRs 
adjacent to genes associated with trafficking, including Klf2 and S1pr1 (Fig 2.6F), and 
the Znf683 locus (Fig 2.5C). We further inferred transcription factor occupancy in 
regulatory elements by motif analysis and found that RUNX, AP-1 and ETS families 
belonged to the most enriched motifs in CD69+ CD8+ T cells, while CD69- CD8+ T cells 
showed enriched motifs belonging to the PAX, TCF and KLF families, demonstrating that 
unique transcription factor families are likely cooperatively responsible for regulating 





Figure 2.5. RNA-seq, ATAC-seq and CCR7 analysis of LN TRM (A) Gating strategy for 
RNA- and ATACseq sort to get a pure mesLN memory CD69- and CD69+ CD8+ T cell 
population. (B) Normalized enrichment score (NES) of down- and upregulated gene sets 
from lung TRMs (CD69+CD103+) (Hombrink et al., 2016) in mesLN CD69+ compared to 
CD69- memory CD8+ T cells. (C) ATAC-seq tracks for the Znf683 (Hobit) locus. (D) 
CD69 frequency on sorted CD69+ CD8+ T cells after 9 days in culture with CCL19/21 or 
without. Both conditions contained also rhIL-7. (E) MFI of CD69 on CCR7+ and CCR7- 
CD69+ CD8+ T cells after 9 days in culture with rhIL-7. (F) Expression of resident and 
effector molecules on CCR7+ and CCR7-CD69+ CD8+ T cells. *P < 0.05, **P < 0.01 and 












Figure 2.6. CD69+ CD8+ T cells display functional and transcriptional TRM 
signatures in LTs. (A) RNA-seq heat-map showing differentially expressed genes (fold 
change > 2; P < 0.05) between human MesLN memory CD69− and CD69+ CD8+ T 
cells. (B) Ingenuity pathway analysis based on all differentially expressed genes (P < 
0.05) between CD69− and CD69+ CD8+ T cells in the RNA-seq dataset. The top 
pathways involved in the “physiological system development and function” arm are 
shown in the table. (C) Differential expression patterns of TRM-related and TCM/EM-related 
genes between human LN memory CD69− and CD69+ CD8+ T cells (top) and between 
splenic CD69− and CD69+ CD8+ T cells from P14 TCR-transgenic mice 
(bottom). (D) ATAC-seq volcano plot showing open chromatin regions adjacent to 
specific genes. Green marks ATAC-seq peaks that are differentially enriched (fold 
change > 2; P < 0.05) in human hepatic LN memory CD69− and CD69+ CD8+ T 
cells. (E) ATAC-seq tracks from human LN memory CD69− (red) and CD69+ (blue) 
CD8+ T cells. (F) Enriched ATAC-seq de novo motifs for CD69+ (left) and CD69− (right) 
CD8+ T cells (G) Human memory CD69− and CD69+ CD8+ T cells from spleen, tonsil, 
and hepatic LNs (n = 2 each) were assessed over time for CD69 expression in the 
presence or absence of rhIL-7. Lines represent mean ± SD. Conventional flow cytometry 
was used for all stains in this figure. 
 
To further support the concept that CD69+ CD8+ T cells are enriched for TRM in vivo, we 
performed a variety of functional experiments. We sorted human LT memory CD69– and 
CD69+ CD8+ T cells, and found that CD69 was stably expressed on the surface of TRM 
for up to 9 days (Fig 2.6H). Classical TRM express low levels of CCR7 and CD62L 
(Schenkel & Masopust, 2014). We found no evidence that supplementation with CCR7 
ligands (CCL19 or CCL21) influenced CD69 downregulation on LT memory CD69+ CD8+ 
T cells (Fig 2.5D). However, CD69 was downregulated significantly on CCR7+ CD69+ 
CD8+ T cells after 9 days in culture (Fig 2.5E), and markers associated with residency 
and effector functions were predominantly expressed by CCR7– CD69+ CD8+ T cells ex 
vivo (Fig 2.5F). Altogether, these data show that LT CD69+ CD8+ T cells show enriched 




The majority of HIV-specific CD8+ T cells in LTs are CD69+  
The observation that memory CCR7–CD69+ CD8+ T cells are expanded in HIV-infected 
LNs (Fig 2.1) led us to postulate that HIV-specific cells are TRM. In contrast to matched 
blood, most LN HIV-specific CD8+ T cells expressed CD69 (Fig 2.7A and 2.8). To 
confirm that HIV-specific CD69+ CD8+ T cells do not leave LTs, we collected thoracic 
duct lymph (TDL) from HIV+ subjects. Akin to our previous findings, we detected only 
very low levels of CD69 on bulk and HIV-specific CD8+ T cells in TDL (Fig 2.7A). Of 
note, CD69 expression on HIV-specific CD8+ T cells was unaffected by ART status (Fig 
2.7A), indicating that antigen load is not necessarily a determinant of CD69 expression, 
in contrast to classical immune activation markers in blood (Buggert, Frederiksen, et al., 








Figure 2.7. Majority of HIV-specific CD8+ T cells display a TRM phenotype in LNs. 
(A) Flow cytometry plots of on memory CD8+ T cells showing CD69 expression on 
matched HIV-tetramer+ cells in blood and LNs (left), and matched HIV-tetramer+ cells in 
blood and TDL (middle). Frequency of CD69 expression on HIV-tetramer+ cells in blood 
(n = 13 subjects), ART− LNs (n = 4 subjects), ART+ LNs (n = 4 subjects), and TDL (n = 7 
subjects) (right). (B) Distribution of LN HIV-tetramer+ (spec) CD69+ CD8+ T cells among 
the naïve (CD45RO− CCR7+), TCM (CD45RO+ CCR7+), TEM (CD45RO+ CCR7−), and 
effector (TEFF; CD45RO− CCR7−) compartments. (C) CD69 and CD103 expression 
profiles for blood (blue), LN (red: ART−; orange: ART+), and TDL (yellow) HIV-specific 
CD8+ T cells. (D) Representative flow cytometry plots showing memory CMV-
tetramer+ (left) and HIV-tetramer+ (right) CD8+ T cell frequencies in blood (top) and LNs 
(bottom) from the same subject. (E) Frequency of CD69 and CD103 expression on LN 
CMV-NV9-specific and HIV-FK10-specific CD8+ T cells in the same subjects with 
detectable tetramer+ responses to both viruses. Each color represents a matched 
subject and a matched tetramer+ response. (F) Representative flow cytometry plots 
showing CD69 expression on Perforin+ Granzyme B (GzmB)+ HIV-specific CD8+ T cells 
in LNs (left). Frequency of CD69–/+ cells among Perforin+ (n = 20 responses) and 
GzmB+ (n = 16 responses) HIV-specific CD8+ T cells in ART+ and ART− LNs 
(right). (G) Flow plots showing CXCR5 and CD69 co-expression on blood, LN, and TDL 
memory CD8+ T cells in HIV+ subjects (matched for blood and LNs, but not for TDL). 
Frequency of CXCR5 expression on memory CD8+ T cells in blood, LNs (red: ART−; 
orange: ART+), and TDL. (H) Frequency of CD69 expression on blood, LN, and TDL 
CXCR5+ memory CD8+ T cells in HIV+ subjects. (I) Frequency of CCR7 expression on 
LN CD69+ CXCR5+ memory CD8+ T cells in HIV+ subjects. Bar plots are based on all 
subjects in Fig. 2.6A. (J) Representative flow cytometry plots showing CXCR5 and CD69 
co-expression on blood, LN, and TDL HIV-tetramer+ CD8+ T cells (matched for blood and 
LNs, but not for TDL). (K) Frequency of CD69 expression on blood (n = 18 responses), 
LN (n = 21 responses), and TDL (n = 10 responses) HIV-specific CXCR5+ CD8+ T 
cells. (L) Frequency of CCR7 expression on LN (n = 21 responses) HIV-specific 
CD69+ CXCR5+ CD8+ T cells. (M) Frequency of CD69+ CXCR5+ cells among LN CMV-
specific and HIV-specific CD8+ T cells in subjects with detectable tetramer+ responses to 
both viruses. Each dot represents a single tetramer+ response in all scatter plots. Each 
color represents a matched subject and a matched tetramer+ response. *P < 0.05, **P < 






In line with our previous findings, most HIV-specific CD69+ CD8+ T cells (median = 
84.1%) did not express CCR7 (Fig 2.7B). Moreover, HIV-specific CD8+ T cells in LNs 
demonstrated a predominant CD69+ CD103+ or CD69+ CD103– profile, in contrast to 
HIV-specific CD8+ T cells in blood and TDL (Fig 2.7C). We further examined 
cytomegalovirus (CMV)-specific CD8+ T cells for markers of residency, because CMV 
does not replicate primarily in LTs (Jarvis & Nelson, 2007; Myerson, Hackman, Nelson, 
Ward, & McDougall, 1984). In subjects with detectable CMV-specific and HIV-specific 
CD8+ T cell responses, we consistently found that HIV-specific CD8+ T cells were 
present in blood and LNs, while CMV-specific CD8+ T cells were always more prevalent 
in blood compared with LNs (Fig 2.7D) (Ellefsen et al., 2002). HIV-specific CD8+ T cells 
also expressed higher levels of CD69 and CD103 than CMV-specific CD8+ T cells in LNs 
(Fig 2.7E). In addition, HIV-specific CD69+ CD8+ T cells were more likely to express 
cytolytic proteins (perforin and/or Granzyme B) than HIV-specific CD69– CD8+ T cells 
(Fig 2.7F).   
Virus-specific CXCR5+ follicular CD8+ T cells have recently been shown to play a key 
role in immune protection against chronic viral infections (Adnan et al., 2016; Im et al., 
2016; Leong et al., 2016; Li et al., 2016; Mylvaganam et al., 2017). However, it is unclear 
if human CXCR5+ CD8+ T cells exhibit TRM properties akin to TFH (J. Y. Lee et al., 2015). 
In HIV+ subjects, we observed higher frequencies of CXCR5+ CD8+ T cells in LNs 
compared with blood and TDL (Fig 2.7G). The majority of CXCR5+ CD8+ T cells in LNs 
co-expressed CD69 and lacked CCR7 (Fig 2.7H and I). Similarly, we found very low 




LTs (Fig 2.7J), likely because the majority of LT HIV-specific CXCR5+ CD8+ T cells 
displayed a residency phenotype, including high levels of CD69 (Fig 2.7K) and low 
levels of CCR7 (Fig 2.7L). In addition, we found that LT HIV-specific CD8+ T cells more 
commonly expressed a CD69+ CXCR5+ phenotype compared with LT CMV-specific 
CD8+ T cells (Fig 2.7M). These data suggest that HIV-specific CXCR5+ are TRM and 
induced due to preferential localization of HIV in B cell follicles.  
 
Figure 2.8. tSNE analysis of LN and blood HIV-specific CD8+ T cells. tSNE plot 
based on total LN and blood CD8+ T cells from one HIV+ donor. Clustering is based on 
CCR7, CD45RO, CD69, CD103 and CXCR5 expression. LN/CD69+ CD8+ T cells 
generate a unique memory cluster (green), while blood/CD69- cells generate an opposite 
positioned memory cluster (red). The HIV-specific CD8+ T cells from LN and blood are 





HIV-specific CD8 TRM are enriched in LNs of ECs and are transcriptionally 
distinct 
Recent work has shown that LT CD8+ T cells suppress viral replication in SIV elite 
controller rhesus macaques (Fukazawa et al., 2015). In human ECs, we found that the 
majority of LN HIV-specific CD8+ T cells displayed a TRM phenotype (Fig 2.9A). Human 
ECs also displayed higher LN/blood ratios of HIV-specific CD8+ T cells (Fig 2.9B), and 
higher frequencies of HIV-tetramer+ CD69+ CD8+ T cells (Fig 2.9C), compared with other 
HIV+ subjects. In HLA-B*5701+ ECs, we found that TRM selectively targeted 
immunodominant HLA-B*5701-restricted epitopes, rather than immunodominant non-
HLA-B*5701-restricted epitopes (Fig 2.9D).   
 
Figure 2.9. ECs exhibit high frequencies of CD69+ HIV-specific CD8+ T cells in LNs. 
(A) Representative flow cytometry plots of memory CD8+ T cells showing CD69 
expression on HIV-tetramer+ cells in matched blood and LN samples from an HIV elite 
controller (EC). (B) Relative distribution of HIV-specific CD8+ T cells in blood and LNs 
from ECs (black) and other HIV+ subjects. (C) Magnitude of LN HIV 
tetramer+ CD69+ CD8+ T cell responses in ECs and other HIV+ subject. (D) Magnitude of 
LN HIV-tetramer+ CD69+ CD8+ T cell responses specific for immunodominant HLA-
B*5701-restricted and non-HLA-B*5701-restricted epitopes in ECs. Data points were 




analysis biases. Each dot represents a single tetramer+ response in all scatter plots. 
Red: ART−; Orange: ART+. *P < 0.05; **P < 0.01.  
 
We next index-sorted HLA-B*2705–restricted and/or HLA-B*5701– restricted Gag-
specific CD8+ T cells from LNs and blood of two ECs and conducted single-cell RNA-seq 
(scRNAseq) (Fig 2.10A). HIV-specific CD8+ T cells from LN and blood clustered 
differentially in the single-cell space (Fig 2.10B). Immune-related pathways, including 
interferon signatures, were higher in blood, whereas pathways related to maintenance of 
cell location were higher in LNs, suggesting that both immunological and trafficking 
properties distinguish the LN response from blood (Fig 2.10C). We next compared blood 
versus LN CD69− HIV-specific CD8+ T cells and found that specific cytolytic genes and 
pathways involved in lymphocyte degranulation were higher in blood (Fig 2.10D). 
Cytolytic differences at the transcript level were not seen between blood and LN CD69+ 
HIV-specific CD8+ T cells (Fig 2.10F). Last, to assess whether residency was associated 
with any specific functional gene signatures, we compared CD69− versus CD69+ HIV-
specific CD8+ T cells in LNs (Fig 2.11). LN CD69+ HIV-specific CD8+ T cells were 
enriched for cytolytic and effector-differentiated genes (Fig 2.11) and gene set 
signatures (Fig 2.12), whereas LN CD69− HIV-specific CD8+ T cells demonstrated a less-
differentiated phenotype instead (Fig 2.11 and 2.12). Together, these findings support 





Figure 2.10. Index sorting strategy and scRNAseq analysis. (A) Gating strategy for 
index sorting of LN and blood HIV-specific CD8+ T cells and purity of index-sorted HIV-
specific CD8+ T cells. Memory cells were gated as non-CCR7hi non-CD95- to include 
stem-cell memory T cells (TSCMs). (B) tSNE plot of single HIV-specific CD8+ T cells from 
LN (blue) and blood (red) from ECs (n=2). The plot is based on the top 200 significant 
genes differentially expressed between groups in the scRNAseq data set. (C) Significant 
GSEAs of gene sets involved in immunological reactions and trafficking from LN versus 
blood HIV-specific CD8+ T cells. (D) Violin plots and GSEAs for genes and gene sets 
involved in cytolytic T cell responses from LN CD69- and blood HIV-specific CD8+ T cells. 






Figure 2.11. LN HIV-specific CD69+ and CD69- are transcriptionally distinct. Single-
cell RNA-seq (scRNAseq) was conducted on CD69+ and CD69− index sorted HLA-
B*2705-restricted and/or HLA-B*5701-restricted Gag-specific CD8+ T cells from LNs of 
two ECs. The heat-map (left) illustrates the single-cell gene expression variability of 
differentially expressed genes (P < 0.01) and violin plots (right) immune-related genes 
differentially expressed between CD69+ and CD69− single HIV-specific CD8+ T 






Figure 2.11. Gene set enrichment analysis (GSEA) between CD69+ and CD69- CD8+ 
T cells using the Gene Ontology (GO) and Immunological Signature database. The 
size of circles indicates the number of genes in each gene set found to be enriched in a 









TRM provide constant immunosurveillance and early protection against secondary 
challenge in NLTs. Here, we show that CD8+ T cells with a TRM phenotype also 
accumulate in LTs and dominate the LT CD8+ T cell response against HIV. Our key 
findings were: (i) CD69+ CD8+ T cells are highly expanded in HIV-infected LNs; (ii) LT 
CD69+ CD8+ T cells are largely not recently activated and instead bear transcriptional 
and epigenetic signatures of TRM cells distinct from non-resident T cells in LTs; (iii) LT 
CD69+ TRM do not recirculate to the blood via the thoracic duct; and (iv) LT CD69+ TRM 
most often dominate the HIV-specific CD8+ T cell response in LNs. Moreover, we found 
high magnitudes of LT HIV-specific TRM in ECs and demonstrate that CD69 expression 
is closely linked to the distribution of HIV-specific clonotypes between LN and blood. 
Collectively, these data advance our current understanding of immunosurveillance in 
LTs and define that ongoing CD8+ T cell-mediated immunity against HIV in LTs is in part 
mediated by TRM. 
Previous studies have identified bona fide LT CD8+ TRM in mice (Schenkel et al., 2014), 
but generally at low levels (Steinert et al., 2015), especially compared with the 
frequencies of human LT CD69+ CD8+ T cells recently described by Farber and 
colleagues (Sathaliyawala et al., 2013; Thome et al., 2014). These human studies have 
generated some debate as CD69 expression may be triggered by brain death-induced 
immune activation (Floerchinger et al., 2012). Our data show that high frequencies of 
non-cycling CD69+ CD8+ T cells are indeed generally present in multiple human LTs, 




signatures of NLT TRM (Hombrink et al., 2016b; Mackay et al., 2013; Pan et al., 2017). A 
recent study confirmed that human spleen and lung CD69+ CD8+ T cells share several 
prototypical genes of TRM (Kumar et al., 2017); however, this study was done on a blood-
filtering lymphoid organ (spleen) from brain-dead organ donors whereas our study solely 
focused on LNs from alive subjects. As such, the genes that are differentially expressed 
between CD69- and CD69+ CD8+ T cells are not entirely similar between our and the 
data set derived from spleen (Kumar et al., 2017). Notably, similar to other studies in the 
human TRM field, we do not find an association between residency in human LTs and the 
murine TRM-associated transcription factor Hobit (Hombrink et al., 2016b; Pallett et al., 
2017). We also report the epigenetic structure of human LT CD8+ TRM; clear epigenetic 
differences were apparent between the proximal regulatory regions of many genes in 
CD8+ TRM versus non-TRM, including genes associated with cellular motility, migration, 
adhesion, and function. Here, we indeed found OCRs for Blimp-1 that were more readily 
detected, suggesting a potential role in TRM development (Mackay et al., 2016). These 
results strongly support the notion that LT CD69+ cells are enriched for TRM.  
Our data indicate that CD69 can be expressed on CCR7+ cells, including naïve-like cells, 
whereas CD69+CCR7- cells usually represent bona fide TRM in both NLTs and LTs in 
mice. We cannot formally exclude the possibility that CCR7+CD69+ could modulate 
CD69 to exit LTs. Likewise, it remains unclear whether also CD103+CD69-CCR7+ CD8+ 
T cells originate from CD8+ TRM in LTs that modulate expression of CD69 and CCR7, or 
if these cells represent a recirculating CD8+ T cell memory population transiently 




identified CD103+CD69-CCR7+ migrating CD4+ T cells in both draining lymph nodes and 
blood originating from the skin after photo-activation that share the same phenotype we 
observed in both LT and TDL CD8+ T cells (Bromley, Yan, Tomura, Kanagawa, & Luster, 
2013). One possible mechanism by which T cells can downregulate CD69 is through 
extensive cycling, leading to increased KLF2 and S1PR1 expression (Rivera, Proia, & 
Olivera, 2008). This concept aligns with our acute SIV infection data, which show that 
CD69+ CD8+ T cell frequencies decline dramatically in LTs when antigen-specific T cells 
reach a cycling plateau, however then accumulate progressively as LT SIV-specific 
CD8+ T cells no longer cycle. It remains unclear whether these kinetic changes reflect 
homeostatic expansion of the original population or the conversion of recirculating cells 
into TRM. However, if all LT CD8+ TRM were free to transiently modulate CD69 and 
equally recirculate, it would be difficult to explain the observed clonotypic disequilibrium 
between LNs and blood in subjects with prominent HIV-specific CD8+ CD69+ responses. 
Importantly, clonotypic disequilibrium has also been observed in LTs with high levels of 
CD4+ TRM, such as in Peyer’s patches (Ugur, Schulz, Menon, Krueger, & Pabst, 2014). 
Coupled with the lack of CD69+ cells in the thoracic duct and extensive expansion of 
CD69+CCR7- cells in HIV infection, these data suggest that HIV-specific CD8+ T cells, 
which mostly bear the CD69+CCR7- phenotype, become resident as a consequence of 
local antigen exposure in LTs.  
In light of the fact that CD8+ TRM are abundant in all human LTs, it seems plausible that 
these cells serve as regional sentinels that scan all antigen-presenting cells originating 




population-level specificities as a function of pathogen exposure history within different 
LNs. There are estimated to be at least 600 distinct LNs/LTs in the human body (Goroll, 
May, & Mulley, 1987), without necessarily including ectopic/tertiary lymphoid structures 
at mucosal sites (Ruddle, 2016) that can number in the thousands in the large intestine 
alone (Langman & Rowland, 1986). HIV replicates actively in all of these tissues. 
Accordingly, HIV-specific CD8+ T cell responses must be deployed to all LT sites at all 
times to maintain overall control of viremia in HIV+ subjects. It should be noted in this 
context that we only compared the clonal distribution of HIV-specific CD8+ T cells 
between peripheral blood and a single LT site. In previous studies of peripheral blood, 
we showed that individual CD8+ T cell clonotypes specific for the same viral antigen can 
have distinct functional and phenotypic properties (Price et al., 2005). The observation 
that residency status directly influences the anatomical distribution of HIV-specific CD8+ 
T cell clonotypes therefore has far-reaching implications for our understanding of 
protective immune responses against HIV. First, our data indicate that HIV-specific CD8+ 
T cells in blood do not necessarily parallel HIV-specific CD8+ T cells in LTs. Second, 
there may be distinct HIV-specific CD8+ TRM populations between different LTs, which 
could impart differential immune pressure on viral replication at each site. Third, it 
becomes clear that we need to develop a comprehensive understanding of the functional 
abilities and potential deficiencies of LT HIV-specific TRM, because these cells exist in 
continuous proximity to HIV-infected CD4+ T cells and likely spearhead the cellular 
immune response against HIV. This view is supported by the observation that ECs 




In summary, our data indicate that CD8+ TRM likely play a central role in 
immunosurveillance against HIV. Further studies are now warranted to examine the 
precise mechanisms through which LT CD8+ TRM control HIV replication, potentially 
informing new approaches to the development of therapeutic vaccines and other 




Lymph node (LN) biopsies, peripheral blood, and TDL were collected from individuals 
classified as HIV– (n = 47), HIV+ chronic and naïve to ART (n = 35), HIV+ chronic on ART 
(n = 19), HIV+ ECs (n = 9), and HIV+ acute/early seroconverters (Fiebig IV–VI; n = 8). 
Recruitment occurred at four sites: INER-CIENI in Mexico City (HIV+ ART+/ART– blood 
and matched cervical LNs); Case Western Reserve University (HIV– mesenteric LNs); 
University of Pennsylvania (HIV– blood, spleen, iliac LNs, tonsils, and TDL; HIV+ blood, 
iliac LNs, and TDL); and University of California, San Francisco (HIV+ EC inguinal LNs). 
Subject grouping, tissue types, and clinical parameters are summarized in Table S1. All 
participants enrolled in this study provided written informed consent as per protocols 
approved by the INER-CIENI Ethics Committee and the Federal Commission for the 
Protection against Sanitary Risk (COFEPRIS), and the Institutional Review Boards of the 
University of Pennsylvania and Case Western Reserve University. HIV– LN and TDL 




tonsils from sleep apnea patients), mesenteric LNs (normal structures from patients 
undergoing abdominal surgery), iliac LNs (normal structures from kidney transplant 
donors), spleen (splenectomy due to trauma or surgical intervention), and TDL (patients 
with chylopericardium and chylothorax due to trauma or idiopathic disease). Sample 
sizes were based on the availability of biological samples rather than a pre-specified 
effect size. Investigators were not blinded to group identity during the course of 
experimentation. 
Cells and tissues 
Peripheral blood mononuclear cells (PBMCs) were purified from whole blood or 
leukapheresis products using Ficoll-Hypaque density gradient centrifugation. Lymph 
node mononuclear cells (LNMCs) and splenocytes were isolated using mechanical 
disruption. PBMCs and LNMCs were cryopreserved and stored at –140°C. 
TDL was accessed as described previously (G. Nadolski & Itkin, 2013; G. J. Nadolski & 
Itkin, 2012). In short, a 25-gauge spinal needle was advanced into an inguinal LN under 
ultra-sound guidance and an oil-based contrast agent (Ethiodol, Savage Laboratories) 
was injected under fluoroscopic guidance at a rate of approximately 1 mL per 
minute.  After opacification of the cisterna chyli, access was gained via an anterior 
transabdominal approach using a 21–22-gauge Chiba needle (Cook Medical Inc.). A 
V18 control guide wire (Boston Scientific) was then advanced into the thoracic duct and 
manipulated cephalad. Over the wire, a 60-cm 2.3F Rapid Transit microcatheter (Cordis 




stored in heparin tubes and centrifuged over a Ficoll-Hypaque density gradient on the 
same day to remove contrast agents. TDL samples were cryopreserved as described 
above or used directly in flow cytometry experiments. 
Conventional flow cytometry (FACS)  
Human cryopreserved PBMCs, LNMCs, and TDL samples were thawed and rested in 
RPMI-1640 media supplemented with 10% FBS, 1% L-glutamine, and 1% 
penicillin/streptomycin for at least 1 hour. Cells were then washed with PBS and pre- 
stained for chemokine receptors and adhesion molecules at 37oC for 10 minutes. After 
staining with LIVE/DEAD Aqua (Invitrogen) for 10 minutes, an optimized antibody 
cocktail was added for a further 20 minutes to detect additional surface markers. Cells 
were then washed with FACS buffer (PBS containing 0.1% sodium azide and 1% BSA), 
fixed, and permeabilized using a Cytofix/Cytoperm Buffer Kit (BD Biosciences) or a 
FoxP3 Transcription Factor Buffer Kit (eBioscience). An optimized antibody cocktail was 
then added for 1 hour to detect intracellular markers. In the relevant experiments, 
tetramers were added for 10 minutes at room temperature immediately before pre-stain. 
Stained cells were fixed in PBS containing 1% paraformaldehyde (Sigma-Aldrich) and 
stored at 4oC. All samples were acquired within 3 days using an LSRII (BD 
Biosciences). Data were analyzed with FlowJo software (version 9.8.8 or higher, 
TreeStar). The gating strategies are depicted in the relevant figures.  
For sorting experiments, thawed and rested PBMCs and/or LNMCs or fresh splenocytes 




higher concentrations of antibodies (i.e. not diluted 1:50 in FACS buffer). Cells were then 
washed with PBS and suspended in RPMI-1640 media without phenol red. All sorting 
experiments were carried out using a FACSAriaII (BD Biosciences).  
The following antibodies were used for human FACS experiments: anti-CCR7 APC- Cy7 
(clone G043H7, BioLegend), anti-CD49a PE-Cy7 (clone TS2/7, BioLegend), anti- 
CXCR6 BV421 (clone K041E5, BioLegend), anti-CX3CR1 PE (clone 2A9-1, BioLegend), 
anti-CCR5 BV650 (clone 3A9, BD Biosciences), anti-CXCR3 BV711 (clone G025H7, 
BioLegend), anti-CD14 BV510 (clone M5E2, BioLegend), anti-CD19 BV510 (clone 
HIB19, BioLegend), anti-CD3 AF700 or APC-R700 (clone UCHT1, BD Biosciences), 
anti-CD3 (clone UCHT1, BioLegend), anti-CD4 PeCy5.5 (clone S3.5, Invitrogen), anti-
CD8a BV570, BV605, BV711, or BV785 (clone RPA-T8, BioLegend), anti-CD27 AF700, 
BV650 or BV785 (clone O323, BioLegend), anti-CD45RO BV650 or PE-CF594 (clone 
UCHL1, BD Biosciences), anti-CD45RA BV650, PE or PE-CF594 (clone HI100, BD 
Biosciences), anti-CD69 BV421 or PE-Cy5 (clone FN50, BioLegend), anti-CD69 PE-Cy5 
(clone TP1.55.3, Beckman Coulter), anti-CD103 BV605 or PE-Cy7 (clone Ber-ACT8, 
BioLegend), anti-CD52 FITC (clone HI186, BioLegend), anti-CXCR5 AF488 or AF647 
(clone RF8B2, BD Biosciences), anti-PD-1 BV421 or PE (clone EH12.2H7, BioLegend), 
anti-HLA-DR BV605 or BV650 (clone G46-6, BD Biosciences), anti-CD38 APC or BV711 
(clone HIT2, BioLegend), anti-CD25 PE (clone M-A251, BD Biosciences), anti-4-1BB 
BV421 (clone 4B4-1, BioLegend), anti-OX40 APC (clone ACT35, BD Biosciences), anti-
ICOS PE-EF610 (clone ISA-3, eBioscience), anti-PD-L1 BV785 (clone 10F.9G2, 




B27, Invitrogen), anti-TNF PE-Cy7 (clone MAb11, BD Biosciences), anti-perforin BV421 
or PE-Cy7 (clone B-D48, BioLegend), anti-perforin PE- Cy7 (clone dG9, eBioscience), 
anti-granzyme B Alexa700 (clone GB11, BD Biosciences), anti-T-bet PE (clone 4B10, 
eBioscience), anti-T-bet PE-Dazzle 594 (clone 4B10, BioLegend), anti-Eomes AF647 
(clone WD1928, eBioscience), and anti-Ki67 FITC (clone B56, BD Biosciences). 
LIVE/DEAD Aqua (Invitrogen) was used to discriminate dead cells. 
Tetramers 
MHC class I tetramers conjugated to PE or BV421 were used to detect CD8+ T cells 
specific for HIV-SLYNTVATL (SL9)/HLA-A*0201, HIV-ILKEPVHGV (IV9)/HLA-A*0201, 
HIV-FLGKIWPSHK (FK10)/HLA-A*0201, HIV-TLNAWVKVV (TV9)/HLA-A*0201, HIV-
NLVPMVATV (NV9)/HLA-A*0201, HIV-RYPLTFGW (RW8)/HLA-A*2402, HIV-
KYKLKHIVW (KW9)/HLA-A*2402, HIV-GPGHKARVL (GL9)/HLA-B*0702, HIV-
HPRVSSEVHI (HI10)/HLA-B*0702, HIV-SPAIFQSSF (SM9)/HLA-B*0702, HIV-
KRWIILGLNK (KK10)/HLA-B*2705, HIV-KAFSPEVIPMF (KF11)/HLA-B*5701, HIV-
TSTLQEQIGW (TW10)/HLA-B*5701, HIV-ISPRTLNAW (ISW9)/B*5701, and HIV-
QASQEVKNW (QW9)/HLA-B*5701. All fluorochrome-conjugated peptide-HLA-
monomers were received from the NIH Tetramer Core Facility at Emory University or as 
gifts from Dr. David Price. All monomers were produced and tetramerized as previously 
described (Price et al., 2005). 
SIV-TTPESANL (Tat-TL8)/Mamu A*01 APC conjugated tetramers and SIV-CTPYDINQM 




Emory University. Gag-CM9 Mamu A*01-BV421 tetramers were prepared in our 
laboratory as previously described (Price et al., 2005). 
Kinetics of CD69 expression 
Memory CD69– and CD69+ CD8+ T cells were isolated from LTs using a FACSAriaII 
(BD Biosciences). Cells were then cultured for 9 days in 96-well plates in the presence 
or absence of 10 ng/mL rhIL-7 (R&D Systems). 
CCL19/21 stimulations 
Memory CD69– and CD69+ CD8+ T cells were isolated from LTs using a FACSAriaII (BD 
Biosciences). Cells were then cultured for up to 9 days in 96-well plates in the presence 
or absence of 100 ng/mL rhCCL19 and 100 ng/mL rhCCL21 (R&D Systems).  
Bulk RNA sequencing (RNA-seq) 
Memory CD69– and CD69+ CD8+ T cells from MesLNs (250 cells per subset) were 
sorted using a FACSAriaII (BD Biosciences) directly into lysis buffer provided with the 
SMART-Seq v4 Ultra Low Input RNA Kit (Takara) and snap frozen. RNA-seq libraries 
were prepared using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara) according to 
manufacturer’s protocols. Briefly, 3’ SMART-Seq CDS (oligo-dt) Primers were hybridized 
to the poly(A) tail of all the mRNA and reverse transcribed with the SMARTScribe RT 
enzyme. cDNA was pre-amplified using SeqAmp DNA polymerase and frozen. Amplified 
material was purified using Agencourt AMPure XP beads (Beckman) and cDNA quantity 




BioAnalyzer (Agilent). The PCR products were next indexed using the Nextera XT DNA 
Library Prep Kit (Illumina) according to manufacturer’s protocol. Briefly, products were 
tagmented using the Amplicon tagment mix, containing Tn5 transposase, and indexed 
using Nextera index 1 (i7) and index 2 (i5) primers. The libraries were again cleaned-up 
with Agencourt AMPure XP beads, pooled, quantified and sequenced across 75 base 
pairs (bp) using a paired-end strategy with a 150-cycle high output flow cell on a 
NextSeq 550 (Illumina). Three biological replicates were sequenced per experiment. 
Fastq files from three sequencing runs were concatenated and aligned using STAR 
2.5.2a and hg38 to generate a final unique paired mapped read depth ranging from 8 
million to 13.6 million reads per sample. The aligned files were normalized using Deseq2 
(Love, Huber, & Anders, 2014).  
Bulk RNAseq analysis 
Differential expression analysis - Differentially expressed genes on normalized RNA-seq 
counts between LN CD69– and CD69+ CD8+ T cells were assessed using a t-test (P < 
0.05) with the R limma package (v3.28.21). Genes of interest were then submitted to 
ingenuity pathway analysis (IPA, Qiagen Bioinformatics) to identify overrepresented 
pathways and upstream predictors. Differentially expressed genes with a larger than 2-
fold difference between LN CD69– and CD69+ CD8+ T cells were visualized using the 
Pheatmap package in R (v. 1.0.8).  
Gene set enrichment analysis (GSEA) - Normalized RNA-seq counts from sorted LN 




using Broad Institute software (http://www.broadinstitute.org/gsea/index.jsp). Gene 
signatures from LN CD69– and CD69+ CD8+ T cells were compared with gene signatures 
indicative of lung TRM programs (Hombrink et al., 2016b). 
ATAC sequencing (ATAC-seq) 
ATAC-seq was performed as described previously with minor modifications (Buenrostro, 
Giresi, Zaba, Chang, & Greenleaf, 2013). Memory CD69– and CD69+ CD8+ T cells from 
hepLNs (30,000–50,000 cells per subset) were sorted using a FACSAriaII (BD 
Biosciences) directly into R10 media. Cells were pelleted, washed with PBS, and treated 
with lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-
630). Nuclear pellets were resuspended in a transposition reaction with Tn5 transposase 
(Illumina) for 30 minutes to tag and fragment accessible chromatin, and the reaction was 
incubated in a water bath at 37ºC. Tagmented DNA was purified using a MinElute 
Reaction Cleanup Kit (Qiagen) and amplified using PCR. Libraries were then purified 
using a QIAQuick PCR Purification Kit (Qiagen) and paired-end sequenced (38bp + 
37bp) on a NextSeq 550 (Illumina). Two biological replicates were sequenced per 
experiment.  
Single-cell RNA sequencing 
Single-cell clonotypic analysis was derived from a previously published method (63). In 
brief, single HIV-tetramer+ cells were index sorted using a FACSAria II (BD Biosciences) 
directly into 96-well microtiter plates containing lysis buffer. In total, 552 cells were 




recovered by processing the lysates with an RNEasy Plus Micro Kit (Qiagen) and then 
binding to RNAClean (SPRI) beads (Beckman Coulter). ERCC RNA control (Ambion) 
was diluted 1 in 107 from stock, and 10% by volume was added to the RNAClean beads 
prior to purification. mRNA was then reverse transcribed from an anchored oligo-dT 
primer that includes a universal priming site at the 5’ end. RT reactions also included a 
template-switch oligonucleotide to allow the incorporation of the universal priming site at 
cDNA 3’ ends. Whole transcriptome cDNA was then amplified by PCR for 22–24 cycles 
using universal priming sites primers and Kapa HiFi Hot Start ReadyMix. After post-PCR 
clean-up, amplified whole transcriptome cDNA was incorporated into barcoded Illumina 
Nextera libraries and sequenced to a depth of about 2 million 150bp paired-end 
reads/cell on a HiSeq 4000 (Illumina). 
Single-cell RNAseq analysis 
Data were initially filtered for quality. Paired-end sequencing reads were then trimmed to 
remove adaptor sequences and low-quality basecalls using the utility Trimmomatic. 
Reads were subsequently aligned using Bowtie against a genomic repeat element 
database derived from RepeatMasker software to quantify and remove transcript reads 
considered to be irrelevant for the analysis in hand (rRNA, rRNA, LINEs, SINEs, etc). 
The remaining reads were aligned against the most recent human genome build, hg38, 
using the splice-site aware aligner, STAR. As a bioinformatic measure of library quality, 
the total frequency of reads that could be mapped to the transcriptome was determined, 
and outliers were excluded from further analysis. Transcripts were then quantified and 




number of libraries display low complexity and lack expression of highly expressed 
housekeeping genes. In most systems, a set of housekeeping genes should be 
expressed in every cell. We therefore use qPCR to identify viable samples expressing 
two distinct housekeeping genes. Samples with low or no expression of these genes are 
removed from Nextera library construction. To further ensure exclusion of data from 
single cells for which library construction was unsuccessful, we determined diversity 
(Shannon entropy and count of detected genes) using the R package, Vegan, and 
discarded outliers. 
For differential gene expression analysis of CD69- and CD69+ HIV-specific CD8+ T 
cells, raw counts were normalized using the R package, SCnorm. The normalized data 
was then transformed using z-transformation and analyzed for differential expression 
using the R package, ROTS. 
For gene set enrichment analysis (GSEA), normalized single cell RNAseq counts from 
were subjected to GSEA using Broad Institute software 
(http://www.broadinstitute.org/gsea/index.jsp).  
General statistical analysis 
Mann-Whitney or unpaired t-tests were used to compare differences between 
unmatched groups, and Wilcoxon matched-pairs single rank or paired t-tests were used 
to compare differences between matched samples. Spearman or Pearson tests were 
used for correlation analyses. Non-parametric or parametric tests were conducted based 




performed using R studio or Prism v7.0 (GraphPad). Cell ACCENSE (Automatic 
Classification of Cellular Expression by Nonlinear Stochastic Embedding) analyses were 
conducted to visualize phenotypic relationships within multivariate data sets (Shekhar, 













CHAPTER 3: CD8+ T CELLS DISPLAY DISTINCT 
TRANSCRIPTIONAL AND FUNCTIONAL SIGNATURES 
ASSOCIATED WITH ELITE CONTROL OF HIV IN LYMPHOID 
TISSUES 
This chapter is presented as a reprint (with permission) of the article titled “Elite control of HIV is 
associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells ” 
by Nguyen S, Deleage C, Darko S, Ransier A, Truong D, Agarwal D, Sada Japp A, Wu VH, Kuri-
Cervantes L, Abdel-Mohsen M, Del Rio Estrada PM, Ablanedo-Terrazas Y, Gostick E, Price DA, 
Hoxie JA, Naji A, Reyes-Terán G, Estes JD, Douek DC, Deeks SG, Buggert M, Betts MR. 
Science Translational Medicine. 2019 Dec 18, 11(523), eaax4077. 
doi:10.1126/scitranslmed.aax4077 
Son Nguyen was directly involved with data collection and/or analysis of all experiments  
3.1 Introduction 
It is established that virus-specific CD8+ T cells are critical determinants of the EC 
phenotype in humans and rhesus macaques (Deeks & Walker, 2007; Fukazawa et al., 
2015). In addition, HIV-specific CD8+ T cells in ECs are qualitatively distinct from HIV-
specific CD8+ T cells in chronic progressors (CPs), typically displaying enhanced 
polyfunctionality (Almeida et al., 2007; Betts et al., 2006), cytolytic activity (Hersperger et 
al., 2010; Migueles et al., 2002; Migueles et al., 2008), and proliferative capacity 
(McKinnon et al., 2012; Migueles et al., 2002), as well as a more differentiated memory 
phenotype and a distinct immunodominance profile (Addo et al., 2007; Almeida et al., 
2007; Goulder et al., 1997; Migueles et al., 2000). These attributes have been 
documented primarily among circulating lymphocytes, however, whereas HIV replication 
occurs predominantly in lymphoid tissues  (Pantaleo et al., 1991; Pantaleo et al., 1993; 




Lymphoid tissues are major reservoir sites for HIV. Recent studies have further 
demonstrated that almost 99% of viral RNA (vRNA)+ cells in SIV-infected rhesus 
macaques occur in lymphoid tissues (J. D. Estes et al., 2017), reinforcing the need to 
understand anatomically colocalized mechanisms of immune control. It has long been 
known that circulating CD8+ T cells are more cytolytic than CD8+ T cells in the lymphoid 
tissues of donors infected with HIV (Andersson et al., 1999). Moreover, a state of 
immune privilege exists in lymphoid tissues, which limits immunosurveillance by cytolytic 
HIV-specific CD4+ and CD8+ T cells (Buggert, Nguyen, McLane, et al., 2018; Reuter et 
al., 2017). In conjunction with the identification of distinct lymphoid tissue-resident 
memory CD8+ T cell subsets (Buggert, Nguyen, Salgado-Montes de Oca, et al., 2018; 
Kumar et al., 2017; Woon et al., 2016), these observations suggest that HIV-specific 
CD8+ T cells limit viral replication in lymphoid tissues via effector mechanisms that differ 
from those used by circulating HIV-specific CD8+ T cells (Buggert, Nguyen, Salgado-
Montes de Oca, et al., 2018). It also seems reasonable to propose that non-cytolytic 
suppression rather than cytolytic eradication dictates effective immune control of HIV, 
given reports of ongoing viral evolution (Mens et al., 2010; O'Connell et al., 2010) and 
the presence of replication-competent viral strains in ECs (Blankson et al., 2007). 
However, this proposition remains unproven to date, because previous studies have not 
defined the antiviral efficacy and functional characteristics of HIV-specific CD8+ T cells in 
the lymphoid tissues of ECs.  
In this study, we used a variety of methodological approaches, including polychromatic 




functional and transcriptional properties of HIV-specific CD8+ T cells in the peripheral 
blood and lymph nodes (LNs) of ECs and CPs. Our findings demonstrate that immune 
control of viral replication is associated with the occurrence of polyfunctional HIV-specific 
memory CD8+ T cells that exhibit a weak cytolytic signature and preferentially home to B 
cell follicles in the LNs of ECs.  
3.2 Results 
CD8+ T cells actively suppress HIV replication in the LNs of ECs  
To define the nature of protective CD8+ T cell responses in LNs, where HIV replicates in 
vivo, we obtained tissue biopsies (cervical, iliac, inguinal, mesenteric, pelvic, or 
peribronchial LNs) and fine needle aspirates (inguinal LNs) from HIV+ individuals on 
antiretroviral therapy (ART) and untreated HIV+ individuals categorized as acute 
seroconverters, ECs, or CPs (Table 3.1). Extremely low numbers of vRNA+ cells were 
detected in the LNs of ECs compared with the LNs of CPs (p = 0.0174; Fig. 3.1A). In line 
with previous findings (Boritz et al., 2016), vRNA+ cells were visualized in the B cell 
follicles and the paracortical region (T cell zone) (Fig. 3.2). Total CD4+ T cell-associated 
HIV DNA and RNA measurements were also lower in the LNs of ECs compared with the 
LNs of CPs (p = 0.0428 and p = 0.0016, respectively; Fig. 3.1B), and CD8+ T cells from 
the LNs of ECs displayed greater efficacy in a modified viral suppression assay (Saez-
Cirion, Shin, Versmisse, Barre-Sinoussi, & Pancino, 2010) compared with CD8+ T cells 




ART (p = 0.0323; Fig. 3.1C). These results suggest that CD8+ T cells maintain active 
control of HIV replication in the LNs of ECs.   
Table 3.1. Clinical characteristics of donors included in the study. Estimated 
duration of disease was based on the date of first HIV+ test (self-reported for EC and 
ART or clinically tested for CP and Acute) and the date of specimen collection. For the 
CP and Acute groups, patients did not present any symptoms of an acute infection and 
the status was confirmed with PCR, Western blot, and ELISA (in conjunction with clinical 
status for the Acute group). Values represent median and interquartile range.  
 EC ART CP Acute (Fiebig IV-VI) 
Number 12 14 18 7 




















10 Males / 1 
Female / 1 Male 
to Female 
8 Males / 1 
Female / 5 No 
Info 
10 Males / 
1 Female 
/ 7 No Info 
7 Males / 0 Female 
Protective 
HLA Alleles  
(HLA-
B*27/B*57) 
4 Yes/ 3 No / 5 
No Info 
0 Yes / 7 No 
/7 No Info 
0 Yes /12 





































Figure 3.1. CD8+ T cells from the LNs of ECs display superior antiviral efficacy. (A) 
Representative RNAscope images of paraffin-embedded lymph node (LN) biopsies from 
one EC and one CP (left) and data quantification (right). TCZ, T cell zone; BCF, B cell 
follicle. Elite controllers (EC): n = 7, ART-treated individuals (ART): n = 10, chronic 
progressors (CP): n = 11. (B) Quantification of cell-associated HIV DNA and RNA from 
negatively-selected LN CD4+ T cells by qPCR. One data point on the DNA plot was 
adjusted from 0 to 1 to display on the log scale. Error bars represent median and 
interquartile range. EC: n = 5, CP: n = 8. (C) Representative flow plots from a viral 
suppression assay using LN-derived CD8+ T cells co-cultured with autologous LN-
derived CD4+ T cells infected with HIV BAL virus in vitro (left) and data quantification 
(right). Dotted lines represent median and interquartile range. EC: n = 4, ART: n = 8, CP: 
n = 6. Flow cytometry data were pre-gated on single live CD8- T cells. Significance was 
determined using the Kruskal-Wallis test with Dunn’s correction (A), an unpaired t-test 





Figure 3.2. HIV RNA is present in B cell follicles and the T cell zone in LNs. (A) 
Gating scheme used to sort LN-derived CD4+ T cell subsets for viral quantification. 
Representative flow plots were generated from the LNs of one EC. (B) Quantification of 
HIV RNA in LN-derived CD4+ T cell subsets by qPCR. The limit of detection value was 
used in the absence of detectable HIV RNA (open circles). EC: n =. , ART: n = 2, CP: n 
= 2. (C) Frequency distribution of vRNA+ cells in B cell follicles (BCF) and T cell zone 
(TCZ). (D) Percent frequency of vRNA+ cells in B cell follicles, as determined by 
RNAscope. EC: n = 7, ART: n = 10, CP: n = 11. Error bars represent mean and SEM (B) 
or median and interquartile range (C). Significance was determined using a two-way 






Cytolytic CD8+ T cells are rare in LNs of ECs  
In peripheral blood, the frequency of cytolytic HIV-specific CD8+ T cells, defined by 
expression of perforin and granzyme B, correlates inversely with plasma viral load (pVL) 
(Hersperger et al., 2010; Migueles et al., 2002; Migueles et al., 2008). We therefore 
hypothesized that enhanced CD8+ T cell-mediated cytolytic activity may underlie viral 
control in the LNs of ECs. However, lower frequencies of perforin+, granzyme B+, and 
perforin+ granzyme B+ memory CD8+ T cells were detected in the LNs of ECs compared 
with the LNs of CPs (p = 0.0001, p = 0.0025, and p = 0.0003, respectively; Fig. 3.3A and 
Fig. 3.4A and B). The frequency of perforin+ granzyme B+ memory CD8+ T cells also 
correlated positively with pVL (r = 0.8213, p < 0.0001; Fig. 3.3B). Importantly, perforin 
and granzyme B were broadly expressed among circulating memory CD8+ T cells in 
donor-matched samples from ECs, indicating that the non-cytolytic phenotype was 
restricted to LNs (Fig. 3.4C). Immunohistochemical analyses confirmed that fewer 
perforin+ CD8+ T cells, but not granzyme B+ CD8+ T cells, were present in the LNs of 





Figure 3.3. Cytolytic CD8+ T cells are rare in the LNs of ECs. (A) Representative 
flowplots showing perforin and granzyme B expression in LN memory CD8+ T cells (left) 
and data quantification (right). EC: n = 13, ART: n = 11, CP: n = 13, acutely-infected 
individuals (acute): n = 7. (B) Correlation between the frequency of perforin+ granzyme 
B+ LN memory CD8+ T cells and plasma viral load (pVL). Values for pVL below the limit 
of detection were plotted as 40 copies/mL. Significance was determined using 
Spearman’s rank correlation. (C) and (D) Representative immunohistochemistry images 
of LN biopsies (left) stained for perforin (C) or granzyme B (D) and data quantification 
across donor groups (right). EC: n = 5, ART: n = 9, CP: n = 14. (E) Representative flow 
plots showing HIV-specific tetramer staining of LN memory CD8+ T cells (left) and data 




Representative flow plots showing HIV-specific tetramer+ cells (colored contours) 
overlaid on total LN memory CD8+ T cells (grey background) gated to display perforin 
and granzyme B expression (left) and data quantification (right). Each data point 
represents a distinct tetramer+ population. EC: n = 25, ART: n = 6, CP: n = 8. (G) 
Representative flow plots of redirected killing assays (left) and data quantification (right). 
Data was pre-gated on single live TFL4+ cells. Flow cytometry data, except in (G), were 
pre-gated using scheme shown in fig. S2A. Significance was determined using the 
Kruskal-Wallis test with Dunn’s correction (A, C, D, E, F, H, I, and K) or a two-way 
ANOVA (G). * p < 0.05, ** p < 0.01, *** p < 0.001.  
We then used human leukocyte antigen (HLA) class I-matched tetramers to examine 
HIV-specific CD8+ T cells. Higher frequencies of tetramer+ CD8+ T cells were present in 
the LNs of ECs compared with the LNs of CPs (p = 0.04; Fig. 3.3E). However, a very 
low frequency of HIV-specific CD8+ T cells expressed perforin and granzyme B, 
especially in the LNs of ECs (Fig. 3.3F). In response to cognate peptide stimulation, 
HIV-specific CD8+ T cells from the LNs of ECs also failed to upregulate either perforin or 
granzyme B, unlike CD8+ T cells paired by donor and specificity from the peripheral 
blood of ECs (Fig. 3.5A). Moreover, CD8+ T cells from the LNs of ECs did not exhibit 
discernable expression of perforin or granzyme B after 3 days in culture with HIV-





Figure 3.4. Fewer CD8+ T cells from the LNs of ECs express perforin and granzyme 
B. (A) Gating scheme used in flow cytometry experiments. Representative plots were 
generated from the LNs of one EC. Flow cytometry data shown in this report were pre-
gated on memory CD8+ T cells unless specified otherwise. (B) Quantification of perforin 
and granzyme B expression in LN-derived CD8+ T cells across donor groups. (C) 
Representative flow plots showing perforin and granzyme B expression in matched 
peripheral blood and LN-derived CD8+ T cells from one EC (left) and data quantification 
across donor groups (right). EC: n = 13, ART: n = 11, CP: n = 13. Significance was 
determined using the Kruskal-Wallis test with Dunn’s correction (B) or the Wilcoxon 







To quantify rather than infer cytolytic activity, we performed ex vivo redirected killing 
assays based on the detection of active caspase 3, which reliably identified non-viable 
target cells (Fig. 3.6A and B). In contrast to circulating CD8+ T cells, donor-matched 
CD8+ T cells from the LNs of ECs largely failed to kill P815 mastocytoma target cells pre-
coated with a CD3-specific monoclonal antibody, which mimics signals delivered via the 
T cell receptor (Fig. 3.3G). A similar anatomical discrepancy was observed using paired 
samples from CPs (Fig. 3.3G). Moreover, no significant increases in target cell death 
were observed after extended incubation (24 hours), ruling out the involvement of 
temporally delayed killing mechanisms (Fig. 3.6B).  
Collectively, these data suggest that cytolytic activity is unlikely the major mechanism of 










Figure 3.5. CD8+ T cells from the LNs of ECs do not upregulate cytolytic molecules 
in response to cognate antigen exposure. (A) LNMCs were stimulated for 6 hours 
with peptides representing optimal epitopes derived from HIV. Perforin and granzyme B 
were quantified in HIV-specific CD8+ T cells. Colored dots in the representative flow plots 
(left) depict HIV-specific CD8+ T cells defined by the expression of at least one of the 
following markers: CD107a, IFNg, TNF, MIP-1b, or IL-2. Black and red numbers indicate 
the frequency of HIV-specific CD8+ T cells before and after background subtraction, 
respectively. Background was the unstimulated condition. EC: n = 18, ART: n = 5, CP: n 
= 19. (B) Frequency of LN-derived perforin+ granzyme B+ CD8+ T cells after 3 days in 
culture with HIV-infected autologous LN-derived CD4+ T cells, as shown in Fig. 1c. EC: 
n = 4, CP: n = 6. Significance was determined using the Kruskal-Wallis test with Dunn’s 





Figure 3.6. Active caspase-3 detection captures the majority of killed target cells. 
CD8+ T cells isolated from the LNs, tonsils, and peripheral blood of HIV– individuals were 
incubated with anti-CD3-coated P815 cells at an target:effector ratio of 1:6 for 4 or 24 
hours. (A), Representative flow plots showing the detection of killed target cells via 
active caspase 3 versus LIVE/DEAD Aqua (L/D Aqua). Numbers represent frequencies 
of cells in each gate before (blue) or after background subtraction (red). (B) Breakdown 
of the total killing after 4 hours. Casp, active caspase-3. Each pie chart represents total 
killing after background subtraction. (C) Summary plot of redirected killing assays at 4 
hours and 24 hours. % target killed represents the sum of Casp–Aqua+, Casp+Aqua+, and 
Casp+Aqua– after background subtraction. LN: n = 2, Tonsil: n = 4, Blood: n = 4. Error 
bars represent mean and SEM. Significance was determined using a two-way ANOVA 





CD8+ T cells in LNs of ECs displayed increased follicle-homing potential 
B cell follicles are thought to represent immunoprivileged sites that potentiate HIV 
persistence as a consequence of limited immunosurveillance by CD8+ T cells (Connick 
et al., 2014; Connick et al., 2007; Folkvord et al., 2003; Folkvord et al., 2005; Fukazawa 
et al., 2015). Previous studies have also demonstrated an inverse correlation between 
the frequency of follicle-homing (CXCR5+) CD8+ T cells and pVL (Li et al., 2016; 
Rahman et al., 2018; Reuter et al., 2017). In line with these findings and the relative 
absence of vRNA+ cells in the B cell follicles of ECs (Fig. 3.2C and D), we detected 
higher frequencies of CXCR5+ memory CD8+ T cells in the LNs of ECs compared with 
the LNs of CPs (p = 0.0288; Fig. 3.7A). No increased frequencies were observed for 
HIV-specific CXCR5+ CD8+ T cells (p = 0.124; Fig. 3.7B). However, perforin and 
granzyme B were typically expressed at higher frequencies among CXCR5– CD8+ T 
cells compared with CXCR5+ CD8+ T cells, reaching significance in the ART cohort (p = 





Figure 3.7. CD8+ T cells in LNs of ECs display increased follicle-homing potential. 
(A) Representative flow plots showing CXCR5 expression on LN-derived memory CD8+ 
T cells (left) and data quantification across donor groups (right). EC: n = 12, ART: n = 9, 
CP: n = 8. (B) Quantification of CXCR5 expression on LN tetramer+ memory CD8+ T 
cells. Each data point represents a distinct tetramer+ population. EC: n = 26, ART: n = 6, 
CP: n = 8. (C), Representative flow plots showing perforin and granzyme B expression in 
LN-derived CXCR5+ and CXCR5– memory CD8+ T cells (left) and data quantification 
(right). Error bars represent median and interquartile range. EC: n = 12, ART: n = 9, CP: 
n = 8. Significance was determined using the Kruskal-Wallis test with Dunn’s correction 




HIV-specific CD8+ T cells have a distinct transcriptional profile in the LNs of ECs  
To identify potential correlates of viral control in lymphoid tissues, we analyzed the 




3.8A). The scRNAseq data were initially processed using an unsupervised kernel-based 
algorithm to determine cellular similarity in a global manner (see Methods). Clusters of 
transcriptionally distinct cells were present in each donor group (Fig. 3.8B). Importantly, 
normalized expression of PRF1 and GZMB was lower in HIV-specific CD8+ T cells from 
the LNs of ECs compared with HIV-specific CD8+ T cells from the LNs of CPs (Fig. 
3.8C), and normalized expression of transcripts encoding other cytolytic molecules, 
including GZMA, GZMH, GZMK, GZMM, FASL, and TNFSF10 (Russell & Ley, 2002; 
Voskoboinik et al., 2015), was either comparable between groups or enriched in HIV-
specific CD8+ T cells from the LNs of CPs compared with HIV-specific CD8+ T cells from 








Figure 3.8. Distinct transcriptomic signatures characterize HIV-specific CD8+ T 
cells from the LNs of ECs and CPs. (A) Set-up of the scRNAseq experiment, including 
data exclusion criteria. (B) tSNE visualization of the unsupervised kernel-based 
algorithm. (C) Violin plots of cytolysis-related genes showing z-normalized expression. 
(D) Average percent error of k-fold cross-validation of support vector machine (SVM) 
models using subsets of the L0-norm-ranked gene list. Each cross-validation was 
reiterated 100 times. (E) Heatmap showing z-normalized expression of the 200 feature 
genes. (F) Gene ontology (GO) analysis of the feature gene list using topGO. The top 25 
enriched terms were reported, and p-values were calculated using the classic Fisher 
method. (G) tSNE feature plots showing the distribution of gene expression. tSNE 
coordinates were calculated using the first 50 principal components and iterated 1,000 
times. The color gradient displays relative log-normalized gene expression. Significance 
was determined using scDD calculations (C and G). * p < 0.05, ** p < 0.01, *** p < 0.001.   
 
We then applied a supervised machine-learning algorithm to determine which transcripts 
best characterized HIV-specific CD8+ T cells from the LNs of ECs and HIV-specific 
CD8+ T cells from the LNs of CPs (see Methods). A set of 200 genes reliably 
distinguished each donor group (average error < 0.5%) (Fig. 3.8D). Hierarchical 
clustering of these ‘feature’ genes clarified the key inter-group differences (Fig. 3.8E), 
most of which could be assigned to immune response pathways via gene ontology (GO) 
analysis (Fig. 3.8F), and t-Distributed Stochastic Neighbor Embedding (tSNE) 
visualization generated two distinct clusters of HIV-specific CD8+ T cells that clearly 
differentiated ECs from CPs (Fig. 3.8G). Overlaying transcript abundance of specific 
‘feature’ genes onto the tSNE plot further revealed that HIV-specific CD8+ T cells from 
the LNs of CPs preferentially expressed inhibitory receptors, such as TIGIT, LAG3, and 
CD244, as well as the terminal differentiation marker KLRG1 and the transcription factor 




2014; Tauriainen et al., 2017; Wherry & Kurachi, 2015), whereas HIV-specific CD8+ T 
cells from the LNs of ECs preferentially expressed IL7R, which is crucial for homeostasis 
(Carrette & Surh, 2012), and several chemokines/cytokines, such as CCL5 and IL32, 
collectively indicating a highly functional memory phenotype (Fig. 3.8G).  
To confirm and extend these findings, we reanalyzed our scRNAseq data using the 
reproducibility optimized test statistic (ROTS) (Suomi, Seyednasrollah, Jaakkola, Faux, 
& Elo, 2017), a Bayesian model of differential distribution (scDD) (Korthauer et al., 
2016), and Seurat (Butler, Hoffman, Smibert, Papalexi, & Satija, 2018). A total of 2,264 
differentially expressed genes achieved significance in at least two of these independent 
analytical frameworks (Fig. 3.9A). These genes were enriched for immune-related 
terms, such as ‘immune response’, ‘immune system process’, and ‘defense response’, in 
GO analyses (Fig. S3.9B). Of particular note, ingenuity pathway analysis (IPA) further 
identified a core cassette of 11 transcripts encoding predicted secreted factors that were 
selectively upregulated in HIV-specific CD8+ T cells from the LNs of ECs, including TNF, 
CCL5, RNASE1, and IL32, which have been shown to suppress HIV replication (Appay 
& Rowland-Jones, 2001; Bedoya et al., 2006; Cocchi et al., 1995; Lane et al., 1999; 
Monteleone et al., 2014; Ribeiro-Dias, Saar Gomes, de Lima Silva, Dos Santos, & 




Figure 3.9. Differential expression analysis of the scRNAseq data. (A) Venn 
diagram showing the overlap of differentially expressed genes detected by each of the 
three algorithms. A total of 2,264 genes achieved significance (p < 0.05) in at least two 
of the three algorithms. These genes are listed in table S2. (B) The top 25 GO terms 
enriched among the 2,264 differentially expressed genes. (C) List of secreted molecules 
that were upregulated in ECs, as determined by IPA. Expression p-values were derived 
from the scDD algorithm. Expr Log Ratio represents log fold-change values obtained 
from the ROTS algorithm; positive values indicate higher expression levels in ECs 






HIV-specific CD8+ T cells are polyfunctional and translate proteins efficiently in 
the LNs of ECs   
To examine functionality of HIV-specific CD8+ T cells, we stimulated lymph node 
mononuclear cells with HIV peptides and measured the upregulation of various 
cytokines by flow cytometry. In response to cognate peptide stimulation, higher 
frequencies of HIV-specific CD8+ T cells from the LNs of ECs produced TNF compared 
with HIV-specific CD8+ T cells from the LNs of CPs (p = 0.0003) and HIV-specific CD8+ T 
cells from the LNs of HIV+ individuals on ART (p = 0.039) (Fig. 3.10A and B). A similar 
difference was observed for IFNg (p = 0.045), but the differences for MIP-1b and IL-2 did 
not reach statistical significance (Fig. 3.10B). Moreover, HIV-specific CD8+ T cells from 
the LNs of ECs were frequently polyfunctional, whereas HIV-specific CD8+ T cells from 
the LNs of CPs were predominantly monofunctional (Fig. 3.10C and D).  
To seek an explanation for these findings, we returned to our GO analysis of the 200 
‘feature’ genes. In addition to immune-related terms, several protein translation-related 
terms were also highlighted, including ‘SRP-dependent cotranslational protein targeting 
to membrane’, ‘protein targeting to ER’, and ‘translation initiation’ (Fig. 3.10F). Most of 
these genes encoded ribosomal protein subunits that were preferentially expressed in 
HIV-specific CD8+ T cells from the LNs of ECs (Fig. 3.10E). Gene set enrichment 
analysis (GSEA) similarly identified ‘translation’, ‘SRP-dependent cotranslational protein 
targeting to membrane’, and ‘3’ UTR-mediated translation regulation’ as the most highly 




We then performed in vitro translation experiments which measure the uptake of 
fluorescently labeled amino acid analog L-homopropargylglycine (HPG) in resting and 
activated CD8+ T cells from the LNs of ECs, CPs, and HIV+ individuals on ART. Higher 
frequencies of resting memory CD8+ T cells from the LNs of ECs incorporated HPG into 
newly synthesized proteins compared with resting memory CD8+ T cells from the LNs of 
CPs (p = 0.003) (Fig. 3.10G). These differences emanated primarily from the central 
memory compartment (Fig. 3.10G). After stimulation with HIV-derived peptides or anti-
CD3, functionally responsive CD8+ T cells from the LNs of ECs also incorporated more 
HPG than functionally responsive CD8+ T cells from the LNs of CPs (p = 0.008 and p = 
0.01, respectively) and functionally responsive CD8+ T cells from the LNs of HIV+ 
individuals on ART (p = 0.04 and p = 0.004, respectively) (Fig. 3.10G). These results 
suggest that efficient protein translation can explain, at least in part, the antiviral efficacy 








Figure 3.10. Polyfunctionality is associated with protein translation efficiency in 
HIV-specific CD8+ T cells from the LNs of ECs. (A) Representative flow plots showing 
the production of TNF and IL-2 by HIV-specific CD8+ T cells from the LNs of one EC and 
one CP in response to cognate peptide stimulation. Plots were pre-gated on total 
memory CD8+ T cells using scheme shown in fig. S2A. (B) Quantification of cytokine 
production by HIV-specific CD8+ T cells from LNs. The total response for each readout 
was determined by summing the corresponding frequencies after background 
subtraction of all Boolean gates using permutations of CD107a, IFNg, TNF, MIP-1b, and 
IL-2. Error bars represent median and interquartile range. (C) Polyfunctionality plot of 
HIV-specific CD8+ T cells from LNs. Only combinations of 4 and 5 functions are shown. 
Error bars represent mean and SEM. EC: n = 49, ART, n = 10, CP: n = 27. (D) Pie 
charts summarizing all combinations of functions. (E) Heatmap showing z-normalized 
expression of genes from the feature list identified by GO protein translation terms. (F) 
Gene set enrichment analysis (GSEA) of the scRNAseq data with reference to the 
Reactome Pathway Database, reporting the top 10 enriched pathways in ECs and CPs. 
(G) Quantification of protein translation efficiency in LN-derived CD8+ T cells. LNMCs 
were incubated with HPG in methionine-free medium for 6 hours in the presence or 
absence of HIV-derived peptides or anti-CD3. Responding cells were defined using 
Boolean gating for IFNg+ and/or TNF+ events. CM, central memory; EM, effector 
memory. EC: n = 3, ART: n = 3, CP: n = 4. Error bars represent mean and SEM. 
Significance was determined using a one-way ANOVA (D and G), or a two-way ANOVA 
(B). * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
3.3 Discussion 
In this study, we found that weakly cytolytic CD8+ T cells homed to B cell follicles, which 
constitute a major viral reservoir in vivo (Fukazawa et al., 2015; Pantaleo et al., 1991; 
Pantaleo et al., 1993; Pantaleo et al., 1994; Perreau et al., 2013), and potently 
suppressed HIV replication in the lymphoid tissues of ECs. Moreover, these LN-derived 
CD8+ T cells downregulated inhibitory receptors, upregulated multiple soluble factors 
and cytokines, and displayed efficient protein translation. Although cause and effect 




identify a protective immune signature, because CD8+ T cells from the LNs of HIV+ 
individuals on ART failed to acquire the characteristics of CD8+ T cells from the LNs of 
ECs even in the absence of viremia.  
Ultrasensitive assays have revealed ongoing viral replication and evolution in the plasma 
of ECs (Blankson et al., 2007; Mens et al., 2010; O'Connell et al., 2010). In line with the 
notion of anatomically localized immune control, however, we detected very few vRNA+ 
cells and very little HIV DNA and RNA in the LNs of ECs. We also found that CD8+ T 
cells from the LNs of ECs suppressed HIV replication in autologous CD4+ T cells far 
more efficiently than CD8+ T cells from the LNs of CPs and HIV+ individuals on ART. 
Depletion studies in non-human primates have shown that CD8+ T cells are required to 
maintain effective control of SIV (Cartwright et al., 2016; Fukazawa et al., 2015). 
Moreover, we and others have demonstrated that circulating CD8+ T cells exhibit 
superior cytolytic activity in ECs (Hersperger et al., 2010; Migueles et al., 2008). It was 
therefore surprising to find that very small CD8+ T cells from the LNs of ECs did not 
express cytolytic molecules compared with CD8+ T cells from the LNs of CPs. This 
particular finding suggests that  limited immunosurveillance by cytolytic T cells is a 
general phenomenon in HIV-infected lymphoid tissues (Reuter et al., 2017). Although we 
cannot exclude a role for cytolytic mechanisms, especially during the early stages of 
infection, our data clearly show that a potent cytolytic response is not a prerequisite for 
durable immune-mediated suppression of HIV. These data are consistent with the 




cytolytic, primarily circulate in the blood and patrol highly vascularized organs rather than 
other tissue sites (Thome et al., 2014).  
The general exclusion of cytolytic CD4+ and CD8+ T cells from lymphoid tissues is likely 
a conserved feature of the immune system that has evolved to limit the destruction of 
antigen-presenting cells and stromal tissues under conditions of persistent stimulation. 
Non-cytolytic effector functions may therefore be necessary for effective immune control 
of viruses and other pathogens that specifically target these sites. Indeed, an equivalent 
scenario has been described in the liver, where hepatitis B virus-specific CD8+ T cells 
eliminate the infection without killing hepatocytes via the secretion of IFNγ and TNF 
(Guidotti et al., 1996). Similarly, non-cytolytic mechanisms of immune control have been 
described in the context of infection with herpes simplex virus, measles virus, and 
vaccinia virus (Guidotti & Chisari, 1996, 2001), as well as HIV and SIV infection (Klatt et 
al., 2010; C. M. Walker et al., 1986; Wong et al., 2010). Our results add to this body of 
literature and further suggest that spatial distribution and the efficient translation of 
antiviral proteins are key features of a protective HIV-specific CD8+ T cell response in 
lymphoid tissues.   
A limitation of our study was the small sample size, which was most apparent in the 
scRNAseq experiment. Ideally, we would validate signatures identified in this dataset 
with an independent cohort. However, such cohorts are not easily accessible, given the 
extremely low frequency of ECs (<1% of all infected individuals) and the increasingly 
early initiation of ART. Several of the key gene signatures were nonetheless confirmed 




generalizable. The interpretation of the scRNAseq data was potentially confounded by 
antigen load since the comparison was limited to only between ECs and CPs. Technical 
difficulties and the low frequency of HIV-specific CD8+ T cells in LNs of ART-treated 
individuals did not permit the inclusion this group in our scRNAseq experiment. In order 
to alleviate this caveat, we included the ART-treated group in most of our functional 
experiments. Since CD8+ T cells from LNs of ECs were more polyfunctional, suppressed 
viral replication more potently, and translated proteins more efficiently than CD8+ T cells 
from LNs of both CPs and ART-treated individuals, these major signatures could not be 
explained by antigen load per se. 
In summary, we have shown that non-cytolytic CD8+ T cells with distinct functional, 
phenotypic, and transcriptional signatures, including the upregulation of known or 
predicted soluble factors, efficient protein translation, and a high ribosome biogenesis, 
suppress viral replication in the LNs of ECs. These observations are highly pertinent in 
light of current “kill” strategies designed to achieve a functional cure for HIV (Trautmann, 
2016). Collectively, our data support a model in which viral suppression rather than viral 
eradication dictates immune efficacy, without excluding a role for cytolytic mechanisms, 
and provide fresh impetus in the search for novel antiviral factors that may complement 






Peripheral blood samples, tissue biopsies (cervical, iliac, or inguinal LNs), and fine 
needle aspirates (inguinal LNs) were obtained from HIV+ individuals on ART (n = 14) and 
untreated HIV+ individuals categorized as acute seroconverters (Fiebig stage IV–VI, n = 
7), ECs (n = 12), or CPs (n = 18). Donors were recruited at three different sites: INER-
CIENI, Mexico City, Mexico; the University of California, San Francisco, USA; and the 
University of Pennsylvania, Philadelphia, USA. Clinical characteristics are summarized 
in table S1. Paraffin-embedded LN slides from CPs (n = 7) for microscopy experiments 
were obtained via the Pathology Core at the Hospital of the University of Pennsylvania 
(Philadelphia). All donors provided informed consent in line with protocols approved by 
the INER-CIENI Ethics Committee, the Federal Commission for the Protection against 
Sanitary Risk (COFEPRIS), and the Institutional Review Boards of the University of 
California (San Francisco) and the University of Pennsylvania (Philadelphia). Sample 
sizes were not predetermined by power calculations but instead were dependent on 
sample availability. Investigators were not blinded to group identity during the course of 
the study. Primary data are reported in data file S1. 
Sample processing and storage  
Peripheral blood mononuclear cells (PBMCs) were isolated using standard density 




biopsies via mechanical homogenization. Fine needle aspirates were processed for 
immediate experimentation. PBMCs and LNMCs were cryopreserved at –140 °C.  
RNAscope  
Next-generation in situ hybridization was performed on LN biopsies as described 
previously (Deleage, Wietgrefe, et al., 2016).  
qPCR quantification of cellular HIV-1 DNA and RNA  
Cell-associated DNA and RNA were purified using an AllPrep DNA/RNA Mini Kit 
(Qiagen), concentrated in a SpeedVac System (Thermo Fisher Scientific), and 
normalized to cell equivalents via quantitative PCR (qPCR) with reference to genomic 
telomerase reverse transcriptase for DNA and expressed ribosomal protein lateral stalk 
subunit P0 for RNA (Thermo Fisher Scientific). Total cell-associated HIV DNA and RNA 
were quantified via qPCR using a QuantStudio 6 Flex RealTime PCR System (Applied 
Biosystems) with the LTR-specific primers F522-43 (5’-
GCCTCAATAAAGCTTGCCTTGA-3’; HXB2 522–543) and R626-43 (5’-
GGGCGCCACTGCTAGAGA-3’; HXB2 626–643) and a FAM-BQ probe (5’-
CCAGAGTCACACAACAGACGGGCACA-3’). Cell-associated HIV DNA copy number 
was determined in a final reaction volume of 20 μL incorporating 4 pmol of each primer, 
4 pmol of probe, 5 μL of DNA, and 10 μL of 2x TaqMan Universal Master Mix II, with 
UNG (Thermo Fisher Scientific). Thermal parameters were as follows: 50 °C for 2 
minutes (1 cycle), 95 °C for 10 minutes (1 cycle), and 95 °C for 15 seconds followed by 




in a final reaction volume of 20 μL incorporating 4 pmol of each primer, 4 pmol of probe, 
5 μL of RNA, 0.5 μL of reverse transcriptase, and 10 μL of 2x TaqMan RNA-to-CT 1-
Step (Thermo Fisher Scientific). Thermal parameters were as follows: 48 °C for 20 
minutes (1 cycle), 95 °C for 10 minutes (1 cycle), and 95 °C for 15 seconds followed by 
59 °C for 1 minute (60 cycles). For HIV DNA measurements, external quantification 
standards were prepared from the ACH-2 cell line in a background of HIV– human 
cellular DNA, calibrated against the Division of AIDS Virology Quality Assurance 
Program HIV-1 DNA Quantification Standard (National Institutes of Health AIDS 
Reagent Program). For HIV RNA measurements, external quantification standards were 
prepared from full-length NL4-3 virion RNA, and copy number was determined using a 
Real-Time HIV-1 Viral Load Assay (Abbott Molecular), calibrated against the Division of 
AIDS Virology Quality Assurance Program HIV-1 RNA Quantification Standard (National 
Institutes of Health AIDS Reagent Program). Copy number for all samples was 
determined in triplicate by extrapolation against a seven-point standard curve (1–10,000 
cps).  
Peptide stimulation assay  
Cryopreserved LNMCs and PBMCs were thawed and rested overnight at 37 °C in RPMI 
medium supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% 
penicillin/streptomycin (R10). Cells were then washed in R10 and resuspended at 2 x 
106 cells/mL. Approximately 0.5 x 106 to 1 x 106 cells were used per condition, with lower 
bounds defined by cell availability in each sample. All stimulation conditions included 




BD Biosciences), and brefeldin A (1 µg/mL, Sigma-Aldrich). Cells were stimulated for 6 
hours at 37 °C with peptides previously described HLA-specific optimal HIV epitopes  
(each at a final concentration of 1 µg/mL, New England Biolabs). Positive controls 
incorporated staphylococcal enterotoxin B (1 µg/mL, Sigma-Aldrich). Degranulation was 
detected via the addition of anti-CD107a–PE-Cy5 (eBioH4A3, eBioscience) at the start 
of the assay to capture surface-mobilized events in real time (Betts et al., 2003).  
Flow cytometry  
LNMCs and PBMCs were stained with anti-CCR7–APC-Cy7 (G043H7, BioLegend) for 
10 minutes at 37 °C. Cells were then labeled with LIVE/DEAD Fixable Aqua (Thermo 
Fisher Scientific) for 10 minutes at room temperature to identify non-viable events, 
stained with a cocktail of directly-conjugated monoclonal antibodies for 20 minutes at 
room temperature to detect surface markers, fixed/permeabilized using a 
Cytofix/Cytoperm Kit (BD Biosciences), stained with another cocktail of directly-
conjugated monoclonal antibodies for 1 hour at room temperature to detect intracellular 
markers, and fixed in 1% paraformaldehyde (Sigma-Aldrich). Data were acquired using 
an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo software v9.9.4 
(Tree Star Inc.).  
Antibodies   
The following directly-conjugated reagents were used in flow cytometry experiments. 
Tetramer panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 (M5E2, 




BioLegend), anti-CD4–PE-Cy5.5 (S3.5, Thermo Fisher Scientific), anti-CD8–BV570 
(RPA-T8, BioLegend), anti-CD27– BV785 (O323, BioLegend), anti-CD45RO–BV650 
(UCHL1, BioLegend), anti-CD69–PE-Cy5 (TP1.55.3, Beckman Coulter), anti-CD103–
BV605 (2E7, BioLegend), anti-CXCR5–AF488 (RF8B2, BD Biosciences), anti-perforin–
PE-Cy7 (dG9, eBioscience), anti-granzyme B–AF700 (GB11, BD Biosciences), anti-
Tbet–PE-Dazzle (4B10, BioLegend), and anti-Eomes–AF647 (WD1928, eBioscience). 
Peptide stimulation panel: anti-CD107a–PE-Cy5 (eBioH4A3, eBioscience), anti-CCR7–
APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–
BV510 (HIB19, BioLegend), anti-CD3–BV711 (UCHT1, BioLegend), anti-CD4–PE-Cy5.5 
(S3.5, Thermo Fisher Scientific), anti-CD8–BV570 (RPA-T8, BioLegend), anti-CD27–
BV785 (O323, BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), anti-CXCR5–
AF647 (RF8B2, BD Biosciences), anti-IFNg–FITC (B27, BD Biosciences), anti-TNF–
BV605 (MAb11, BioLegend), anti-IL-2–APC-R700 (MQ1-17H12, BD Biosciences), anti-
MIP-1b–PE-Cy7 (D21-1351, BD Biosciences), anti-perforin–BV421 (B-D48, BioLegend), 
anti-granzyme B–PE-TxRed (GB11, Thermo Fisher Scientific), and anti-Tbet–PE (4B10, 
eBioscience). Redirected killing assay panel: anti-active caspase 3–FITC (C92-605, BD 
Biosciences), anti-CD3–PE (SK7, BD Biosciences), and anti-perforin–PE-Cy7 (dG9, 
eBioscience). Suppression assay panel: anti-p24–FITC (KC57, Beckman Coulter), anti-
CD14– BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–
BV711 (UCHT1, BioLegend), anti-CD4–PE-Cy7 (RPA-T4, BioLegend), anti-CD8–BV570 
(RPA-T8, BioLegend), anti-CD25–Tricolor (CD25-3G10, Thermo Fisher Scientific), anti-




Fisher Scientific). Translation assay panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend), 
anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-
CD3–BV711 (UCHT1, BioLegend), anti-CD4–APC (S3.5, Thermo Fisher Scientific), anti-
CD8–BV570 (RPA-T8, BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), azide–
AF488 (A10266, Thermo Fisher Scientific), anti-TNF–PE-Cy7 (MAb11, Thermo Fisher 
Scientific), and anti-IFNg–AF700 (B27, BD Biosciences). Viral quantification panel: anti-
CCR7–APC-Cy7 (G043H7, BioLegend), anti-CD3–APC-R700 (UCHT1, BD 
Biosciences), anti-CD4–PE-Cy7 (RPA-T4, BioLegend), anti-CD8–PE-Cy5.5 (RPA-T8, 
eBiosciences), anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19, 
BioLegend), anti-CD45RA–PE-CF594 (HI100, BD Biosciences), anti-CXCR5–AF647 
(RF8B2, BD Biosciences), and anti-PD-1–BV421 (EH12.2H7, BioLegend).  
Tetramers  
HLA class I tetramers conjugated to BV421 or PE were produced as described 
previously (Price et al., 2005). The following specificities were used to detect HIV-
specific CD8+ T cells: A*0201-IV9 (ILKEPVHGV), A*0201-SL9 (SLYNTVATL), A*0201-
FK10 (FLGKIWPSHK), A*0201-TV9 (TLNAWVKVV), A*2402-RW8 (RYPLTFGW), 
A*2402-KW9 (KYKLKHIVW), A*2402-RL9 (RPMTYKGAL), B*0702-GL9 (GPGHKARVL), 
B*0702-HI10 (HPRVSSEVHI), B*0702-SM9 (SPAIFQSSF), B*2705-KK10 
(KRWIILGLNK), B*3501-VY10 (VPLDEDFRKY), B*3501NY9 (NSSKVSQNY), B*5701-
KF11 (KAFSPEVIPMF), B*5701-TW10 (TSTLQEQIGW), B*5701-ISW9 (ISPRTLNAW), 




Immunohistochemistry   
LN biopsy material was cut at a thickness of 5 µm and processed as described 
previously (Schuetz et al., 2014). Briefly, tissue sections were heated in 0.01% citraconic 
anhydride containing 0.05% Tween-20 and incubated overnight at 4 oC with monoclonal 
or polyclonal antibodies specific for perforin (1:100, 5B10/VP-P967, Vector Laboratories 
Inc.) or granzyme B (1:200, HPA003418, Sigma-Aldrich). Slides were then washed in 
TBS containing 0.05% Tween-20, and endogenous peroxidases were blocked using 
1.5% (v/v) H2O2 in TBS, pH 7.4. Antigens were revealed using mouse Polink-1 or rabbit 
Polink-2 HRP in conjunction with ImmPACT DAB (Vector Laboratories Inc.) and Warp 
Red (Biocare Medical Inc.). Slides were then washed in H2O, counterstained with 
haematoxylin, mounted in Permount (Thermo Fisher Scientific), and scanned at 200x 
magnification using a ScanScope CS System (Aperio Technologies). Representative 
regions of interest (0.4 mm2) were identified visually, and high-resolution images were 
extracted from the whole-tissue scans. The percent area positive for CD4+ T cells was 
quantified using CellProfiler v3.1.5 (Carpenter et al., 2006).  
Single-cell RNAseq  
The experimental setup was described previously in Buggert et al. (Buggert, Nguyen, 
Salgado-Montes de Oca, et al., 2018). Briefly, single HIV tetramer+ cells were index 
sorted directly into 96-well microtiter plates containing lysis buffer using a FACSAria II 
flow cytometer (BD Biosciences). Cellular nucleic acids were recovered using an 




Performance was assessed using External RNA Controls Consortium (ERCC) RNA 
Spike-In Mix (Ambion). Reverse transcription was performed using oligo-dT primers, and 
cDNA was amplified over 22–24 PCR cycles using universal primers and Kapa HiFi 
HotStart ReadyMix (Kapa Biosystems). After clean-up, amplified cDNA was barcoded 
using Illumina Nextera libraries and sequenced to a depth of approximately 2 million 150 
bp paired-end reads/cell on a HiSeq 4000 (Illumina). Whole transcriptome data were 
obtained from 221 cells (n = 552 sorted cells). 
Single-cell RNAseq analyses  
Semblance, a kernel-method learning framework was used to assess the pairwise 
similarity between cells and compute the distance metric that best fitted the structure of 
the data (Agarwal & Zhang, 2019). Cell-to-cell similarity was learned using a rank-based, 
nonparametric function, and tSNE kernelization allowed the use of data from all available 
features. Dimensionality reduction was performed using kernel tSNE, wherein the 
pairwise similarity between cells was computed using the Semblance kernel as a 
distance measure. In determination of the cell-to-cell similarity matrix, the Gini index was 
used to account for the distribution of each gene and weigh it appropriately in the kernel 
calculation. The Gini index enabled the prioritization of genes with high variance as the 
genes that were more likely to provide useful features for niche group detection. Single 
cells were then projected onto a two-dimensional space using kernel tSNE, enabling 
intuitive visualization of hidden structures within the data. The supporting code is freely 





For support vector machine (SVM) analyses, genes were selected using a t-score cut-off 
of p < 0.01. Selected genes were then ranked using L0-norm regularization. The L0-
norm-ranked gene lists were fed into the SVM algorithm for cross-validation (k-fold = 10) 
in subsets (increment = 100 genes). The average prediction error for each cross-
validation was used to determine how well each subset of genes classified the desired 
labels. All steps were performed in MATLAB (MathWorks). L0-norm regularization was 
implemented using the MATLAB Feature Selection Library (MathWorks).  
Differentially expressed genes were identified using three approaches: ROTS (Suomi et 
al., 2017), which optimizes the t-statistics based on the inherent characteristics of the 
data; scDD (Korthauer et al., 2016), which is a differential expression analysis method 
that accounts for the possibility of multimodally distributed gene expression; and Seurat 
(Butler et al., 2018), which uses the non-parametric Mann-Whitney U-test to assess the 
null hypothesis that a randomly selected mean expression value for a given gene in one 
group will have an equal chance of being less than or greater than a randomly selected 
mean expression value for the same gene in a second group. As different genes in the 
dataset exhibited different distribution properties, these approaches in combination 
allowed us to winnow the list of differentially expressed genes, specifying a cut-off of p < 
0.05 in at least two of the three outputs. The scDD p-values are reported for simplicity.  
The topGO package Bioconductor v3.8 was used for GO analyses 
(https://bioconductor.org/packages/release/bioc/html/topGO.html). GO terms associated 
with each gene were obtained using the August 2017 ENSEMBL Database. Significance 




software developed by the Broad Institute (Mootha et al., 2003; Subramanian et al., 
2005).  
Redirected killing assay  
P815 mastocytoma target cells were labeled with LIVE/DEAD Violet (Thermo Fisher 
Scientific) and TFL4 (OncoImmun), washed twice in PBS, and incubated for 30 minutes 
at room temperature with anti-CD3 (5μg/mL, UCHT1, BioRad). CD8+ T cells were 
negatively selected from LNMCs or PBMCs using a CD8+ T Cell Enrichment Kit 
(StemCell Technologies). Isolated CD8+ T cells were rested in R10 for at least 45 
minutes at 37 °C and then incubated with anti-CD3-coated P815 cells at different 
effector-to-target ratios in a 96-well V-bottom plate for 4 hours at 37 °C. Cells were then 
stained as described above (see Antibodies section) and acquired using an LSRII flow 
cytometer (BD Biosciences).  
Killing capacity was calculated by subtracting the frequency of active caspase3+ TFL4+ 
LIVE/DEAD– P815 cells in target-only wells from the frequency of active caspase3+ 
TFL4+ LIVE/DEAD– P815 cells in wells containing effector cells.  
Viral suppression assay  
The viral suppression assay was modified from Sáez-Cirion et al. (Saez-Cirion et al., 
2010). Briefly, CD4+ T cells were positively selected from LNMCs or PBMCs using a 




Technologies) and activated using a cocktail of IL-2 (100 U/mL, Chiron), anti-CD3 (1 
µg/mL, UCHT1, Bio-Rad), anti-CD28 (1 µg/mL, L293, BD Biosciences), and anti-CD49d 
(1 µg/mL, L25, BD Biosciences). Concurrently, autologous CD8+ T cells were negatively 
selected from LNMCs or PBMCs using a CD8+ T Cell Enrichment Kit (StemCell 
Technologies) and rested in R10. After 2 days, CD4+ T cells were infected with HIV-1 
BAL (UPenn CFAR Virology Core) by spinoculation and incubated with or without 
autologous CD8+ T cells in the absence of exogenous IL-2. Cells were harvested after a 
further 3 days, stained as described above (see Antibodies section), and acquired using 
an LSRII flow cytometer (BD Biosciences).  
Suppression capacity was calculated by dividing the frequency of p24+ CD4+ T cells in 
wells containing autologous CD8+ T cells by the frequency of p24+ CD4+ T cells in wells 
lacking autologous CD8+ T cells.  
HPG translation assay  
The protein translation assay was adapted from Araki et al. (Araki et al., 2017). Briefly, 
LNMCs were rested overnight and incubated for 30 minutes in methionine-free R10. The 
cultures were then supplemented with Click-iT HPG (100 µM, Thermo Fisher Scientific). 
Cells were stimulated with PepMix HIV (GAG) Ultra (2µg/mL/peptide, JPT Peptide 
Technologies), PepMix HIV (NEF) Ultra (2µg/mL/peptide, JPT Peptide Technologies), or 
anti-CD3 (5μg/mL, UCHT1, BioRad) in the presence of GolgiStop (0.7 µL/mL, BD 
Biosciences) and brefeldin A (1 µg/mL, Sigma-Aldrich). After 6 hours, cells were stained 




(BD Biosciences), following the instructions in the Click-iT Plus Alexa Fluor Picolyl Azide 
Toolkit (Thermo Fisher Scientific).  
Statistics for non-sequencing data  
Data were checked for normality using the Shapiro-Wilk normality test. Parametric tests 
were used if the data passed the normality test, and non-parametric tests were used if 
the data failed the normality test. Multiple corrections for two-way ANOVA were 
performed using the two-stage linear step-up procedure of Benjamini, Krieger, and 
Yekutieli. Specific tests are indicated in the relevant figure legends. Analyses were 






CHAPTER 4: EPILOGUE 
4.1 Summary and implications 
Recent studies suggest that CD8+ T cells in tissues, including LTs, have a distinct 
phenotype compared to their blood counterparts. This dissertation aims to determine 
whether this concept is applicable to HIV infection by defining the identity of CD8+ T cells 
that are associated with effective control of HIV replication in LNs.   
In chapter 2, we demonstrated that a large portion of CD8+ T cells in LN of HIV-infected 
individuals are TRM and their frequency is positively linked to the effective immune-
mediated control of HIV in ECs. The key findings of this chapter are: (i) CD69+ CD8+ T 
cells are present in high frequency in HIV-infected LNs but do not resemble recently 
activated cells; (ii) instead they exhibit transcriptional and epigenetic profiles of TRM cells 
that are distinct from non-resident T cells in LNs; (iii) CD69+ TRM most often dominate the 
HIV-specific CD8+ T cell response in LNs; and (iv) most importantly, we found high 
magnitudes of LN HIV-specific TRM in ECs. Collectively, these data extend our current 
understanding of immunosurveillance in LTs and strongly suggest that ongoing CD8+ T 
cell-mediated immunity against HIV in LTs is, at least in part, mediated by TRM. 
In chapter 3, we defined the transcriptional and functional signatures of LN CD8+ T cells 
from ECs. Specifically, we showed that (i) there is an extremely low level of viral 
replication detected in LNs of ECs; (ii) LN CD8+ T cells from ECs exhibit a superior level 




by cytotoxic mechanisms as LN CD8+ T cells from ECs, including HIV-specific ones, 
produce a very low level of cytolytic proteins, such as perforin and granzyme B, and kill 
target cells very poorly; (iv) instead these cells upregulate the transcription of non-
cytolytic antiviral molecules, produce multiple cytokines upon stimulation, are more 
poised to traffic to BCFs, and display a high level of protein translation potential. These 
data support a model where viral suppression rather than elimination is the major 
mechanism of maintaining HIV control in LTs during the chronic phase of infection (Fig 
4.1). 
 
Figure 4.1 Model of effective CD8+ T cell-mediated HIV control in LTs. In this model, 
HIV-specific CD8+ T cells exhibit a TRM profile to remain local to surveil LTs, the critical 
reservoirs for persistent viral replication. These cells utilize non-cytolytic, rather than 
cytolytic, mechanisms to control HIV replication in LTs. In addition, the suppression 
activities likely occur in both TCZ and BCFs, leading to almost complete suppression of 




Collectively, the findings included in this dissertation substantially extend our knowledge 
on CD8+ T cell responses in LTs during HIV infection. For the first time, we provided 
evidence for the participation of CD8+ TRM in anti-HIV immunity in LTs. This finding 
emphasizes the notion that immunity in blood does not fully recapitulate immunity in 
tissues, including LTs. By definition, these TRM remain at a location for a long time 
without entering circulation. Therefore, sampling the peripheral blood for immunological 
studies fails to capture this population and tissue-specific immunological features. 
Since their discovery, TRM have been shown to be critical in immune responses to 
pathogens and cancers (Amsen et al., 2018; Rosato, Beura, & Masopust, 2017). These 
cells are thought to form the front line defense that can immediately respond to a 
reinfection. They can act as immediate effector cells that quickly kill infected host cells or 
as immune mediators by inducing a local antiviral state and recruit other immune cells 
via cytokine and chemokine secretion (Rosato et al., 2017). This concept is important for 
pathogenic infection, including HIV, as most of the viral replication occurs in tissues such 
as LTs (J. D. Estes et al., 2017; Pantaleo et al., 1991; Pantaleo et al., 1993). Emerging 
evidence indicates that HIV reservoirs in tissues are harbored by CD4+ TRM (Cantero-
Perez et al., 2019). This finding further emphasizes the importance of understanding 
anti-HIV immunity directly in tissues in order to better inform a cure strategy. The fact 
that we detected an elevation of HIV-specific CD8+ TRM in LNs of ECs suggests that 
CD8+ TRM are a novel correlate of effective immune-mediated control of HIV. Moreover, 




pathogenesis (Kiniry, Li, et al., 2018). Therefore, TRM should be a target for cure 
strategies and even for prophylactic vaccines.  
Learning from other infections, this approach is a promising one. Therapeutic and 
prophylactic vaccines inducing CD8+ TRM in the genital mucosa have shown protection 
against Herpes Simplex Virus-2 reactivation and infection, respectively, in animal models 
(Shin & Iwasaki, 2012; Srivastava et al., 2017; Srivastava et al., 2019). Similarly, a 
prophylactic live-attenuated influenza virus vaccine that induces lung TRM has 
demonstrated protection against heterosubtypic infection in a mouse model (Zens, 
Chen, & Farber, 2016). Intravenous BCG immunization inducing strong lung TRM 
responses in rhesus macaques has been shown to protect 90% of animals challenged 
with Mycobacterium tuberculosis (Darrah et al., 2020). An experimental prophylactic 
tuberculosis vaccine using a Rhesus Cytomegalovirus (RhCMV) vector protected 41% of 
rhesus macaques from Mycobacterium tuberculosis infection. This protection was 
associated with strong pathogen-specific TRM  responses (Hansen et al., 2018). The 
same platform has been tested for SIV infection where a RhCMV/SIV vaccine protected 
50% of animals intrarectally challenged with pathogenic SIVmac239 (Hansen et al., 2011; 
Hansen et al., 2013). This vaccine induced strong TEM responses at sites of viral 
replication such as LNs and mucosal tissues (Fukazawa et al., 2012; Hansen et al., 
2009). Though they have not been definitely shown, these responses resemble 
characteristics of TRM. On the other hand, using the RhCMV platform for therapeutic 
purposes has been proven to be challenging. In fact, RhCMV/SIV vaccine did not 




ART as early as 4-9 days post-infection (Okoye et al., 2018). This finding indicates that 
the induction of TRM alone is likely not sufficient for a sterilizing cure; but it is still valid to 
be explored for a functional cure. 
The fact that effective responses against HIV are associated with the presence of TRM in 
LTs raises a few important points for consideration. Since we were able to examine only 
a few out of hundreds of LNs present in the body, it remains to be determined if the level 
of viral control differs between LNs. Is it possible that there is ongoing viral replication 
and evolution in some LNs but not others? And if that is the case, how is it related to 
different aspects the CD8+ TRM responses? If indeed the level of viral control varies 
among LNs, it will be critical to determine if there is ongoing viral evolution at some sites 
but not others? What is the threshold (i.e. the number of sites where control is achieved) 
for a functional cure? It is also important to determine how long these TRM stay resident 
in a specific LN and whether that duration has implications for a functional cure. 
In addition to the identification of HIV-specific LT CD8+ TRM, we also defined the 
functional and transcriptional features associated with effective CD8+ T cell-mediated 
viral control in LNs of ECs.  Results in chapter 3 indicate that these features in LNs are 
not exactly the same as what have been previously described in blood. CD8+ T cells in 
LNs of ECs exhibit low cytolytic capacity, typified by very low expression levels of 
cytolytic proteins such as perforin and granzyme B as well as low target cell-killing 
activity. These levels are much lower compared to blood (Kiniry, Hunt, et al., 2018; 
Reuter et al., 2017). Though these data are only cross-sectional and do not provide 




mechanism that maintains viral control in LTs. As described in 1.6, in blood, cytotoxicity 
is one of the strongest correlates of the EC status (Hersperger et al., 2010; Migueles et 
al., 2002; Migueles et al., 2008). Therefore, the absence of this signature in LNs of ECs 
is unexpected and very striking. However, this finding does not invalidate the correlation 
between blood cytolytic CD8+ T cells and the EC status. In fact, a robust cytolytic profile 
of blood CD8+ T cells from ECs might reflect the effective elimination of infected cells in 
the spleen, where cytolytic CD8+ T cells can potentially interact with infected targets. 
Despite their low cytolytic capacity, LN CD8+ T cells from ECs are highly polyfunctional 
and display superior viral suppression capacity, indicating that CD8+ T cells in LTs might 
utilize alternative non-cytolytic mechanisms to control viral replication. This finding has 
major implications for HIV cure research. 
Currently, one of the most prominent HIV cure strategies is “shock and kill.” Briefly, this 
is a two-steps approach in which the first step involves the reactivation of the HIV latent 
reservoirs and the second step involves the utilization of cytolytic mechanisms to 
eliminate infected cells (Deeks, 2012). The success of this strategy rests on the 
assumption that immune cells, namely CD8+ T cells, can effectively kill infected cells at 
sites of HIV reservoirs. In other words, the strategy assumes that LT CD8+ T cells are 
highly cytotoxic. Nevertheless, LT CD8+ T cells, as demonstrated in this study, are 
largely not cytotoxic, the prospect of the “shock and kill” strategy is now called into 
question. In fact, clinical trials of the “shock and kill” strategy using histone deacetylase 
inhibitors have successfully “shocked” but failed to “kill”, as no measurable reduction in 




can be partially due to the negative impact of the histone deacetylase inhibitors used in 
“shock and kill” on the antiviral functions of CD8+ T cells (Walker-Sperling, Pohlmeyer, 
Tarwater, & Blankson, 2016). Additionally, it is well-established that CD8+ T cells fail to 
accumulate in BCFs, which are major sanctuaries for persistent viral replication 
(Bronnimann et al., 2018; Connick et al., 2014; Connick et al., 2007; Fukazawa et al., 
2015). Our study sheds light on an additional challenge for “shock and kill” to overcome, 
which is the rarity of cytolytic CD8+ T cells in LT and the inability of these cells to quickly 
upregulate them upon stimulation. 
In contrast to the “shock and kill” approach, our results reignite an old avenue of HIV 
cure research, which is to identify the non-cytolytic mechanisms that are capable of 
suppressing viral replication in LTs. This avenue was established very early in the 
pandemic. In fact, non-cytolytic response mediated by CAF was the first type of CD8+ T 
cell responses observed in HIV-infected individuals, one year prior to the description of 
the cytolytic response (B. D. Walker et al., 1987; C. M. Walker et al., 1986). Enhanced 
CAF activities in both blood and LTs have been associated with improved disease 
clinical state (Blackbourn et al., 1996; Mackewicz, Ortega, & Levy, 1991). CAF is 
exclusively produced by CD8+ T cells and can be composed of one or more secreted 
soluble factors (Levy, 2003; C. M. Walker & Levy, 1989). It can be active against multiple 
retroviruses, including HIV-1, HIV-2, SIV, murine retroviruses, and avian retroviruses 
(Copeland, McKay, & Rosenthal, 1995; Levy, 2003). Mechanistically, it blocks LTR-
driven HIV transcription by interfering with RNA polymerase II accumulation (Blazek, 




Shridhar, Chen, & Gupta, 2014). Multiple studies have attempted to identify the exact 
identity of CAF but all failed. Though multiple soluble factors, such as α-defensins, beta-
chemokines, and TOE1, exhibit viral inhibition activities resembling of CAF, none of 
them fully recapitulate CAF characteristics (Cocchi et al., 1995; Sperandio et al., 2015; 
L. Zhang et al., 2002).  
Independent of the exact identity of CAF, non-cytolytic control of HIV has been 
demonstrated in vivo. Depletion of CD8+ T cells in rhesus macaques does not increase 
the life-span of productively SIV-infected cells, indicating that direct killing is not the main 
mechanism antagonizing viral replication (Klatt et al., 2010; Wong et al., 2010). In 
addition, the equivalent life-span of wild-type virus-infected cells and escape-mutant-
infected cells in pigtail macaques infected with a SIV-HIV chimeric virus (SHIV) suggests 
that non-cytolytic viral control is at work (Balamurali et al., 2010). Our results significantly 
extend these findings by demonstrating the relevance of this viral control mechanism in 
LTs. We also identified potential antiviral molecules for validation including IL-32 and 
RNase 1. If cure strategies inducing cytolytic elimination of HIV-infected cells is termed 
“shock and kill”, strategies inducing non-cytolytic control of HIV replication can be termed 
“block and lock”. Ultimately, the elimination of HIV reservoirs through “shock and kill” is 
required for a sterilizing cure. However, if non-cytolytic mechanisms are indeed 
responsible for the maintenance of viral suppression in ECs, who can remain aviremic 




4.2 Open questions and future directions 
Despite the exciting potential of transferring the knowledge unveiled in this dissertation 
into a functional HIV cure, many questions remained to be answered before this 
potential can be realized. 
Which non-cytolytic mechanisms should be induced?  
It is clear through Results in chapter 3 that non-cytolytic mechanisms are contributing to 
the maintenance of viral control in LNs of ECs. However, this current study fell short of 
identifying the exact mechanisms that are at work. In the future, advanced technologies 
such as high-throughput drug screens, CRISPR/Cas9 screens, and highly sensitive 
proteomic approaches, should be utilized to identify non-cytolytic molecules that can 
suppress HIV replication. Nevertheless, via transcriptional analysis, we have identified a 
list of secreted molecules that can contribute to the non-cytolytic control of HIV (Fig 
3.9C). Some of those molecules have been shown to exert antiviral activities, such as IL-
32 and RNase 1. 
IL-32 is a cytokine that was discovered in 1992. Originally, it was termed NK4 transcript 
and was found to be produced by NK and T cells upon activation with IL-2 or mitogens, 
respectively (Dahl, Schall, He, & Cairns, 1992). However, studies have shown that IL-32 
can also be produced by other cell types, including but not limited to fibroblasts, 
monocytes/macrophages, epithelial cells, and fibroblasts (Ribeiro-Dias et al., 2017). 
Interestingly, this cytokine has no homology with other well-studied cytokines and is not 




full-length γ and smaller spliced isoforms α, β, δ, θ, ε, ζ, and η. This cytokine can be 
released upon necrotic death or secreted via exosomes. To date, the receptor for IL-32 
still has not been identified (Ribeiro-Dias et al., 2017).  
Despite many unknowns, IL-32 has been shown to be relevant for HIV immunity. In fact, 
IL-32 is elevated in serum, LNs, and gut of HIV-infected individuals (Rasool et al., 2008; 
A. J. Smith et al., 2011). However, conflicting reports exist on whether IL-32 has a pro-
HIV or anti-HIV role during the infection. On one hand, IL-32 induces the production of 
immunosuppressive molecules such as IDO and ILT4, which dampen immune cell 
activation, reduce the production of cytotoxic molecule, and promotes HIV replication in 
LTs (A. J. Smith et al., 2011). On the other hand, knocking down endogenous IL-32 
results in an increase of HIV LTR activity, indicating that IL-32 can antagonize HIV 
replication (Rasool et al., 2008). Exogenous addition of IL-32 can also suppress HIV 
production from macrophages (Nold et al., 2008). Since IL-32 exists in multiple isoforms, 
variation in biological activities between isoforms can potentially account for the 
contradictory roles of this cytokine in HIV infection. IL-32γ is proinflammatory through the 
induction of IL-6 and IFNγ but IL-32α is largely anti-inflammatory through the induction of 
IL-10 (S. H. Kim, Han, Azam, Yoon, & Dinarello, 2005; Zaidan et al., 2019). Meanwhile, 
IL-32β exerts both pro- and anti-inflammatory properties (Zaidan et al., 2019). Higher 
plasma levels of IL-32γ and β but not α at an earlier clinic visit predicts disease 
progression at a later visit in a cohort of slow progressors (El-Far et al., 2016). 
Additionally, IL-32γ but not α and β can induce HIV production in latently infected CD8+ 




have shown that the exogenous addition of IL-32α into a culture of HIV-infected CD4+ T 
cells results in a 30-50% reduction in viral production (Fig 4.2A and B). In contrast, the 
addition of IL-32β induces only a minimal level of viral suppression (Fig 4.2A and B). 
These results indicate that IL-32α but not β can suppress HIV replication, at least in 
vitro; and this cytokine is potentially involved in the non-cytolytic suppression of HIV 
replication in LNs of ECs. However, this finding requires further validation. Key questions 
include: Which IL-32 isoforms are predominant in LNs of ECs? What are the protein 
levels? And how can the expression of this cytokine be manipulated? 
 
Figure 4.2 IL-32α but not β can suppress HIV replication. CD4+ T cells were isolated 
from HIV- donors and activated for 2 days with α-CD3/CD28 prior to infection with 5ng 
with HIV BAL virus in the presence or absence of IL-32. IL-32 was added after 45 
minutes of virus spinoculation. After 3 days, the culture was stained for intracellular p24 
(A) Representative flow cytometry plots showing the % of p24+ cells in the culture. (B) 
Quantification %p24 reduction for each condition (calculated by (%p24+ in cultures with 
IL-32/%p24+ in cultures without IL-32)*100). 5ng: n =4, 50ng: n=8, 500ng: n=4. Bars 





RNase 1, also known as RNase A, is another secreted molecule that was found to be 
upregulated in HIV-specific CD8+ T cells in LNs of ECs. This RNase is one of eight 
members of the protein ribonuclease A (RNase A) superfamily (Koczera, Martin, Marx, & 
Schuerholz, 2016). It can induce the production of proinflammatory cytokines such as 
TNF, IL-6, and IL-12 by DCs (Koczera et al., 2016; D. Yang et al., 2004). Exogenous 
addition of RNase 1 into cultures of HIV-infected CD4+ T cells resulted in a decrease in 
p24 level in the supernatant, demonstrating the antiviral activity of this RNase (Bedoya 
et al., 2006). In addition, it has also been shown that RNase 1 is partially responsible for 
the anti-HIV activity by CD8+ T cell-mediated HLA-alloantigen recognition (Pinto, Sharpe, 
Cohen, & Shearer, 1998; Rugeles et al., 2003). Another study observed an anti-HIV 
effect of RNase 1 extracted from human chorionic gonadotropin preparations, 
suggesting its potential protective role during pregnancy (Lee-Huang et al., 1999). 
RNase 4, which is closely related to RNase 1, has been implicated in the CD8+ T cell-
mediated suppression of X4-tropic HIV replication (Cocchi et al., 2012). These results do 
support a role for RNase 1 in the non-cytolytic control of HIV. However, similar to IL-32, 
further experimentation is required to confirm the contribution of RNase 1 in anti-HIV 
immunity.  
Though we currently do not know the exact mechanism, through this dissertation we 
hope to bring to attention the relevance of non-cytolytic HIV control. It remains to be 
determined whether IL-32 or RNase 1 or other molecules implicated in our study is the 




have to be dependent on just one specific molecule. Instead, it could be a combination 
of multiple molecules. In addition, it does not have to be due to some unidentified 
molecules but could be due to an enhancement of existing molecules. Our data on 
polyfunctionality and protein translation potential support this concept. In fact, we 
observed a signature of polyfunctionality that is coupled to enhanced protein translation 
potential by HIV-specific CD8+ T cells in LNs of ECs. This enhanced potential, which is a 
totally novel feature of effective HIV-specific CD8+ T cells, possibly poise these cells to 
quickly produce proteins, including known cytokines and other non-cytolytic antiviral 
molecules, upon activation. This augmented responsiveness of LN HIV-specific CD8+ T 
cells in producing known soluble molecules might be sufficient to effectively control HIV 
replication, even in the absence of a novel antiviral molecule. If this is true, boosting 
protein translation efficiency of CD8+ T cells can be explored as a part of a cure strategy. 
Ultimately, in order to turn the concept of non-cytolytic HIV control into practice, one 
would need to determine a way to induce these mechanisms. Without a definite target, it 
is challenging to identify a rational induction approach. Therefore, once the exact non-
cytolytic mechanism is identified, the design of an induction strategy is more feasible. 
Can inducing cytotoxic CD8+ T cells in LTs still be used as a cure strategy?  
Our results, though strongly supporting a role for non-cytolytic HIV control, do not 
exclude the viability of targeting CD8+ T cell-mediated cytotoxicity as a cure strategy. As 




cells. Since we observed only weak cytotoxicity in LTs of HIV-infected individuals, an 
enhancement of this effector function is needed to make it viable for a cure strategy.  
Chimeric antigen-receptor (CAR) T cells have been considered as a cure strategy for 
over 25 years (Kuhlmann, Peterson, & Kiem, 2018; Wagner, 2018). CAR is an 
engineered cell therapy approach that endows T cells with a new or enhanced specificity 
to a target of interest for therapeutic purposes. For example, CAR T cells targeting 
CD19, which is expressed on all B cells, have shown more than 80% efficacy in 
combating pediatric acute lymphoblastic leukemia (Davila et al., 2014; D. W. Lee et al., 
2015; Maude et al., 2014). Several CAR designs have been studied for targeting HIV-
infected cells, namely CD4 and/or broadly neutralizing antibodies (Wagner, 2018). 
Potent anti-HIV activities mediated by CAR T cells have been in vitro and in animal 
models (Ali et al., 2016; Anthony-Gonda et al., 2019; Hale et al., 2017; Leibman et al., 
2017). However, different anti-HIV CAR T cell designs have only shown limited 
effectiveness in human clinical trials (Deeks et al., 2002; Mitsuyasu et al., 2000; R. E. 
Walker et al., 2000). It is important to emphasize that the success of CAR T cell cure 
strategies relies on the intrinsic cytotoxic capacity of the engineered cells, their ability to 
traffic to LTs, and their retention in these sites. Published data in mice indicate that 
during homeostasis CD8+ T cells with the strongest cytolytic potential, i.e. CX3CR1+/hi, 
are constrained to the blood vasculature and do not recirculate through LTs (Bottcher et 
al., 2015; Gerlach et al., 2016). In other words, cytolytic CD8+ T cells are not recruited to 
LTs under homeostasis. Therefore, successful CAR T cell cure strategies must be able 




Regarding strategies that boost CD8+ T cell cytotoxicity, IL-15 has been actively 
investigated. It can induce cytotoxic functions of CD8+ T cells via perforin granzyme B 
upregulation (Fig 4.3A) (Tamang et al., 2006; Ye, Young, & Liu, 1996; Younes et al., 
2016). In mouse tumor models, the combination of a IL-15 superagonist (N-803) and the 
immune checkpoint blockade anti-PD-L1 result in an increased expression of granzyme 
B by CD8+ T cells at the site of metastasis compared to monotherapy with either reagent 
alone (Knudson, Hicks, Alter, Schlom, & Gameiro, 2019). This enhancement effect of a 
IL-15 on CD8+ T cell cytotoxicity has been observed in other cancer models (B. Liu et al., 
2016; R. B. Liu et al., 2013). In the context of HIV/SIV infection, CD8+ T cells from ART-
treated individuals upregulate perforin expression upon IL-15 stimulation (White et al., 
2007) . The administration of a native heterodimeric IL-15 in SHIV-infected rhesus 
macaques results in an increased frequency of granzyme B+ CD8+ T cells as well as a 
reduced levels of viral RNA in LNs (Watson et al., 2018). In addition to enhancement of 
cytotoxic functions, IL-15 superagonist can increase CD8+ T cell traffic into BCFs via the 
upregulation of CXCR5 (Webb et al., 2018; Webb et al., 2020). This added benefit is 
highly relevant for HIV/SIV infection as BCFs are sites of persistent viral replication that 
are typically devoid of CD8+ T cells (Bronnimann et al., 2018; Connick et al., 2014; 
Connick et al., 2007; Fukazawa et al., 2015). Not only impacting CD8+ T cell function, IL-
15 superagonist does show some latency reversal activities (R. B. Jones et al., 2016; 
McBrien et al., 2020). The combinatory effect of cytotoxicity inducing, BCF trafficking 
enhancing, and latency reversal makes IL-15 superagonist an attractive candidate for a 




in ART-naïve rhesus macaques after IL-15 superagonist administration is only transient 
as T cells become less responsive to the therapy (Ellis-Connell et al., 2018) In addition, 
the latency reversal activity of IL-15 superagonist appears to be weak in vivo (McBrien et 
al., 2020; Webb et al., 2020). These results call into question the sufficiency of IL-15 
superagonist as a cure strategy. In reality, it is likely going to require a combination of IL-
15 superagonist, an immune checkpoint blockade, and a latency reversal agent to make 
this approach a viable cure strategy. However, this concept remains to be tested. 
Dual-affinity re-targeting antibody (DART) is another strategy that employs CD8+ T cell 
cytotoxicity. This approach utilizes engineered antibodies that are bi-specific, one 
specific for effector cells and one for target cells, in order to induce lysis of HIV-infected 
cells by CD8+ T cells (Fabozzi, Pegu, Koup, & Petrovas, 2019; H. Yang, Wallace, & 
Dorrell, 2018). A DART combining a non-neutralizing Env-specific antibody (A32 or 7B2) 
and an anti-CD3 antibody has been shown to mediate ex vivo  CD8+ T cell-mediated 
lysis of HIV-infected CD4+ T cells (Sung et al., 2015). A different study using a DART 
combining several broadly neutralizing antibodies (PGT121 and PGT145) and an anti-
CD3 antibody also showed killing of low Env-expressing resting CD4+ T cells by CD8+ T 
cells. In the same study, the addition of two DARTs into ex vivo PBMC cultures isolated 
from ART-treated individuals resulted in a reduction of viral RNA after 14 days, 
suggesting that DARTs have the potential of targeting HIV latent reservoirs (Sloan et al., 
2015). Another DART construct that utilizes the broadly neutralizing antibody VRC07 
has demonstrated both a latency reversal and a CD8+ T cell-mediated lysis effect on 




are promising, it is important to emphasize that DARTs have mainly been tested ex vivo 
and using blood CD8+ T cells, which are highly cytolytic. One study has gone on to test 
the effect of DART using LT CD8+ T cells. This study showed that DART enhanced the 
ex vivo ability to lyse HIV-infected CD4+ T cells by follicular CD8+ T cells isolated from 
HIV- tonsils or HIV+ LNs (Petrovas et al., 2017). The in vivo safety and efficacy of DART 
are to be determined as a phase 1 clinical trial (NCT03570918) is currently underway. 
CAR T cells, IL-15, and DART all show promise as cytolytic-centric cure strategies. 
However, is cytotoxicity required for a cure? And is it the most desirable strategy? For 
the first question, our results indicate that the answer is likely to be no for a functional 
cure. For the second question, implications from our results, other viral infections, and 
autoimmunity indicate that cytolytic-centric cure strategies might not be the most 
desirable ones. In chapter 3, we demonstrated that the frequency of perforin+ granzyme 
B+ CD8+ T cells in LNs positively correlated with viral, indicating that the expression of 
these cytolytic molecules are associated with increased inflammation. In fact, we 
observed an elevated level of IL-15, which is  known to induce perforin expression, in 
LNs of CPs compared to ECs (Fig 4.3 B). This finding corroborated a previous finding 
suggesting that IL-15 drives activation of bystander CD8+ T cells, which in turn is 
associated with disease progression in untreated HIV+ individuals as well as increased 
morbidity and mortality in ART-treated individuals (Younes et al., 2016). As a side note, 
since viral control in ECs is linked to low levels of IL-15 in LNs , the usage of IL-15 
superagonist as a cure strategy should be reassessed. On the other hand, deleterious 




including leishmaniasis, malaria, Chagas disease, Coxsackie virus, and Zika virus 
infections (Ferreira et al., 2017; Henke, Huber, Stelzner, & Whitton, 1995; Jurado et al., 
2018; Nitcheu et al., 2003; Novais et al., 2017; Novais et al., 2013). In these diseases, 
aberrant cytotoxicity mediated by pathogen-specific CD8+ T cells in tissues is linked to 
pathology. Similarly, CD8+ T cell-mediated cytotoxicity is involved in the pathology of 
autoimmune diseases such as type 1 diabetes (Coppieters et al., 2012; Coppieters & 
von Herrath, 2011; Knight et al., 2013; Trivedi et al., 2016); psoriasis and vitiligo (Cheuk 
et al., 2017; Cheuk et al., 2014; van den Boorn et al., 2009); and multiple sclerosis (Deb 
et al., 2010; Ifergan et al., 2011; Murray et al., 1998; Zhao et al., 2018). 
 
Figure 4.3 Elevated level of IL-15 in LNs of CPs. (A) Tonsil CD8+ T cells from HIV- 
individuals were pre-labeled with CFSE and stimulated for 5 days ± 10ng/mL IL-15 (left: 
representative flow plots, right: data quantification). Perforin and granzyme B expression 
were quantified in dividing CD8+ T cells (CFSE low). (B) Immunohistochemistry staining 
of LN biopsies for IL-15 (left) and data quantification (right). Bars represent mean ± 
SEM.  Significance was determined using paired T-test (A) and one-way ANOVA with 
Tukey test (B). * p < 0.05, ** p < 0.01. Experiment performed by Son Nguyen, Alberto 




Together, these insights have led us to speculate that inducing cytotoxic CD8+ T cells in 
LTs as a cure strategy for HIV might have unwanted pathological effects. In fact, it is 
tempting to postulate that the absence of strong cytolytic activities in LTs, or tissues in 
general, is a evolutionarily conferred mechanism to protect these compartments from 
chronic inflammation and HIV conveniently exploits this property to its own advantage. A 
few lines of evidence exist to support this postulation. First, as mentioned earlier in this 
section, cytolytic CD8+ T cells are restricted to the blood vasculature and do not traffic to 
LTs under homeostasis (Bottcher et al., 2015; Gerlach et al., 2016). Second, though LN 
CD8+ T cells can upregulate perforin and granzyme B during 5 days of in vitro 
stimulation, these cells require at least two rounds of cell division and concurrently lose 
the expression of CD69, which decreases their ability to stay resident in LTs and primes 
them for tissue egress (Reuter et al., 2017). Third, human CMV-specific CD8+ T cells, 
which exhibit a strong cytolytic profile in blood, express cytolytic proteins at low levels in 
LNs, implying that the LT microenvironment is not conducive for cytotoxic activities 
(Hertoghs et al., 2010; Remmerswaal et al., 2012).  
In the light of possible deleterious effects and the natural lack of cytotoxicity in LTs, the 
pursuit of a cytolytic-centric cure for HIV needs to be carefully reexamined. The success 
of this approach will come with a cost, most likely in the form of tissue damage. 
Currently, the molecular mechanisms that hamper cytotoxicity in LTs have not been 
identified. Some questions of interest not only to the HIV cure field but also to the 
general immunology community are: what is the epigenetic architecture at cytolytic loci 




What are the microenvironmental factors in LTs that reduce the production of cytolytic 
proteins? And what do LT CD8+ T cells degranulate?. The identification of these 
regulators will unveil potential points of intervention through which the cytotoxic capacity 
of CD8+ T cells can be unleashed, either genetically or pharmacologically. However, 
these studies should be accompanied by the search for a way to limit damage to LTs 
caused by CD8+ T cell-mediated cytotoxicity. Alternatively, non-cytolytic-centric HIV cure 
strategies can be explored, especially given that this mechanism occurs naturally in ECs 
and likely spares LTs of cytotoxicity-mediated damages.  
What happens during the acute phase of infection in ECs? 
A classical question that has always been asked of studies on ECs is “Which is the 
chicken and which is the egg?” In other words, are the described immunological 
signatures the cause or consequences of the low viral loads in ECs?  This question can 
only be answered by looking at early events that happen during acute infection. 
However, most of what we know about ECs have been restricted to chronic infection. 
This is an intrinsic caveat of studying ECs because these individuals, by definition, 
cannot be identified until their viral loads have already reached the set point. Therefore, 
there is very little information on acute HIV infection in ECs. 
During acute infection, ECs can experience plasma viral loads in the range of 106 
copies/mL (Goujard et al., 2009). Their CD4+ T cell counts and CD4+ T cell frequencies 
are both higher than non-controllers (Goujard et al., 2009). Viral control is established by 




al., 2009). In a cohort of eleven HIV-infected individuals identified during peak viremia, 
the strength of HIV-specific cytolytic CD4+, but not CD8+, T cell responses during acute 
infection predicts chronic viral set point, suggesting that this effector mechanism is 
crucial for the establishment of viral control (Soghoian et al., 2012). Some case studies 
have associated robust HIV-specific CD8+ T cell responses to the establishment of 
spontaneous HIV control (Moosa et al., 2018; Morley et al., 2019). In hyperacute HIV-
infection, the frequencies of proliferating cytolytic CD8+ T cells and of a precocious NK 
cell subset one-week post-viremia detection were elevated in future controllers (Kazer et 
al., 2020). It is clear that these studies were largely anecdotal; the study size were very 
small and not controlled; and the studied immunologic features were restricted to the 
peripheral blood. Therefore, there is still a need to bridge our gaps in the knowledge 
regarding the establishment of viral control during acute infection.  
Since it is almost impossible to study the acute phase of infection in human ECs, the 
rhesus macaque model provides an opportunity to study this question in a controlled and 
systematic manner. It has been reported that approximately 50% of Mamu-B*08+ and 
20% of Mamu-B*17+ rhesus macaques infected with SIVmac239 achieve EC status (P. A. 
Mudd & Watkins, 2011). In this model, SIV-specific CD8+ T cell responses targeting 
Mamu-B*08 epitopes during acute infection is responsible for the establishment of viral 
control (Valentine et al., 2009). However, it is unclear what features of acute SIV-specific 
CD8+ T cells, including those in LTs, mediate viral control. Therefore, future studies 
should utilize this animal model in order to determine the correlates of viral control 




SIV-specific CD8+ T cell responses in blood and tissues of EC animals and non-
controller animals? Are CD8+ T cells from EC animals primed differently during primary 
infection? What effector functions of CD8+ T cells in blood and tissues are enriched in 
EC animals during acute infection? And are these mechanisms different from 
mechanisms that maintain viral control during chronic infection? 
It is important to emphasize that the questions of viral control establishment and 
maintenance are two separate but equally important questions. This dissertation, similar 
to previous studies on ECs, does not address the question of establishment. However, it 
does address the question of maintenance. This is essential because regardless of how 
viral control is established, during chronic infection CD8+ T cells still actively maintain 





4.3 Concluding remarks 
According to the World Health Organization, as of 2018, almost 38 million peoples are 
still living with HIV. Moreover, within 2018 alone, almost 2 million were newly infected 
with HIV and almost 1 million people lost their lives to illnesses associated with this 
infection. These numbers highlight the pressing need for a cure and vaccine for HIV, 
neither of which is available in spite of over 30 years of intensive research. 
The design of a HIV vaccine or cure can greatly benefit from insights on anti-HIV 
immunity, especially at sites of viral reservoirs such as LTs. By studying HIV ECs, this 
dissertation uncovered two novel correlates of effective anti-HIV immune responses in 
LTs:  increased frequency of CD8+ TRM and enhancement of non-cytolytic antiviral 
activities mediated by CD8+ T cells. These findings highlight a few important concepts. 
First, location matters. Because the majority of HIV-specific CD8+ T cells in LNs are TRM, 
studying CD8+ T cell responses to HIV in blood does not reflect the nature of the 
responses at sites of viral persistence. Furthermore, the elevation of CD8+ TRM frequency 
in LNs of ECs indicates that constant local immune pressure exerted on HIV-infected 
cells in LTs is key to the successful control of viral replication. Second, cell-mediated 
cytotoxicity might not be the only or best path to a cure. In fact, suppressing cytotoxic 
activities in LTs is likely a natural mechanism that protects these tissues from damages 
caused by chronic inflammation. In addition, since non-cytolytic mechanisms mediated 
by CD8+ T cells appear to be sufficient to maintain viral control in LTs, these 




With the identification of CD8+ TRM and non-cytolytic viral suppression signatures, we 
believe that future cure, and even vaccine, strategies should aim to induce these 
features. The induction of CD8+ TRM can potentially be achieved by an appropriate 
choice of vectors and/or immunization routes. The CMV vector has shown some 
promises by inducing effector memory CD8+ T cell responses in tissues, including LTs, 
that resemble TRM in rhesus macaques (Fukazawa et al., 2012; Hansen et al., 2011; 
Hansen et al., 2013; Hansen et al., 2009). Intralymphatic, mucosal, and intravenous 
immunization, in contrast to intradermal and intramuscular, have been shown to induce 
tissue-resident CD8+ T cell responses that are effective in tumor and infection models 
(Bialkowski et al., 2016; Cuburu et al., 2012; Darrah et al., 2020). On the other hand, the 
induction of non-cytolytic viral suppression mechanisms in CD8+ T cells will require 
significantly more works. It should begin with the identification of the exact mechanisms 
involved and continue with determining optimal induction approaches. These are all 
exciting directions for research. With the implications from this dissertation and results 
from upcoming research, the goal of developing a functional cure for HIV will hopefully 
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